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Long-term dopaminergic therapy in Parkinson’s disease (PD) can lead to motor complications including 
dyskinesia which can be treated with amantadine, an N-methyl-D-aspartate (NMDA) receptor 
antagonist.  NMDA receptor activation is linked with nitric oxide (NO) production and changes in 
synaptic plasticity, suggesting a role in dyskinesia. This led to the hypothesis that NO, produced by 
neuronal nitric oxide synthase (nNOS), contributes to the occurrence and evolution of dyskinesia in PD. 
Therefore, these studies investigated the effects of nNOS inhibition, using the nNOS inhibitors 
ARR17477 and 7-nitroindazole (7-NI), on the dyskinesia expression and priming processes in rodent and 
primate models of PD following L-dopa and dopamine agonist treatment.  
To explore the role of nNOS inhibition on established dyskinesia, 6-OHDA-lesioned rats, primed to 
exhibit stable abnormal involuntary movements (AIMs), the rodent analogue of dyskinesia, were acutely 
challenged with nNOS inhibitors plus L-dopa or ropinirole.  No reduction in AIMs was observed following 
nNOS inhibition. 
In order to investigate the potential for nNOS inhibitors to reduce the priming for AIMs, naïve 6-OHDA-
lesioned rats were treated chronically with ARR17477 or 7-NI plus either L-dopa or ropinirole. Again, 
there was no beneficial effect of nNOS inhibition on the emergence of L-dopa- or ropinirole-induced 
AIMs.  
nNOS inhibition was also investigated in MPTP-treated primates, the gold standard behavioural model 
of PD.  ARR17477 did not reduce the expression of established dyskinesia following L-dopa or ropinirole 
treatment.  Similarly nNOS inhibition did not attenuate L-dopa-induced priming for dyskinesia in this 
model. 
In conclusion, inhibition of nNOS in 6-OHDA-lesioned rats and MPTP-treated primates did not reduce 
the expression or priming of L-dopa- or ropinirole-induced dyskinesia. These findings do not support a 
role for nitric oxide in processes underlying dyskinesia and suggest that nNOS inhibitors would not be 
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 Chapter 1 
1.1 Parkinson’s disease 
The first in-depth description of the disorder now referred to as ‘Parkinson’s disease’ was provided by 
the English physician, James Parkinson, in 1817 in his essay on the Shaking Palsy (reprinted; Parkinson, 
2002). Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s Disease and affects 1-2 % of the population aged over 55 (Di et al., 2007). Both the 
incidence and prevalence of the disease increase with age with a slightly higher incidence of PD in men 
compared to women (Elbaz et al., 2002). Current demographic trends predict the number of cases will 
double by 2050 (Schapira, 2009). Diagnosis of PD is based on clinical manifestation of resting tremor, 
rigidity, bradykinesia and postural instability (Jankovic, 2008), although these are often accompanied by 
non-motor symptoms. There is no available treatment to prevent the progress of the disease to date 
despite ongoing research efforts, and current therapy focuses on symptomatic management.  
 
1.1.1 Aetiology of PD 
It is increasingly apparent that there is no single causative factor underlying PD, rather a combination of 
genetic and environmental factors are likely to be accountable. These may involve multiple interactions 
between genes, modifying effects by susceptibility alleles, and the influence of environmental agents 
both indirectly via gene expression and directly on the brain itself (Klein & Schlossmacher, 2007).  
PD can be subdivided into sporadic/idiopathic and familial forms, although some genetically determined 
Parkinson syndromes resemble idiopathic PD but may differ neuropathologically. Most known gene 
mutations tend to cause juvenile or early onset of the disease (Alves et al., 2008), and many familial 
identified mutations have been found in apparently sporadic cases (Warner & Schapira, 2003). The 
genes mutations implicate molecular pathways involved in nigral degeneration specifically including 
protein aggregation, defective proteasomal degradation, mitochondrial dysfunction and oxidative stress 
(Litvan et al., 2007a). A number of defined loci are associated with high penetrant autosomal dominant 
or recessive PD, and causative mutations in specific genes have been identified for 7 of these, although 
the precise number is subject to some disagreement. These genes include α-synuclein, parkin, UCH-L1 
(ubiquitin C-terminal hydrolase-L1), PINK1 (phosphatise and tensin homologue induced putative kinase 
1), DJ-1, LRRK2/dardarin (leucine-rich repeat kinase 2) & ATP13A2 (Lee & Liu, 2008; Yang et al., 2009). α-
synuclein was the first gene linked to PD and mutations or multiplications can lead to PD pathology 
specifically including Lewy body formation of which the misfolded and aggregated α-synuclein protein is 
a major component (Polymeropoulos et al., 1997; Kruger et al., 2002). α-synuclein, parkin and DJ-1 have 
all been associated with maintenance of physiological dopaminergic function (Lee & Liu, 2008). 
Additionally, an increased susceptibility to developing PD may be conferred by variants of certain genes 
such as Glucocerebrosidase (Nichols et al., 2009).  
The genetic weighting of the mutations in the idiopathic or sporadic form of PD is small, and accounts 
for only 5-10 % of the overall PD population. However the strikingly consistent and specific phenotype of 
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familial and sporadic PD has led some researchers to believe that one common molecular mechanism 
may underlie PD, although this remains elusive to date (Gandhi & Wood, 2005).  
Similarly no specific environmental agent has been identified as causative in PD. Studies have suggested 
exposure to industrial chemicals in addition to pesticide, herbicide and fungicide products may increase 
the risk, due to neurotoxic effects. Advantage has been taken of some of these agents in creating animal 
models of the disease including the use of rotenone and paraquat (Litvan et al., 2007b). Interestingly 
cigarette smoking has been shown to reduce the risk of developing PD (Elbaz & Tranchant, 2007).   
Additionally nitric oxide synthase alleles have been shown to eliminate the protective effect of smoking 
or the risk associated with pesticides in retrospective population studies (Hancock et al., 2008).  
 
1.1.2 Pathology of PD 
PD is a chronic progressive neurodegenerative disorder of the extrapyramidal cerebral system classically 
affecting the basal ganglia (Kadieva & Mutsueva, 2005). The principal biochemical signs of PD are 
selective degeneration of dopaminergic neurones in the substantia nigra pars compacta (SNc) and the 
presence of proteinaceous cytoplasmic inclusions, termed Lewy bodies, frequently containing α-
synuclein, found in remaining dopaminergic cells (McNaught et al., 2003; Zhang & Goodlett, 2004).  
Further widespread pathology is characteristic of PD and other neurotransmitter systems are also 
affected. Peripherally, decreased tyrosine hydroxylase (TH) activity and decreased dopamine is evident 
in the adrenal medulla. Centrally, neurotransmitter level changes are detected in the nucleus basalis of 
Meynert (cholinergic), locus coeruleus (noradrenergic), and Raphe nuclei (serotonergic) in addition to 
alterations in the glutamatergic and GABAergic pathways (Hodaie et al., 2007). In terms of the evolution 
of pathological markers of the disease, Braak et al. (2003), defined a series of stages of disease 
progression, evoking some controversy, based on comparing brains obtained at autopsy from diagnosed 
PD patients, incidental cases without clinical PD symptoms and controls. Typically the dorsal motor 
nucleus of the medulla oblongata is the first site to be affected by lesions, subsequently extending to 
the pontine tegmentum and the midbrain, and then the basal prosencephalon and mesocortex. In the 
final stages the neocortex is subject to significant pathological changes affecting sensory and motor 
areas. It is only at the stage of loss of approximately 50 % of dopaminergic cells of the substantia nigra 
(SN) accompanied by depletion of about 80 % of striatal dopamine that the clinical symptoms of PD 
become apparent (Braak et al., 2003). More recent findings suggest that the motor signs of PD in fact 
appear when there is only loss of about 30 % of dopaminergic neurons and 50-60 % of striatal dopamine 
(Cheng et al., 2010).   
The degeneration of dopaminergic neurons in the substantia nigra causes a reduction of input to the 
striatum (the main input gateway connecting the motor cortex to the basal ganglia, and comprising the 
putamen and caudate nucleus), and in turn this leads to an inbalance in activity of the direct and indirect 
striatal output pathways (Crossman, 2000). Striatal neurons in the direct pathway project directly from 
the putamen to both the globus pallidus pars interna (GPi) and the substantia nigra pars reticulata (SNr). 
 
19                                                                                   
            
 Chapter 1 
They bear D1 receptors, coexpress the peptides substance P and dynorphin, and provide a direct 
inhibitory effect on GPi and SNr. Meanwhile striatal neurons in the indirect pathway connect the 
putamen with the GPi/SNr via synaptic connections in the globus pallidus pars externa (GPe) and 
subthalamic nucleus (STN). They express D2 receptors and the peptide enkephalin (Obeso et al., 2000b). 
Dopamine has differential effects on these two receptor types facilitating transmission via D1 receptors 
and inhibiting transmission via D2 receptors. Dopamine depletion results in increased activity of the 
indirect pathway and reduced activity of the direct pathway and this alteration has been confirmed by 
measured changes in preproenkephalin A (neuropeptide co-transmitter utilized at D1 receptors) and 
preprotachykinin/preproenkephalin B (neuropeptide co-transmitter utilized at D2 receptors) mRNA 
levels respectively (Gerfen et al., 1990). Within the healthy individual, movement-suppressing pathways 
and movement-promoting pathways interact to support voluntary movement via physiologically 
regulated thalamic output to the motor cortex, whilst this balance breaks down in the parkinsonian 
state resulting in net inhibition of thalamo-cortical output (Obeso et al., 2000b). 
 
1.1.3 Clinical features of PD 
Diagnosis of PD is based on clinical manifestation of rest tremor, rigidity, bradykinesia (slowness of 
movement) and postural instability, although non-motor symptoms including autonomic dysfunction, 
cognitive/neurobehavioural disorders, and sensory and sleep abnormalities are also common (Jankovic, 
2008). Early signs may include a reduced sense of smell (hyposmia) owing to pathologic changes in 
olfactory structures including the olfactory bulb, although hyposmia is often only noticed retrospectively 
(Braak et al., 2003).  
Some of the most debilitating symptoms of Parkinson’s disease are the motor impairments, which are 
proposed to manifest around 6-8 years after nigral degeneration first occurs (Schapira & Obeso, 2006). 
The Unified Parkinson’s Disease Rating Scale (UPDRS) is the most well established scale to assess the 
severity of PD symptoms. It evaluates mentation (part I), activities of daily living (ADL; part II) and motor 
function (part III), and the scores from these subsections are summed to determine the total UPDRS 
score. Part IV of the UPDRS measures complications of therapy, such as dyskinesia, ‘off’ periods and 
sleep disturbance, and is often used in trials of adjunct therapy (Ebersbach et al., 2006; Colosimo et al., 
2010).  
Fortunately PD has benefited from the development of numerous symptomatic medical therapies, 
aimed at the dopamine (DA) system, which have proved disease alleviating to some extent, improving 
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1.2 PD therapy 
The predominant therapeutic strategy for addressing the motor symptoms of PD is the use of 
dopaminergic drugs singularly or in combination, for example Levodopa (L-dopa), dopamine agonists, 
monoamine oxidase type-B (MAOB) inhibitors, and catechol-O-methyltransferase (COMT) inhibitors 
(Schapira, 2009). PD may also be treated with non-dopaminergic agents such as cholinergic receptor 
antagonists. A number of cholinergic agents may be used as monotherapy or as adjuncts, although 
cognitive and neuropsychiatric side-effects including hallucinations tend to limit their use 
(Katzenschlager et al., 2003). Anticholinergic agents, such as trihexyphenidyl and benztropine, are the 
oldest treatments that have been used in PD, and are most effective for treating resting tremor. 
Anticholinergics are typically reserved for the younger patient (<60 years of age) with predominant 
tremor and preserved cognitive function (Simuni et al., 2009). Amantadine, an antiviral agent discovered 
by chance to have antiparkinsonian effects, has demonstrated efficacy for relieving tremor in early PD 
(Olanow et al., 2001). Amantadine is an older medication with many different actions in the central 
nervous system, including inhibition of N-methyl-D-aspartate receptors, enhancement of dopamine 
release from presynaptic terminals, and modest anticholinergic activity, although its mode of action is 
not fully understood (Weintraub et al., 2008).  Treatment regimens tend to need to be adjusted as the 
disease progresses and motor symptoms become more severe, and ultimately all PD patients are 
prescribed L-dopa. 
 
1.2.1 L-dopa  
Since Cotzias et al. first described the beneficial effects of high doses of L-dopa (L-3,4-
dihydroxyphenylalanine) on PD patients in 1967, it remains the most effective agent for treatment of 
motor symptoms in PD  and is widely acknowledged as the ‘gold-standard’ of symptomatic PD therapy 
(Fahn, 2008). Direct use of dopamine in the treatment of PD is not possible due to its high basicity which 
impedes penetration through the blood-brain barrier (BBB). Therefore the precursor of dopamine, L-
dopa, is strategically employed as a prodrug. It is recognised by L-neutral amino acid transport proteins, 
crossing the BBB where it is then converted into dopamine within dopaminergic neurons by DOPA 
decarboxylase (DDC), (Kadieva & Mutsueva, 2005). This conversion can also occur in serotonergic 
neurones and glia when there is extensive neuronal loss (Schapira, 2009). However L-dopa is rarely 
administered alone since most of the compound is decarboxylated to dopamine, under the action of 
peripheral DDC, resulting not only in a low efficacy but also various side-effects including vomiting, 
nausea and arrhythmia (Lim, 2005). Thus L-dopa is administered in combination with peripheral DDC 
inhibitors such as carbidopa or benserazide (See Figure 1-1).  
Other adjunctive treatments can further enhance L-dopa effects as shown in Figure 1-1. MAOB 
inhibitors reduce dopamine metabolism at the synapse and glia thereby enhancing its activity and 
reuptake. It was concluded that the MAOB inhibitors rasagiline and selegiline are effective as 
monotherapy in early disease (Goetz et al., 2005), but MAOB inhibitors are also commonly used as an 
adjunct therapy in more advanced disease to enhance dopamine levels. COMT inhibitors also lessen 
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dopamine metabolism peripherally as well as centrally leading to prolonged L-dopa effects (Lim, 2005). 
Entacapone and tolcapone are two selective COMT inhibitors that have been developed for clinical use. 
 
 
1.2.2 Dopamine agonists   
A range of dopamine agonists are available for use in PD and these fall into the categories of ergot and 
non-ergot derived. Ergot agonists include bromocriptine, cabergoline, and lisuride, whilst non-ergots 
include apomorphine, pramipexole, ropinorole and rotigotine. Ergot derived agonists have recently 
been associated with cardiac valve fibrosis and are less frequently used (Zanettini et al., 2007). 
Dopamine agonists bypass the degenerating neurons and directly stimulate the intact, although 
denervated, postsynaptic receptors in the striatum. Dopamine agonists tend to have substantially longer 
elimination half-lives than L-dopa,  allowing for more prolonged stimulation of receptors (Factor, 2008). 
Figure 1-1 Dopamine pharmacology and management of PD. Entacapone is used as a COMT inhibitor and 
benserazide/carbidopa as a peripheral DDC inhibitor. Rasagiline and selegeline are MAO inhibitors used in 
the clinic. COMT (catechol-o-methyl transferase), DAT (dopamine active transporter), DDC 
(Dopadecarboxylase), DOPAC (3,4 dihydrohylphenylacetic acid), D1 & D2 (dopamine receptors), HVA 
(homovanillic acid), MAO (monoamine oxidase), NMDA (N-methyl-d-aspartate), 3-MT (3-
methoxyltyramine) and 3-OMD (3-O-methyldopa).  
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The multiplicity of dopamine receptors in the brain offers a range of potential targets, and whilst L-dopa 
is non-discriminate in its actions, dopamine agonists display a variation in affinity for specific receptor 
sub-types (see Table 1-1). Most currently used dopamine agonists only activate D2 and D3 dopamine 
receptors and no major advance has been made in producing selective D1 dopamine agonists, a known 
target for anti-Parkinsonian agents. A number of side-effects of dopamine agonists including 
hypotension and nausea are related to their action at D2 receptors (Foley et al., 2004). Partial D2 
dopamine agonists are being developed as they might treat the motor symptoms of PD while 
suppressing both psychosis and dyskinesia (Schapira et al., 2006). 
 
Table 1-1 Receptor affinities of dopamine agonists (Jenner, 2002; Foley et al., 2004; Bonuccelli & 
Pavese, 2007; Factor, 2008). 











1.2.3 L-dopa, dopamine agonists and motor complications 
In the early stages of PD the response to L-dopa is excellent providing relief of the characteristic motor 
symptoms experienced. However, motor complications frequently ensue after long-term treatment with 
L-dopa resulting in “wearing-off” (a decrease in the duration of action of L-dopa) and “on-off 
phenomenon” (unpredictable switching between mobility benefits of L-dopa and the parkinsonian state) 
and also, during ‘on’ periods, dyskinesia (uncontrollable involuntary movements) which may become 
severely disabling in themselves (Duvoisin, 1974). As L-Dopa benefits wear off between doses patients 
commonly fluctuate amid ‘on’ responses whereby they experience a good antiparkinsonian effect and 
‘off’ responses whereby the drug does not adequately treat the parkinsonian features (Obeso et al., 
2000a). Motor complications are attributed to a shortening of response, for the same dose of L-dopa, 
with disease progression from early to later stages of PD (Schapira et al., 2009).  
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Dopamine agonists (with the exception of apomorphine) have a longer plasma half-life than L-dopa in 
man and may thus exert a longer period of symptomatic effects. Dyskinesia has been associated with 
pulsatile stimulation of dopamine receptors and therefore dopamine agonists are often favoured over L-
dopa for initial treatment (Lim, 2005; Jenner, 2008b).  
Although dopamine agonist monotherapy can effectively control motor symptoms for several years, 
most patients inevitably require L-dopa supplementation at some stage during the disease. There are 
conflicting results of holding off L-dopa in reducing motor complications and consideration of the 
adverse events reported is important (Schapira et al., 2009). 
COMT catalyses the conversion of dopamine into 3-O-methyldopamine, and of L-dopa into 3-O-
methyldopa (Jorga et al., 1998). The use of COMT inhibitors in conjunction with L-dopa can therefore 
increase the quantity of dopamine reaching the striatum and reduce the dose of L-dopa required. By 
increasing the half life of L-dopa the duration of effect is also prolonged and pulsatility of dopamine 
receptor activity reduced (Nutt et al., 1994). The addition of COMT inhibitors such as entacapone or 
tolcapone to dopaminergic medication has been shown to increase the amount of time motor disability 
is beneficially reversed (‘on-time’) by 1.3-1.8 h per day in PD patients, although with no accompanying 
reduction in dyskinesia (Group, 1997; Deane et al., 2004). COMT inhibitors may therefore be most useful 
in patients showing wearing-off effects and may require reductions in L-dopa dose.  
Whether continuous dopaminergic stimulation explains all of the differences between L-dopa and 
dopamine agonists is questionable, and there might instead be fundamental differences between the 
actions of these agents. L-Dopa acts on both D1 and D2 receptor families, whereas dopamine agonists 
tend to be more specific to D2-type receptors. In PD patients D1 agonists induce dyskinesia to the same 
extent as L-dopa whereas D2/D3 agonists induce little dyskinesia as monotherapy (Rascol et al., 2006). 
There is also evidence suggesting L-dopa affects multiple pharmacological targets including 
nonadrenaline and 5-hydroxytryptamine (5-HT; serotonin) receptors and might act as a neuromodulator 
in its own right although dopamine agonists may also interact with other neurotransmitter pathways 
(Mercuri & Bernardi, 2005; Schapira et al., 2006). Nigrostriatal neurons also show increased 
responsiveness to L-dopa as compared to the dopamine agonist ropinirole in a rodent model of PD 
(Carta et al., 2008a), although the exact reasons for differences between these agents remains 





The term dyskinesia refers to the abnormal involuntary movements that manifest clinically following L-
dopa treatment in PD patients. Although they are seen most commonly in conjunction with L-dopa their 
expression is also seen after long-term dopamine agonist medication. Indeed up to 80 % of patients 
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receiving dopaminergic treatment show dyskinesia within 5 years (Rascol et al., 2000). Dyskinesia may 
take the form of chorea (rapid dancing movements), dystonia (persistent muscle contraction) or 
athetosis (writhing movements) (Fahn, 2000). Based on the temporal relationship with drug dosing 
these can be further classified as peak-dose or diphasic dyskinesias and off-dose dystonias (Jankovic, 
2005; Thanvi et al., 2007).     
 
1.3.1 Risk factors  
Evidence shows that the onset and severity of dyskinesia is associated with several factors including the 
extent of nigral dopaminergic cell loss, the type of drug administered and also the mode of drug 
delivery. Following initiation of L-dopa, the appearance of dyskinesia occurs earlier in more severely 
affected patients, who accordingly suffer from a greater loss of dopaminergic neurons (Ahlskog & 
Muenter, 2001). L-dopa does not induce dyskinesia in healthy people or animals suggesting nigral 
denervation is a necessary factor (Boyce et al., 1990). There are several exceptions where high doses of 
L-dopa have caused dyskinesia in naive primates (Pearce et al., 2001) implying that the intact basal 
ganglia may be able to generate dyskinesia under extreme conditions, whilst nigral denervation appears 
to lower the threshold for its induction.  
The age of onset of PD is also linked with the extent of dyskinesia which manifests over 5 years of 
treatment (Kumar et al., 2005). With PD onset after 70 years of age, the incidence was 16 %, whereas 
with onset from 40 to 59 years of age, the incidence raised to 50 %. This difference in dyskinesia 
development may be due to age-related physiological changes within the dopaminergic system. Early 
monotherapy employing long-acting dopamine agonists is associated with a lower incidence of 
dyskinesia in the clinic than occurs with L-dopa treatment (Shannon et al., 1997; Rascol et al., 2000; 
Inzelberg et al., 2003). Whilst the use of dopamine agonist drugs as early monotherapy reduces the risk 
of dyskinesia induction when L-dopa therapy is inevitably introduced with disease progression, it 
appears at the same rate as in those patients treated initially with L-dopa (Rascol et al., 2006). Higher 
doses of L-dopa (>400 mg/day) also seem to increase the incidence of dyskinesia, and motor 
complications tend to be more common in woman than men, as well as in patients with a body weight 
under 75 kg (Stocchi et al., 2010). Longer acting dopamine agonists induce lower levels of dyskinesia and 
the occurence of dyskinesia is lower with dopamine agonists compared with L-dopa (Rascol et al., 2000; 
Oertel et al., 2006). This variation is possibly owing to the relatively short plasma half life of L-dopa of 90 
min (Nutt, 2008). This causes pulsatility in receptor stimulation and accordingly it has been shown that 
repeated administration of short acting dopamine agonists produces more dyskinesia than continuous 
infusion of the same drug (Bibbiani et al., 2005a). Controlled-release formulations aim to overcome this 
problem and duodenal L-dopa infusion for example can reduce dyskinesia in some patients (Antonini et 
al., 2007; Devos, 2009).  
1.3.2 Pathophysiology of dyskinesia 
‘Priming’ refers to the induction processes by which the brain becomes sensitised, whereby each 
administration of dopaminergic therapy modifies the response to subsequent dopaminergic treatment 
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(Brotchie, 2005). Priming may take place from first administration of dopaminergic medication and can 
continue with repeated treatment until dyskinesia reaches stable levels. There is a difference between 
the induction of dyskinesia i.e. priming which occurs with both dopamine agonists and L-dopa and the 
expression which may be lower when dopamine agonists are used as compared to L-dopa (Jackson et 
al., 2007). It is the mechanisms underlying priming, and also the consequential expression and 
maintenance of dyskinesia that are still not fully understood. However significant progress toward this 
end has occurred in recent years especially with regard to molecular changes associated with dyskinesia 
(Jenner, 2008b). 
At a circuitry level an array of changes are thought to take place within the basal ganglia which 
differentiate it from the conditions present in the healthy and parkinsonian state. According to the 
schematic model of the basal ganglia (see Figure 1-2), changes opposite to those proposed to underlie 
the parkinsonian state (as described in section 1.1.2), would result in reduced inhibition of thalamo-
cortical neurons and output of motor areas synonymous with dyskinesia i.e. hypoactivity of the indirect 
pathway and hyperactivity of the direct pathway. These changes are supported by electrophysiological 
studies showing increased neuronal activity in the GPe and reduced neuronal firing in the GPi during 
dyskinesia (Filion & Tremblay, 1991; Lozano et al., 2000). However further studies bring to light the 
shortcomingsof this model whereby stereotaxic lesioning of the GPi reduces dyskinesia rather than 
increases it as the model would predict (Parkin et al., 2002). Altered firing patterns within the basal-
ganglia–thalamocortical loops may be as important as overall changes in firing rates to the emergence 
of dyskinesia (Boraud et al., 2001). Whilst the schematic model forms a good basis for considering the 
phenomenon of dyskinesia, examining more specific changes may provide a more comprehensive 
understanding. 
     
Presynaptic changes (resulting from reduced dopaminergic fibres combined with chronic L-dopa 
administration) have been associated with altered efficiency of the dopamine transporter (DAT) in 
dyskinesia, as well as changes in cellular compartments regulating influx and handling of exogenous L-
dopa including serotonergic projections from midbrain raphe nuclei (Tanaka et al., 1999; Troiano et al., 
2009). Striatal expression levels of prodynorphin (pre-proenkephalin B) mRNA and Fos-B/∆Fos-B related 
transcription factors positively correlate with severity of L-Dopa - induced dyskinesia (Cenci et al., 1998; 
Lundblad et al., 2004). Furthermore these two markers are persistently upregulated for several weeks 
following L-Dopa treatment (Andersson et al., 2003). This more long-term biochemical alteration may 
signify plasticity changes related to dyskinesia induction. Overactive signaling through D1 receptors has 
been linked to these changes (Cenci & Lundblad, 2006). 
Various postsynaptic changes in D1 receptors in association with dyskinesia have been reported, 
meanwhile D2 receptors seem only moderately affected in dyskinesia, whilst there is some evidence for 
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Figure 1-2 The basal-ganglia–thalamocortical circuits under normal conditions (a), in the untreated 
parkinsonian state (b), and in L-dopa-induced dyskinesia (c). (black lines indicate chemically composite 
pathways). In b and c, changes in the average activity rate of specific projection pathways are shown as 
thickening (increased activity) or thinning (decreased activity) of the corresponding lines compared with 
the normal state. Alterations in firing patterns are represented by sinuous lines. The striatum and the 
STN provide the input layer for incoming cortical information to the basal ganglia. The GPi and SNr 
provide the output layer communicating with the rest of the brain. These structures exert a strong 
inhibitory control on their projection targets in the thalamus and the brainstem and this tonic inhibitory 
input must be released to enable normal movements to occur. The striatum exerts opposite influences 
on the GPi and SNr via two distinct classes of efferent neurons, the D1-receptor-rich ‘direct pathway’, 
which is positively modulated by dopamine, and the D2-receptor-rich ‘indirect pathway’, which is 
negatively modulated by dopamine. The loss of dopamine in PD (b) causes an imbalance in the activity 
of the two striatofugal pathways and their corresponding cortical inputs. The basal-ganglia-
thalamocortical circuit during the expression of dyskinesia (c), the imbalance assumes an opposite sign. 
(GPe, external segment of the globus pallidus; GPi, internal segment of the globus pallidus; SNc, 
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increased D3 receptor expression within the dorsal striatum (Bordet et al., 1997; Konradi et al., 2004; 
Nagai et al., 2007; Darmopil et al., 2009). Sensitisation of D1 receptors and also their increased density 
have been found in the striatum of MPTP-treated primates exhibiting dyskinesia (Aubert et al., 2005; 
Guigoni et al., 2005). These are thought to initiate further downstream changes in signaling pathways 
involving cAMP and ERK 1/2 possibly due to an increased coupling of D1 receptors to their transducing G 
proteins (Gerfen et al., 2002; Santini et al., 2008). Sensitisation of D1 receptors results in enhanced 
activation of cAMP-dependent protein kinase A which phosphorylates downstream proteins including 
DARPP-32. The striatum-specific signaling protein DARPP-32 is found to show a persistant increase in 
phosphorylation at Thr-34 in dyskinetic animals compared to non-dyskinetic and drug naïve animals 
(Picconi et al., 2003; Santini et al., 2007). Recently down-regulation of CalDAG-GEFI and up-regulation of 
CalDAG-GEFII mRNA’s and proteins, both regulators of ERK signaling, have been found to be closely 
correlated with severity of dyskinesia (Crittenden et al., 2009). It therefore seems D1 receptor related 
changes are important in terms of dopaminergic contributions to dyskinesia.     
Overactivity of glutamatergic systems in the basal ganglia have also been implicated in dyskinesia, and 
increased sensitivity of N-methyl-D-aspartate (NMDA) receptors may contribute to the longer term 
activity dependent alterations in neuronal responses (Chase et al., 2003). In fact a recent PET study in 
PD patients found abnormally enhanced glutamatergic transmission in motor areas following L-dopa 
administration in dyskinetic patients (Ahmed et al., 2011). NMDA and dopamine receptors are 
expressed in close proximity along the dendrites of medium spiny neurons and mechanisms of 
interaction following D1 receptor activation such as protein kinase A dependent phosphorylation of 
NMDA subunits and increased expression of the NMDA receptor subunit 2B (NR2B) have been evident in 
dyskinesia (Leveque et al., 2000; Hurley et al., 2005; Hallett et al., 2006). NMDA receptors showing 
altered subunit composition form complexes with D1 receptors and these are trafficked abnormally 
between the postsynaptic membrane and intracellular compartments or extrasynaptic membrane sites 
in animals showing dyskinesia (Gardoni et al., 2006; Fiorentini et al., 2008). Furthermore NMDA receptor 
antagonists reduce dyskinesia in primate and rodent models of PD (Blanchet et al., 1999; Lundblad et al., 
2002; Nash & Brotchie, 2002; Morissette et al., 2006).  
Due to their gradual development, persistent character and apparent dependence on glutamate-
receptor mechanisms, dyskinesias that arise in PD patients treated with L-dopa have been compared to 
an aberrant form of motor learning and synaptic plasticity (Calabresi et al., 2000; Chase & Oh, 2000). 
Indeed there is a loss of ability for “depotentiation” in the 6OHDA rat model of PD seen only in animals 
expressing dyskinesia (Picconi et al., 2003; Belujon et al., 2010). Additionally, endocannibanoids, opioids, 
serotonin and noradrenaline are all proposed to influence abnormal synaptic transmission underlying 
dyskinesia (Brotchie, 2005). Considering its close link to glutamate and D1 receptor activity, nitric oxide 
is another candidate that has been advocated for involvement in aberrant synaptic plasticity 
mechanisms within the striatum (Calabresi et al., 1999; West & Grace, 2000; Sammut et al., 2006).  
Much of our knowledge concerning pathophysiology and also therapeutics for dyskinesia has been 
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achieved through investigations in animal models of PD (Bove et al., 2005; Lane & Dunnet 2008; Duty & 
Jenner 2011). 
  
1.3.3 Experimental animal models of PD and dyskinesia 
Ideally animal models of disease should demonstrate all the relevant pathology and symptoms present 
in humans, however this is rarely possible. Instead in modelling complex disorders such as PD it is 
important to employ a model which best displays the features associated with a particular line of 
investigation. The recent developments in genetics have led to the generation of transgenic and knock-
out mouse models expressing mutant proteins involved in familial PD (Goldberg et al., 2003; Wakamatsu 
et al., 2008). Whilst useful in studying aetiology they tend to be relatively poor at predicting responses 
to therapeutic agents (Fleming et al., 2005). The most extensively employed models to investigate 
dyskinesia in Parkinson’s disease are the toxin based 6-hydroxydopamine (6-OHDA)-lesioned rat and 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated primate which both reliably reproduce the 
common motor complications seen in man (Jenner, 2008a; Cenci & Ohlin, 2009). Indeed the combined 
use of rodent and primate models affords target identification and preclinical validation of therapeutic 
efficacy in PD (Bezard & Przedborski, 2011).  
 
1.3.3.1 The 6-OHDA-lesioned rat 
The neurotoxin 6-OHDA has become one of the most commonly used toxins for modelling PD in rodents 
since Ungerstedt first established a bilateral working model in 1968. This was later modified to a 
unilateral model owing to a high mortality rate where 6-OHDA had been administered into both sides of 
the brain (Ungerstedt & Arbuthnott, 1970). As the toxin does not efficiently cross the blood-brain barrier 
a direct injection into the brain is necessary. 6-OHDA principally exerts its effects on catecholaminergic 
pathways and its mechanism of action is related to combined effects of reactive oxygen species (ROS) 
and quinines (Przedborski & Ischiropoulos, 2005). The toxin is taken up by dopaminergic neurons via the 
DAT transporter and norepinephrine neurones by the NET transporter. Selective degeneration of 
dopaminergic neurons can be achieved by administration of the NET inhibitor, despiramine prior to 6-
OHDA treatment.  
By using different injection sites and doses of 6-OHDA varying extents of neurodegeneration can be 
reproduced according to the experimental paradigm from inspecting molecular events to modelling 
motor symptoms of PD (Simola et al., 2007). Lesions of the medial forebrain bundle (MFB) which 
projects dopaminergic neurones from the SNc to the striatum causes dopaminergic neurons to 
degenerate within the first 24 h and within 3–4 days almost complete striatal cell death is evident 
(Deumens et al., 2002; Bove et al., 2005). 
Pre-clinically, potential drug treatments for the reduction of dyskinesia are commonly tested in the 
unilateral 6-OHDA-lesioned rat primed to display abnormal involuntary movements (AIMs) by chronic 
dopaminergic therapy over several weeks (Cenci et al., 1998). The AIMs model is a useful behavioural 
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model of motor-abnormalities accompanying long-term dopaminergic medication in PD, with distinct 
advantage over the traditional rotational model, as the animals display abnormal movements which are 
both choreic (e.g. limb) and dystonic (e.g. axial) in nature (Marin et al., 2006; Cenci & Ohlin, 2009). In 
dopaminergic-treated 6-OHDA-lesioned rats there is some divergence on the interpretation of rotational 
behaviour, which is considered to mimic anti-parkinsonian activity and hence beneficial drug activity, 
versus the problematic phenomena of dyskinesia (Marin et al., 2006). Indeed, L-dopa induced rat AIMs 
functionally mimic the peak-dose dyskinesia seen in PD patients and are accompanied by molecular 
changes similar to those evident in primate models of PD displaying dyskinesia (Carta et al., 2006). 
Importantly drugs with proven anti-dyskinetic efficacy in the clinic (e.g. amantadine) also improve motor 
complications in the rat model (Lundblad et al., 2002).     
 
1.3.3.2 The MPTP-treated primate  
The inadvertent discovery of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) following human 
recreational drug use revolutionised pharmacological research of PD. ‘Synthetic heroin’ was injected by 
drug addicts in the 1980’s containing traces of the toxic meperidine metabolite MPTP, leading to the 
rapid onset of a marked and enduring parkinsonism (Langston et al., 1983). This incident paved the way 
for development of the MPTP-treated primate model of PD where formerly only electrolytic or 
radiofrequency lesioning of the basal ganglia had been used in this species (Poirier et al., 1975).  
MPTP readily crosses the blood-brain barrier where it is oxidised by MAOB within glial cells to 1-methyl-
4-phenylpyridinium (MPP+) (Smeyne & Jackson-Lewis, 2005) . MPP+ is selectively taken up by the 
dopamine uptake system where it inhibits complex 1 of the mitochondrial respiratory chain resulting in 
cytotoxic free radical formation (Nicklas et al., 1987; Singer et al., 1988) . Humans and non-human 
primates are particularly susceptible to MPTP-induced toxicity but rodents tend to be resistant to its 
effects with the exception of certain strains of mice. The lack of toxic effects in most rodent species may 
be attributed to the relatively rapid clearance of MPP+ (Johannessen et al., 1985). Systemic 
administration of MPTP over several days leads to an onset of the major motor symptoms of PD in 
primates including bradykinesia, rigidity and postural abnormalities, closely mimicking clinical aspects of 
the disease (Jenner et al., 1984; Crossman et al., 1987). The behavioiural symptoms have been 
characterised in primates including the cynamalogues (Macaca fascicularis), common marmosets 
(Callithrix jacchus) and  squirrel monkeys (Saimiri sciureus), although New World are favoured over Old 
World primates in PD research owing to handling, housing and ethical issues (Brotchie & Fox, 1999).  
Most neuropathological studies in primates have described highly selective damage to dopaminergic 
neurones of the substantia nigra accompanied by a 95-99 % depletion of dopamine in the caudate 
nucleus and putamen (Bloem et al., 1990). Thus it is a model of only selective nigrostriatal degeneration 
with little effect in other regions such as the VTA, although cell loss in the hypothalamus and the locus 
coeruleus have been reported (Crossman et al., 1985; Gibb et al., 1986). Other regions commonly 
affected in PD, including the raphe nuclei, substantia innominata, and dorsal motor nucleus of vagus 
appear undisturbed (Garvey et al., 1986). The loss of dopaminergic neurones is not progressive as in 
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humans and Lewy bodies do not manifest although accumulations of α-synuclein may occur (Kowall et 
al., 2000; Halliday et al., 2009).   
Dopaminergic drugs typically used for the treatment of PD including L-dopa and ropinirole are able to 
reverse the MPTP-induced motor symptoms seen in primates, and animals can be rated on motor 
disability scales based on clinical assessment (Pearce et al., 1998; Imbert et al., 2000). Furthermore the 
chronic administration of L-dopa or dopamine agonists reliably reproduces dyskinesia consisting of 
chorea, dystonia and athetosis and in addition to peak-dose dyskinesia both ‘end-of dose deterioration,’ 
the ‘on–off’ phenomena and rebound worsening have been reported also closely resembling the clinical 
scenario (Clarke et al., 1987; Pearce et al., 1995; Langston et al., 2000; Kuoppamaki et al., 2002). The 
MPTP-primate model has high predictive validity for translation of dopaminergic drugs treating PD into 
the clinic (Fox et al., 2006). All of the dopaminergic drugs used for treatment of PD have proven 
effective in the MPTP-model including apomorphine, bromocriptine, cabergoline, pergolide, 
pramipexole and ropinirole, in addition to antimuscarinic agents tested such as trihexyphenidyl (Close et 
al., 1990; Fukuzaki et al., 2000a; Jenner, 2003; 2008a). Similarily the anti-dyskinetic agent amantadine 
and alterations in dopaminergic dosing regimens have proved effective in reducing motor complications 
in the primate model akin to the human condition (Bedard et al., 1986; Blanchet et al., 1998a; Smith et 
al., 2005). 
 
1.3.4 Therapeutic options addressing dyskinesia 
Aside from adjustments made to dopaminergic medication in an attempt to slow down the induction of 
dyskinesia including the addition of COMT inhibitors and/or MAOB inhibitors to extend the duration of 
activity of L-Dopa (and thus reduce pulsatility), and  combining optimum dose of L-dopa and dopamine 
agonist for maximum antiparkinsonian effect with minimum dyskinesia (Rascol et al., 2002a; Pahwa et 
al., 2006), relatively few options are available in the later stages of PD.  Once dyskinesia manifests, some 
evidence suggests its expression tends to be lower with dopamine agonists as opposed to L-dopa, as 
demonstrated in PD patients and MPTP-treated primates (Kapoon et al., 1989; Facca & Sanchez-Ramos, 
1996; Hadj Tahar et al., 2000; Jackson et al., 2007). Others report that once dyskinesia has appeared it is 
equally evoked by L-dopa and dopamine agonists and switching to dopamine agonist treatment rarely 
works sustainably, and typically any reduction seen in dyskinesias is at the expense of less satisfactory 
control of parkinsonian symptoms (Encarnacion & Hauser, 2008; Stocchi et al., 2008).  
In severe cases, patients may be switched to high dose dopamine agonist monotherapy in an attempt to 
alleviate the dyskinesia but this approach is not tolerated by the majority of patients because of 
psychiatric side effects (Stocchi et al., 2008). Continuous subcutaneous infusion of apomorphine or 
enteral L-dopa infusions can also reduce dyskinesia intensity in some cases (Katzenschlager et al., 2005). 
In particular duodenal L-dopa infusion (Duodopa) can reduce dyskinesia especially in advanced PD 
patients, although practical implications can limit application (Antonini et al., 2007). Where medical 
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therapy does not provide sufficient relief surgical intervention is an option and pallidotomy, or deep 
brain stimulation of STN and GPi, may be highly effective (Delong & Wichmann, 2007). 
Of symptomatic therapy options, the non-competitive NMDA antagonist amantadine is the only 
effective medication available for reducing the severity of dyskinesia without worsening of parkinsonian 
symptoms (Snow et al., 2000; da Silva-Junior et al., 2005; Wolf et al., 2010). Interestingly the beneficial 
effect of amantadine lends further support to a fundamental role for glutamatergic pathways in 
dyskinesia. However there is limited tolerance of amantadine due to side-effects including psychosis and 
oedema, and there is some evidence showing only a small proportion of PD patients respond well and 
accompanying benefit may only last for several months (Crosby et al., 2003; Thomas et al., 2004). 
Given the association of increasing severity of dyskinesia with reductions in quality of life measures and 
significant health care costs it is desirable to find broadly effective medication to suppress if not prevent 
the occurrence of dyskinesias (Pechevis et al., 2005; Buck & Ferger, 2010). To this end many different 
agents have been proposed to date especially those centred upon non-dopaminergic pathways 
implicated in PD including serotonergic, adrenergic, cholinergic & peptidergic systems, as well as further 
glutamatergic drugs beyond amantadine, but few have proved satisfactory in the clinic (Stacy & 
Galbreath, 2008; Buck & Ferger, 2010). Neuronal nitric oxide synthase (nNOS) inhibitors, targeting the 
neurotransmitter nitric oxide, could provide a new angle for addressing unmet therapeutic need for 




1.4 NO, nNOS and nNOS inhibitors  
NO is a ubiquitous signalling molecule readily able to diffuse across cell membranes and involved in a 
wide range of biological responses from gene induction to immune stimulation and smooth muscle 
relaxation (Mayer & Hemmens, 1997; Patel et al., 1999). NO was initially described in 1987 as the 
’endothelial derived relaxation factor’ (Palmer et al., 1987), and much has been learnt about its 
physiological functions since then. NO acts as a neurotransmitter and/or neuromodulator in both central 
and peripheral nervous systems by cyclic guanosine monophosphate (cGMP)-dependent mechanisms 
(Garthwaite, 1991; Prast & Philippu, 2001). Of particular relevance here is its role in mediating excitatory 
glutamatergic neurotransmission in brain regions including the striatum, where the activation of NMDA 
receptors stimulates NO release (which in turn modulates glutamate discharge), (Garthwaite et al., 
1988; Trabace & Kendrick, 2000).  
 
1.4.1 Synthesis of NO 
Endogenous NO is not stored but generated on demand from L-arginine which is oxidised to L-citrulline 
in a calmodulin dependent reaction catalysed by nitric oxide synthase (NOS) enzymes (Marletta et al., 
1998) (see Figure 1-3). Three major NOS isoforms exist named according to the conditions in which they 
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Figure 1-2 The NOS pathway. For enzymatic activity, nitric oxide synthase (NOS) enzymes must 
dimerize and bind the cofactors tetrahydrobiopterin (BH4), haem, flavin mononucleotide (FMN) and 
flavin adenine dinucleotide (FAD). On binding calmodulin (CAL), the active enzyme catalyses the 
oxidation of L-arginine to citrulline and nitric oxide (NO) and requires molecular oxygen and NADPH as 
co-substrates. Each NOS dimer coordinates a single zinc (Zn) atom. (Adapted from Vallance & Leiper, 
2002). 
were first described; endothelial NOS (eNOS), inducible NOS (iNOS) and neuronal NOS (nNOS), (Alderton 
et al., 2001). Additionally mtNOS (mitochondrial NOS) has been recognised and is thought to be an 
isoform of nNOS with post-translational modifications present in the inner mitochondrial membrane 
(Elfering et al., 2002). eNOS and nNOS are constitutively expressed and calcium dependent, whereas 
iNOS is expressed in response to immunological or inflammatory stimulation and its activity does not 
depend on intracellular calcium levels. All the NOS enzymes share 50-60 % sequence homology (Lamas 
S., 1992), and require molecular oxygen and NADPH as co-substrates. Each NOS isoform possesses four 
prosthetic groups: flavin adenine dinucleotide (FAD) and flavin adenine mononucleotide (FMN) form the 
oxygen domain, whilst iron protoporphyrin IX (heme) and tetrahydrobiopterin (BH4) form the reductase 
domain (Alderton et al., 2001). NOS’s are functional only as dimers which it is believed activates the 
enzyme by sequestering iron, generating high-affinity binding sites for arginine and BH4 and allowing 
electron transfer from the reductase to the oxygenase domain (Vallance & Leiper, 2002). A zinc centre is 













Under normal physiological conditions iNOS is not expressed in healthy cells. Instead it is induced in 
response to various inflammatory stimuli such as tumour necrosis factor (TNF), interferon-gamma, or 
lipopolysaccharide (MacMicking et al., 1997). Although first identified in macrophages iNOS can be 
rapidly transcriptionally induced in multiple cell types including vascular endothelial and smooth muscle 
cells where it is functionally located to the cytosol composed of 130 kDa subunits (Stuehr et al., 1991; 
Charles et al., 1993). iNOS expression is important for host defence against certain protozoa, bacteria, 
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fungi & viruses as well as skin wound healing and healing of intestinal mucosa (Bogdan, 2001). Despite 
this favourable role, the large amounts of NO produced by iNOS can contribute to the tissue damage 
seen in a multitude of disorders such as autoimmune and inflammatory diseases (Vane et al., 1994). It 
has also been linked to the pathological cascade of events seen in neurodegenerative diseases including 
Alzheimer’s and indeed Parkinson’s disease (Knott et al., 2000; Heneka & Feinstein, 2001).   
 
1.4.1.2  eNOS  
eNOS is constitutively expressed in endothelial cells of the entire vasculature including vessels of the 
brain and heart (Wu, 2002). It is a 135 kDa protein and the only NOS subtype that is membrane-
associated (Lamas S., 1992). eNOS is localised to the caveolae which are microdomains of the 
plasmalemmal membrane that are implicated in a variety of cellular functions including signal 
transduction events (Garcia-Cardena et al., 1996). Several chemical signals in blood vessels activate 
eNOS including acetylcholine (acting via muscarinic M3 receptors), bradykinin, and vascular endothelial 
growth factor stimulating an increase in intracellular Ca2+ (Benarroch, 2011). Meanwhile shear stress 
elicits eNOS independent from Ca2+ changes. NO generation from the endothelium is important for 
maintenance of the vasculature in a relaxed state and inhibition of the adhesion of platelets and white 
blood cells, in addition to suppression of the replication of smooth-muscle cells (Napoli & Ignarro, 2001). 
The vasoprotective properties conferred by eNOS are confirmed by studies in animal models showing 
vasoconstriction, hypertension, enhanced platelet activation and increased atherogenesis following 
pharmacological NOS inhibition (Vallance & Leiper, 2002). 
 
1.4.1.3 nNOS 
nNOS is expressed in populations of developing and mature neurons, and to a lesser extent in some 
cerebral vessels and glial cells, and is predominantly located in the cytosol distributed in a patch-like 
form (Bredt et al., 1990; Salter et al., 1991). In the CNS nNOS is associated with neurotransmission, 
synaptic plasticity, neurogenesis, regulation of the sleep-wake cycle and body temperature in addition 
to neuroprotective and neurotoxic effects (Calabrese et al., 2007). High levels of nNOS are found in the 
mammalian cerebellum, olfactory bulb, striatum and hippocampus (Bredt et al., 1991; Egberongbe et 
al., 1994). Innervation of the basal ganglia involves nNOS; in the subthalamic nucleus (STN) more than 
95 % of neurons are NOS mRNA positive whilst in the striatum 1.5 to 2 % of neurons are NOS positive, 
although levels of expression per neuron are considerably higher in the striatum compared to the STN 
(Nisbet et al., 1994; Blum-Degen et al., 1999). 
Neuronal NOS of striatal medium aspiny interneurones colocalises with the peptidergic modulators 
somatostatin and neuropeptide Y in addition to the neurotransmitter GABA, and all nNOS interneurones 
co-express nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d), (Dawson et al., 1991; 
Kubota et al., 1993; Figueredo-Cardenas et al., 1996). nNOS has a PDZ (post-synaptic density protein, 
discs-large, ZO-1) domain through which it can interact with other proteins, and is thought to enable 
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linking of signal transduction pathways in multiple complexes (Chanrion et al., 2007).  Four splice 
variants of nNOS have recently been identied (nNOSb, nNOSg, nNOSm and nNOS-2) and these appear to 
exhibit distinct cellular and tissue localisation, although in the brain the full length 160 kDa nNOSα is 
predominant (Alderton et al., 2001). nNOS can be located either pre- or post-synaptically and is 
particularly implicated in neural signalling, neurotoxicity, synaptic plasticity and modulation of 
behavioural pathways such as learning or expression of pain (Esplugues, 2002). 
 
1.4.2 NO, the basal ganglia and synaptic plasticity 
In the CNS nitric oxide (NO) is released following stimulation of nNOS in response to NMDA receptor 
activation (Garthwaite et al., 1989). Within the striatum, dopamine plays an important modulatory role 
in association with glutamate in regulating long term-plasticity (LTP) and long-term depression (LTD), 
which are both activity-dependent forms of modified transmission efficacy occurring at synapses (West 
et al., 2002). These changes are able to alter neurotransmission efficacy within the basal ganglia (see 
Figure 1-5).  
Whilst most studies indicate that NO is derived from nNOS at striatal neurons, work involving mice 
lacking the eNOS gene suggests that NO released from the vasculature may also be capable of 
modulating corticostriatal transmission (Doreulee et al., 2003). The presence of NOS immunoreactivity 
in striatal axon terminals supports the hypothesis that NO can be released by synaptic terminals 
(Guevara-Guzman et al., 1994). There is also evidence for convergence of such inputs from the cortex 
and substantia nigra at individual spines of striatal medium spiny projection neurons in the rat (Smith & 
Bolam, 1990). This localisation may provide a specific site for the interaction of nigrostriatal 
dopaminergic input with input from the cerebral cortex, and NOS terminals synapsing with spines may 
allow for direct regulation of the activity of striatal spiny projection neurones in addition to cortical and 
thalamic inputs (Morello et al., 1997; Hidaka & Totterdell, 2001). 
 
Figure 1-3 Domain arrangement in rat nNOS (Stuehr, 1999). 
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Striatal nNOS interneurones receive asymmetric synapses from glutamatergic afferents and express 
NMDA in addition to AMPA and metabotropic glutamate receptors (Gracy & Pickel, 1997). NMDA 
receptors are a key element in facilitating synaptic plasticity changes in the central nervous system, and 
these glutamate-gated oligomeric ion channels are formed by co-assembly of members of three 
receptor subunit families; NMDA receptor I (NR1), NR2A-NR2D and NR3A-NR3B (Dingledine et al., 1999; 
Nishi et al., 2001). Activation of NMDA receptors causes an influx of calcium ions (Ca²+) through the 
receptor channel which is an absolute requirement for LTP/LTD induction (Collingridge et al., 2004). In 
turn this Ca²+ influx can stimulate the nNOS mediated synthesis of NO at the post-synaptic density 
provided the calcium ion concentration meets the 400nM required for calmodulin to bind to nNOS and 
hence activate the enzyme (Garthwaite et al., 1989; Knowles et al., 1989). Both nNOS and the NMDA 
receptor are bought into close proximity as they bind to the postsynaptic density protein PSD-95 so 
directly exposing nNOS to the Ca²+ (Tomita et al., 2001). Indeed the intrastriatal infusion of NMDA has 
Figure 1-4 Schematic diagram of convergent action of dopaminergic, glutamatergic and nNOS 
transmission on medium spiny striatal neurones. NO released from nNOS interneurones is capable of 
modulating striatal activity and triggering cGMP pathways linked to synaptic plasticity. The close 
proximity of the different neurones allows for multiple interactions of dopamine-glutamate for 
regulation of NO production. 
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been shown to activate NO efflux in vivo (Babu et al., 1998; Crespi & Rossetti, 2004). NMDA receptor 
antagonists also appear much more effective when injected intrastriatally than when given systemically 
or injected into other structures of the basal ganglia in a rodent model of PD (Marin et al., 1996). 
Subsequent production of NO can then influence cGMP levels via the activation of soluble guanylate 
cyclase (sGC) present in these cells (Boulton et al., 1995). sGC acts as an NO receptor and its expression 
and activity are higher in the striatum than any other brain region (Hofmann et al., 1977; Matsuoka et 
al., 1992).  
In the striatum, stimulation of the NO/cGMP pathway within corticostriatal fibres is capable of 
modulating processes such as LTD that has been linked to dyskinesia induction (Calabresi et al., 1999). It 
has recently been demonstrated that dopamine modulates striatal nNOS activity which becomes 
upregulated by activation of D1 receptors and down-regulated by D2 receptors dependent on ongoing 
NMDA receptor activity (Hoque et al., 2010). Dopamine- glutamate interactions involved in regulation of 
nNOS activity within the striatum are likely to be complex as the neurones converge both at the level of 
NOS interneurones in addition to the principle medium-sized spiny neurons (Morello et al., 1997; 
Sancesario et al., 2000; Hidaka & Totterdell, 2001). Physiological dopaminergic modulation of NO 
signalling appears critical for execution of normal motor behaviour and inhibitors of nNOS have caused 
adverse motor effects in rodents including the induction of catalepsy and interference with fine motor 
control (Del Bel et al., 2005).     
 
1.4.3 NOS Inhibitors 
The overproduction of NO is associated with a number of diseases hence the NOS pathway is a desirable 
target for the development of therapeutics. Consideration of NOS isoform selectivity is important to 
prevent undesirable side-effects and it is generally accepted that NOS inhibitors of medical value should 
avoid inhibition of eNOS owing to its critical role in maintaining vascular tone (Babu & Griffith, 1998a). 
For the purpose of this thesis inhibition of nNOS shall be focused upon from herein.  
Early NOS inhibitors were guanidino amino acids being analogues of L-arginine showing little isoform 
selectivity. Several of these analogues, such as N-propargyl-L-arginine and L-thiocitrulline, acted as 
classic competitive inhibitors at the NOS active site with a rapid onset, demonstrating no progress with 
time or covalent modifications of the enzyme and full reversibility by dilution or dialysis (Frey et al., 
1994; Fast et al., 1997). Mechanism-based inactivators were also developed similarly targeting the 
arginine binding site. N-methyl-L-arginine (L-NMA), was one such compound, binding with a tenfold 
higher affinity than L-arginine to the substrate site of NOS and slowly metabolised by active iNOS and 
nNOS resulting in irreversible inactivation of the enzyme (Feldman et al., 1993; Olken & Marletta, 1993). 
N-nitro-L-arginine (L-NNA) is the active NOS inhibitor formed by hydrolysis from the inactive prodrug N-
nitro-L-arginine methyl ester (L-NAME) and shows some selectivity towards nNOS and eNOS (Mayer & 
Andrew, 1998). Dissociation of the L-NNA-NOS complex is slow, so the drug is a highly potent tight-
binding inhibitor of both constitutive NOS isoforms. Substitution of the guanidine group of L-arginine 
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analogues with a short hydrocarbon chain conferred greater selectivity producing N-(1-imino-3-
butenyl)-L-ornithine (vinyl-L-NIO) which is a potent, mechanism based inhibitor that interacts with the 
heme cofactor of NOS and shows appreciable selectivity for nNOS (IC50 for nNOS = 0.1 μM, eNOS = 12 
μM and iNOS = 60 μM) (Babu & Griffith, 1998b). However this compound did not appear to penetrate 
the blood-brain barrier (BBB). 
Various heterocyclic modified L-arginine analogues have been shown to inhibit NOS including the 
nitroindazole group of fused heterocycles competitively interacting with the substrate binding site. 7-
nitroindazole (7-NI) carries a net electronegative charge and consequently binds reversibly to the heme 
prosthetic group of NOS, subsequently interfering with tetrahydrobiopterin binding to the enzyme and 
preventing NO formation (Moore & Handy, 1997; Mayer & Andrew, 1998). Although in vitro data show 
7-NI induces non-selective NOS inhibition (IC50 for nNOS = 8.3 μM, eNOS = 0.7 μM and iNOS = 57 μM), 
administration of 7-NI in vivo results in central nNOS inhibition without cardiovascular effects 
attributable to eNOS inhibition (Babbedge et al., 1993). Its in vivo selectivity for nNOS is suggested to 
result from the xanthine-oxidase-mediated catabolism of 7-NI by intact endothelial cells preventing 
interaction with eNOS (Handy & Moore, 1998). However there is some evidence advocating that 7-NI 
does affect eNOS activity in vivo (Zagvazdin, 1996). Nevertheless 7-NI has been used as an effective 
central NOS blocker in a wide range of experiments, including studies of renal function, learning and 
memory, nociception and neuroprotection against MPTP-induced toxicity (Moore et al., 1993a; 
Przedborski et al., 1996; Li et al., 2002; Wangensteen et al., 2006). 
Inhibitors lacking significant structural similarity to L-arginine but competitively binding to the same 
substrate site have also been developed, although they have often demonstrated poor cellular 
penetration (Paige & Jaffrey, 2007). The isothiourea derived ARR17477 (also referred to as ARL17477) 
based on a simple guanidine and amidine template showed potent and isoform selective nNOS 
inhibition both in vitro and in vivo (IC50 for nNOS = 0.035-0.07 μM, eNOS =1.6-3.5 μM and iNOS =0.33-5.0 
μM), rapidly penetrating the brain and resulting in long-lasting inhibition (Reif et al., 2000; Vallance & 
Leiper, 2002). ARR17477 has also proved effective in animal models of ischaemia (Zhang et al., 1996; 
O'Neill et al., 2000).  
Northwestern University and Neuraxon have both endeavoured to create novel nNOS- specific inhibitors 
with increased selectivity in recent years but progress has been hindered by sub-optimal penetration of 
the BBB on moving into in vivo models, a property which would be essential for addressing diseases 
affecting the CNS (Joubert & Malan, 2011). Northwestern University patented a series of aminopyridines 
showing potent nNOS inhibition (IC50 for nNOS = 28 - 103 nM) and selectivity over eNOS (96-156-fold) 
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1.4.4 NOS in PD and dyskinesia 
The inhibition of nNOS has shown promise for neuroprotection in Parkinson’s disease by counteracting 
the neurotoxic effects of excess NO at dopaminergic neurons (Hantraye et al., 1996; Castagnoli et al., 
1997; Singh & Dikshit, 2007). However, on starting this thesis, despite strong implications for the 
involvement of NO in PD, nNOS inhibitors had not been investigated towards therapeutic benefit for 
dyskinesia.   
In vivo post-mortem brain studies reveal a significant increase in nNOS mRNA expression in the dorsal 
two thirds of the subthalamic nucleus and the medial medullary lamina of the globus pallidus in patients 
with PD as compared to controls (Eve et al., 1998). Meanwhile there is a significant decrease in NOS 
expression in the putamen in Parkinson’s disease (Eve et al., 1998). These divergences support a role for 
changes in NO synthesis within the basal ganglia in PD. Additionally increased levels of nitrite and the 
NO second messenger cGMP have been found in the serum of PD patients (Qureshi et al., 1995; 
Chalimoniuk & Stepien, 2004). nNOS related susceptibility genes have also been identified in PD patients 
(Hancock et al., 2008). Although the direction of change within these investigations appears 
inconsistent, the data collectively suggest non-physiological levels of NO and related molecules to be 
present in PD.  
Further evidence from PD animal models substantiates these findings and striatal nNOS activity is seen 
to be significantly depressed following nigrostriatal deafferentation in the 6-OHDA lesioned rat (De et 
al., 2000; Sancesario et al., 2004). Indeed corticostriatal plasticity is lost after 6-OHDA-lesioning in rats 
and chronic L-dopa treatment can restore physiological synaptic transmission, but only for animals 
which do not develop AIMs suggesting enduring aberrant storage processes exist in dyskinetic animals 
(Picconi et al., 2003). A further study indicates that the inability to restore regular synaptic plasticity by 
L-dopa treatment is specific to medium spiny neurons of the direct striatonigral pathway (Belujon et al., 
2010). The same study also showed that in dyskinetic rats the regulation of synaptic plasticity in direct 
and indirect pathways is out of balance. Additionally L-dopa has been shown to cause a significant rise in 
the production of NO, as measured by NO3
-  levels, within the striatum (Itokawa et al., 2006). 
Furthermore, in our laboratories, chronic L-dopa treatment of 6-OHDA-lesioned rats resulted in 
increased expression of striatal nNOS mRNA on the lesioned side of the brain compared to drug naïve 
control 6-OHDA lesioned animals (Iravani et al., unpublished data). Indeed, glutamatergic overactivity at 
NMDA receptors may prompt these long-term synaptic changes within the striatum which 
inappropriately modulate motor function.  
Interaction between dopamine D1 and D2 receptors and NMDA receptors is involved in modulation of 
nNOS activity and the control of striatal plasticity (Hoque et al., 2010). These may occur via calcium–
calmodulin-dependent protein kinase II (CaMKII). This protein has been seen to function as a signal 
integrator downstream of dopamine and glutamate receptors at the post-synaptic density of striatal 
spiny neurons and appears to be hyperphosphorylated and accompanied by a higher recruitment of 
activated α-CaMKII to the regulatory NR2 NMDA receptor subunits in PD models (Picconi et al., 2004). 
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Abnormal NO and nNOS activity may therefore be characteristic of PD and dopaminergic treatment may 
subsequently ‘normalise’ levels except where dyskinesia develops the balance is upset once again and 
leads to further downstream molecular changes.   
In light of evidence for glutamatergic overactivity within the basal ganglia in dyskinesia coupled with the 
ability of glutamate to activate NMDA receptors, causing an influx of calcium ions and stimulation of 
nNOS mediated synthesis of NO at post-synaptic densities within the striatum linked to permanent 
changes in synaptic plasticity (see also section 1.4.2), a novel opportunity may be provided for the 
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1.5 Thesis hypothesis 
The identification of adjunctive agents which can effectively control the development of dyskinesia and 
the expression of established dyskinesia in PD without compromising the beneficial behavioural effects 
afforded by dopaminergic medication would be valuable in the clinic. The biochemical changes 
underlying dyskinesia are yet to be fully elucidated but there is strong evidence for the involvement of 
NO produced by nNOS suggesting that its reduction may alleviate or even prevent motor complications. 
Thus it is hypothesised that NO produced by nNOS contributes to the occurrence and evolution of 
dyskinesia in PD, and this can be controlled by nNOS inhibition.     
 
1.6 Thesis aims 
To test this hypothesis, the studies described in this thesis investigated the role of nNOS inhibitors as 
potential antidyskinetic agents in established in vivo models with the capacity to demonstrate abnormal 
involuntary movements akin to dyskinesia. 
More specifically the thesis aimed: 
1. To establish doses of nNOS inhibitor required to cause a significant reduction in central nNOS activity 
2. To investigate the role of nNOS in the expression of pre-existing dyskinesia in 6-OHDA-lesioned rats 
and MPTP-treated primates 
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2.1  Introduction 
The aim of the studies reported in this thesis was to investigate the potential for nNOS inhibitors to 
reduce dyskinesia using in vivo models of PD. For this purpose two well established animal models were 
employed; the 6-OHDA-lesioned rat and the MPTP-treated marmoset. Both of these models provide a 
functional basis for assessing motor changes associated with degeneration of dopaminergic pathways as 
seen in the human condition of PD. These models were specifically used to probe the processes of 
expression of dyskinesia in primed animals, and the development of dyskinesia in drug naïve animals, as 
well as in combination with nNOS inhibitors. The general methodologies utilised for these investigations 
are described below. 
 
 
2.2  The 6-OHDA rat model:   
2.2.1 Introduction 
The neurotoxin 6-OHDA has become one of the most commonly used toxins for modelling PD in rodents 
since Ungerstedt first established a working model in 1968. It principally exerts effects on 
catecholaminergic neurones and stereotaxic injection of 6-OHDA into the medial forebrain bundle (MFB) 
causes loss of dopaminergic neurones projecting from the SNpc to the striatum of up to 99 % on the 
lesioned side. The unilaterally 6-OHDA-lesioned rat shows minimal overt symptoms following recovery 
from surgery, however when challenged with agents affecting the dopaminergic system, such as 
amphetamine or apomorphine, a circling response is elicited. The direction and severity of the response 
is dependent upon the pharmacological mechanism of the drug and also the extent of the lesion 
(Schwarting & Huston, 1996; Deumens et al., 2002). Furthermore, following chronic administration of 
dopaminergic agents abnormal involuntary movements (AIM’s) tend to develop, provided the loss of 
nigrostriatal dopamine neurones exceeds 80 % (Cenci, 2007). These include axial, limb and oral 
movements all of which predominantly manifest on the body side contralateral to the lesion. As in the 
MPTP primate model (see later), 6-OHDA-lesioned rats respond to drugs shown to suppress dyskinesia 
in man, hence providing strong validation for the model (Lundblad et al., 2002). Thus the behavioural 
phenomena characteristic to drug exposure in 6-OHDA-lesioned rats afford an accessible testing bed for 
potential therapeutic interventions for PD.    
  
2.2.2 Animal husbandary 
Male Wistar rats (225-250 g; Harlan, UK or B & K, UK) were used in all procedures and housed 2-3 per 
cage in the Biological Service Unit, King’s College London. Room temperatures were maintained at      
19-21 ˚C at 55 % humidity with a 12 h light-dark cycle and animals had free access to pelleted food and 
water. Animals had a minimum five day acclimatisation period from arrival prior to any procedure. 
Experiments were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986 under 
Home Office project licence no. 70/6019 or 70/6898.      
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Figure 2-1 Co-ordinates used for microinjection of 6-OHDA into the MFB; as taken from The Rat 
Brain: In Stereotaxic Coordinates (Paxinos & Watson, 1986).  
2.2.3 6-OHDA lesion induction  
A unilateral injection of 6-OHDA hydrochloride was administered into the rat brain using standard 
stereotaxic techniques. Animals were initially anaesthetised by placing in an induction chamber with 
isofluorane 4-5 % in 95 % O2 and 5 % CO2 until observable loss of the ‘righting reflex’. They were then 
transferred into a Kopf stereotaxic frame and maintained under 2-3 % isofluorane in 95 % O2 and 5 % 
CO2, with ear bars inserted symmetrically and the incisor bar set to -3.3 mm in accordance with Paxinos 
& Watson (1986). A thermostatic heated blanket was placed under the animal to maintain a 
temperature of 37 ˚C throughout surgery. The rat’s head was shaved, sterilised with an alcohol swab, 
EMLA cream applied and a central anterior-posterior incision made with a disposable scalpel. The skull 
was exposed by retracting the skin and tissue, and a hole made into the skull with a hand-drill above the 
left MFB according to the coordinates of Paxinos and Watson (1986); A-P:-2.6 mm, M-L: +2.0 mm, as 
measured from bregma (see Figure 2-1). The 26S gauge needle of a Hamilton syringe was gently 
lowered to V:-8.8 mm and 6-OHDA hydrochloride (8 µg free base in 4 µl 0.9 % saline containing 0.05 % 
ascorbic acid) injected at a rate of 1 µl per minute using an automated micro-injection pump (Harvard 
Apparatus). The needle remained in place for a further 4 min before withdrawal over another 4 min 
period. Animals then received a 5 ml intraperitoneal (i.p.) injection of 5 % glucose in 0.9 % saline, the 
wound was cleaned with swabs and the skin sutured using three to four separate stitches of dissolvable 
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2.2.4 Post-operative care 
Rats were placed in a warmed incubation chamber to recover from anaesthesia before being returned 
to home cages. Post-surgery, softened rat food mixed with warm water was provided to encourage 
eating, and body weights were monitored until they returned to pre-operative levels or stabilised. 
 
 
2.3  The 6-OHDA rat model: Behavioural assessment  
2.3.1 Automated measurement of rotational activity 
The extent of 6-OHDA lesion was assessed at three-four weeks post-surgery. Following a 30 minute 
habituation period to rotometry arenas, animals were administered amphetamine sulphate (2.5 mg/kg 
i.p. in 0.9 % saline). Tracksys Video monitoring Software and Equipment was used to measure rotational 
movement of the rat by detection of the tip of the head, centre point and start of the tail (see Figure 
2-2) for a 3 h period. Ethovision software processed the readings to provide data for rotations per 
minute for individual animals. Rats exhibiting 7 ipsilateral turns per minute or more at peak activity, 
corresponding to a lesion of >50 % (Hefti et al., 1980), were taken forward for further experiments (see 













Figure 2-2 Tracksys video monitoring of rotational rat behaviour; animals (n=4) are automatically 
detected in arenas and highlighted (yellow) with tip of the head (turquoise), centre point (red) and tail 
join to body (purple) by the software.  
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2.3.2 Dyskinesia assessment 
2.3.2.1 Establishing dyskinesia 
Following amphetamine washout a group of 6-OHDA-lesioned rats, showing ≥7 RPMs upon rotational 
assessment, were dosed daily with L-dopa methyl ester (6.25 mg/kg + benserazide 15 mg/kg) for a 
period of 22 days to establish stable dyskinesia levels as measured by AIMs (for explanation of AIMs 
refer to 2.3.2.2).  Animals were scored for dyskinesia at baseline (day 0) and, from day 1 of dosing, on 
every third day as shown in Figure 2-4. Beyond the priming period animals were dosed twice weekly 
with L-dopa (6.25 mg/kg + benserazide 15 mg/kg) to ensure a persistent dyskinetic response until 
subsequent studies commenced.                   
Figure 2-3 Rotations per minute (RPM) typical data as measured by Tracksys rotometry software and 
equipment. Animals were treated with amphetamine sulphate 2.5 mg/kg i.p. and net  ipsilateral RPM’s 
meaned per 10 min for each rat. Data shown as individual RPM’s for each rat (n=4). Interquartile range 
was typically 5RPM. The dotted line indicates the threshold value for peak RPM’s used to select animals 
with a full MFB lesion. In this case rats 1, 2 & 4 were taken forward for AIM’s experiments.     
  
 




















* ** * ****** ***** ***** ***** *** ***
Figure 2-4 AIMs development during L-dopa priming of 6-OHDA-lesioned rats post rotational screening; 
animals (n=10) were treated with L-dopa methyl ester (6.25 mg/kg + benserazide 15 mg/kg) on a daily 
basis for 22 consecutive days and scored for locomotive, axial, limb and orolingual AIMs every third day; 
total AIMs score data (for a 3 h scoring period) are presented as medians for each behavioural test day 
and interquartile ranges of these parameters were typically 10 AIMs units; ***p<0.001, **p<0.01, 
*p<0.05 compared to Day 0 baseline score for each AIMs subtype (colours used refer to key); Friedman’s 
test followed by post hoc Dunn’s test.(Data taken from Chapter 4).  
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2.3.2.2  AIMs scoring 
All AIMs experiments were carried out between the hours of 8.30 am and 4.00 pm. Rats were placed 
individually into transparent rectangular cages, measuring 20 cm x 36 cm x 18 cm (See Figure 2-5), one 
hour before drug administration to acclimatise. Baseline scores were taken 20 min and 5 min prior to 
dosing. Following drug treatment AIMs were then scored over a duration of 5 min every 15 min for up to 
210 min. Scoring was carried out by a trained observer blinded to treatment. Blinding was achieved by 
coding drug solutions prior to dosing, and administering these according to a modified latin square 








   
To assess dyskinesia in rats four different subtypes of AIMs were scored according to anatomical origin 
of the involuntary movement, and each rated on a scale of 0-4 (See Table 2-1 and Table 2-2). The 
scoring system was based on that devised by Cenci and colleagues (Cenci et al., 1998; Winkler et al., 
2002; Dekundy et al., 2007) with minor modifications. Locomotive, axial, limb and orolingual AIMs (as 
exemplified in Figure 2-6) were assessed by observing the rats’ behaviours in transparent cages 
positioned as in Figure 2-5, in real-time. As a general rule each form of dyskinesia was rated as absent 
(score 0), mild (score 1), moderate (score 2), marked (score 3) or severe (score 4), as described in Table 
2-2. In order to increase the sensitivity of the rating scale incremental scores of 0.5 were also employed 
between 0-4 where applicable. Individual scores for axial, limb and orolingual AIMs sub-types were 
summed together for each assessment period to give an overall dyskinesia level, denoted as ‘ALO AIMs’ 
(axial + limb + orolingual score). Exhibition of these three sub-types in particular are considered to best 
mimic dyskinesia according to published literature (Dekundy et al., 2007). ALO AIMs were regarded as 
absent (score = 0), mild (1-3), moderate (4-6), marked (7-9) or severe (10-12).  Meanwhile locomotive 
scores were considered separately as is commonplace in the literature due to controversy as to whether 
locomotor behaviour truly represents dyskinesia (Lundblad et al., 2002). The duration of ALO AIMs and 
AIM’s subtypes calculated for locomotive, axial and limb AIMs took into account all score periods 
gaining above 0 and in the case of orolingual AIMs included those gaining above 1 (due to animals 
Figure 2-5 Transparent cages set up for measuring AIMs in 6-OHDA lesioned rats; mirrors are placed 
behind cages to increase visibility of rat behaviour as animals move about. 
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frequently showing mild orolingual AIMs during baseline assessments i.e. ~0-1). A mean of the two 
baseline scores was taken on each assessment day to give a single baseline score at t=0.  
Table 2-1 AIMs classification 
AIM’s subtype Description 
Locomotive Rotations contralateral to lesion 
Axial Dystonic or choreic torsion with lateral deviation of the head, neck and/or trunk 
towards the side contralateral to the lesion 
Limb Jerky and/or dystonic movements of the forelimb contralateral to the lesion 
Orolingual Empty jaw movements, facial muscle twitching and/or tongue protrusion, more 











Figure 2-6 The four subtypes of AIMs as typically displayed by 6-OHDA- lesioned rats on dopaminergic 
drug treatment; locomotive (a), axial (b), orolingual (c) and limb (d), (Winkler et al., 2002).  
 
 
48                                                                                   
            
 Chapter 2 







 0 Absent 
 1 Occasional (<50 % of observation time) 
 2 Frequent (>50 % of observation time) 
 3 Continuous but interruptible by external stimuli 
 4 Continuous and not interruptible by external stimuli 
   
Axial 
 0 Absent 
 0.5 Brief periods of lateral deviation of head and neck at ~ 30 ˚ angle 
 1 Consistent lateral deviation of head and neck at ~ 30 ˚ angle 
 1.5 Consistent lateral deviation of head and neck at ~ 30 ˚ angle with brief periods of 
deviation of head and neck at 30 ˚<angle≤60 ˚ angle 
 2 Contralateral deviation of head and neck at 30 ˚<angle≤60 ˚ angle 
 2.5 Contralateral deviation of head and neck at 30 ˚<angle≤60 ˚ angle with brief 
periods of deviation of head, neck and upper trunk at 60 ˚<angle≤90 ˚ angle 
 3 Contralateral deviation of head, neck and upper trunk at 60 ˚<angle≤90 ˚ angle 
 3.5 Contralateral deviation of head, neck and upper trunk at >90 ˚ angle with some loss 
of balance 
 4 Torsion of head, neck and trunk at >90 ˚ angle with persistent loss of balance 
   
Limb 
 0 Absent 
 0.5 Brief and fleeting small paw movements around a fixed position 
 1 Small paw movements around a fixed position 
 1.5 Small paw movements with occasional low amplitude translocation of limb 
 2 Low amplitude paw movements with translocation of distal limb 
 2.5 Low amplitude paw movements with translocation of proximal and distal limb 
 3 Translocation of whole limb with contraction of shoulder muscles 
 3.5 Translocation of whole limb with some contraction of shoulder muscles at high 
frequency or maximal amplitude  
 4 Vigorous limb and shoulder movement of high frequency and maximal amplitude 
   
Orolingual 
 0 Absent 
 0.5 Occasional (<25 % of observation time)  
 1 Occasional (<50 % of observation time)  
 1.5 Occasional (present 50 % of observation time) 
 2 Frequent (>50 % of observation time) 
 2.5 Frequent (>75 % of observation time)  
 3 Continuous but interruptible by external stimuli 
 3.5 Continuous but sometimes interruptible by external stimuli 
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2.3.2.3 Characterisation of the AIM’s model 
Introduction. In combination with L-dopa, amantadine (a weak NMDA antagonist), 8-Hydroxy-2-
(dipropylamino)tetralin (8-OHDPAT; a 5-HT1A agonist), and MK-801 (a non-competitive NMDA 
antagonist) have all been shown to reduce AIMs according to published literature (Dekundy et al., 2007; 
Dupre et al., 2008). For characterisation of the AIM’s model, as established by Cenci et al. (1998), these 
three compounds were tested with L-dopa in cross-over studies in dyskinesia primed 6-OHDA-lesioned 
rats (n=7-8).  
Method. Primed 6-OHDA-lesioned rats (as described in 2.3.2.1) were scored for AIMs in transparent 
cages (as described in section 2.3.2.2). After baseline scores were taken, they were then treated with 
both L-dopa methyl-ester (6.25 mg/kg + benserazide 15 mg/kg i.p.) and also either saline (0.9 % i.p.), 
amantadine hydrochloride (20 or 40 mg/kg i.p.), MK-801 (0.4 mg/kg i.p.), or 8-OHDPAT (0.6  mg/kg i.p.). 
Doses of amantadine, MK-801 and 8-OHDPAT utilised were chosen based on referenced literature in 
combination with previous findings from our lab. All compounds were dissolved in saline (0.9 %). Graphs 
showing time courses and totals were plotted as medians (n=7-8). Total AIMs scores were calculated 
from the time courses by AUC (Graphpad Prism version 5.0) using the trapezoid method where each 
successive 15 min was labelled as a single time-bin. Data were analysed by Friedman’s test followed by 
post hoc Dunn’s test. See Figure 2-7, Figure 2-8, Figure 2-9 & Figure 2-10.  
Results. L-dopa (6.25 mg/kg + benserazide 15 mg/kg) plus vehicle caused animals to exhibit axial AIMs 
from 15-180 min after dosing peaking at a score of 3.5 from 60-120 min. Limb and orolingual AIMs were 
seen from 15 min onwards for up to 180 min both peaking at a score of 2. ALO AIMs reflected these 
behaviours with summed AIMs scores increasing above baseline levels from 15 min up until 180 min, 
these peaked with an ALO AIMs score of 7 at 90 min. Meanwhile, locomotive AIMs lasted until 165 min 
but were less intense than the other three AIMs subcategories with a peak score of 1.5.  
Amantadine 20 mg/kg had no significant effect on any of the four AIM’s subtypes exhibited by L-dopa 
(6.25 mg/kg). However amantadine 40 mg/kg caused a significant reduction in axial and locomotive 
AIMs and a slight reduction in orolingual AIMs at 60-150 min after drug dosing. Amantadine caused a 
stable and long lasting reduction (from 15-180 min), in L-dopa induced ALO AIMs with significant effects 
seen at the highest dose of 40 mg/kg.  
MK-801 0.4 mg/kg reduced all four AIM’s subtypes, compared to L-dopa plus vehicle effects, for the 
majority of the 3 h scoring period indeed inducing axial and locomotive AIMs on the ipsilateral body side 
(denoted by the negative scores). Considering total AIM’s, MK-801 reduced ALO AIMs on the 
contralateral side at all time points following dosing.  
8-OHDPAT 0.6 mg/kg markedly reduced all AIM’s subtypes relative to L-dopa plus vehicle effects, 
causing axial and locomotive AIMs to be ipsilateral to the lesioned side within the first 60 min after drug 
treatment. Orolingual, ALO AIMS and locomotive AIMs were significantly reduced by 8-OHDPAT (0.6 
mg/kg) compared to L-dopa plus vehicle treatment across the observation period.   
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Conclusion. These results are in agreement with the reductions in L-dopa induced dyskinesia 
demonstrated in the AIMs model with amantadine, MK-801 and 8-OHDPAT as cited in the literature. 
Strictly speaking locomotive AIMs are not considered to be specific to dyskinesia per se (e.g. Lundblad et 
al., 2002), therefore more focus will be placed on ALO AIMs for the purpose of this thesis for which 
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Figure 2-7 Amantadine AIMs characterisation axial, limb, orolingual and ALO data following L-dopa 
(LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) plus vehicle or amantadine 20 and 40 mg/kg i.p. 
treatment. Data are presented as medians (n=8); Time-course of AIMs (a) axial, (b) limb, (c) orolingual 
and (d) ALO, and also individual values; Total AIMs (a’) axial, (b’) limb, (c’) orolingual and (d’) ALO; 
*p<0.05, ***p<0.001, compared to L-dopa plus vehicle treatment; Friedman’s test followed by post hoc 
Dunn’s test.  
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Figure 2-8 Amantadine AIMs characterisation locomotive data following L-dopa (LD; 6.25 mg/kg plus 
benserazide 15 mg/kg i.p.) plus vehicle or amantadine 20 and 40 mg/kg i.p. treatment. Data are 
presented as medians (n=8); (a) Time-course of AIMs, and also individual values; (a’) Total AIMs; 
*p<0.05, compared to L-dopa plus vehicle treatment; Friedman’s test followed by post hoc Dunn’s test.  
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Figure 2-9 MK-801 and 8-OHDPAT AIMs characterisation axial, limb, orolingual and ALO data 
following L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) plus vehicle, MK-801 0.4 mg/kg i.p. or 
8-OHDPAT 0.6 mg/kg i.p. treatment. Data are presented as medians (n=7); Time-course of AIMs (a) 
axial, (b) limb, (c) orolingual and (d) ALO and also individual values; Total AIMs; (a’) axial, (b’) limb, (c’) 
orolingual and (d’) ALO; *p<0.05, **p<0.01, ***p<0.001, compared to L-dopa plus vehicle treatment; 
Friedman’s test followed by post hoc Dunn’s test.  
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Figure 2-10 MK-801 and 8-OHDPAT AIMs characterisation locomotive data following L-dopa (LD; 
6.25 mg/kg plus benserazide 15 mg/kg i.p.) plus vehicle, MK-801 0.4 mg/kg i.p.  or 8-OHDPAT 0.6 
mg/kg i.p. treatment. Data are presented as medians (n=7); (a) Time-course of AIMs, and also 
individual values; (a’) Total AIMs; *p<0.05, ***p<0.001, compared to L-dopa plus vehicle treatment; 
Friedman’s test followed by post hoc Dunn’s test.  
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2.3.2.4 Establishing L-dopa and ropinirole doses for AIMs studies 
Introduction Both L-dopa and dopamine agonists such as ropinirole can lead to dyskinesia expression 
after long-term use. To investigate the potential effects of nNOS inhibitors on resulting dyskinetic 
behaviour it was necessary to determine the optimal doses of dopaminergic agents to be used in AIMs 
investigations.  
Method A group of primed 6-OHDA-lesioned rats (n=7-8) exhibiting stable AIMs (as described in 2.3.2.1), 
was administered a range of doses of L-dopa or ropinirole to provide a dose-response curve for both 
drugs. A cross-over study with a modified latin-square design was employed for each dopaminergic drug 
including a minimum 2 day drug washout between doses. Animals were treated with L-dopa methyl-
ester (+ benserazide 15 mg/kg i.p.) (3.125, 6.25, 9.375, or 12.5 mg/kg i.p.), or saline (0.9 %) at 1ml/kg 
and scored for AIMs in transparent cages as described in section 2.3.2.2.  Subsequently animals were 
treated with ropinirole (0.1, 0.2, 0.3, 0.4, or 0.5 mg/kg i.p.), or saline (0.9 %) at 1 ml/kg and AIMs were 
assessed as for the L-dopa treatments.  As for characterisation of the AIM’s model ALO AIM’s time-
course graphs, and totals, represented by area-under-the-curve (AUC), were plotted as medians (n=8).  
Data were analysed by Friedman’s test followed by post hoc Dunn’s test.  
Results As seen in Figure 2-11, L-dopa (+ benserazide 15 mg/kg i.p.) at all doses (3.125, 6.25, 9.375 and 
12.5 mg/kg) caused animals to exhibit dyskinesia as measured by ALO AIMs from 15 min onwards. ALO 
AIMS lasted up to 135 min for the lowest L-dopa dose (3.125 mg/kg) and up to 180 min for the highest 
doses (9.375 and 12.5 mg/kg). Scores peaked at 30-60 min after dosing reaching a maximum of 7-8 for 
all doses and remaining at these levels over a dose-dependent time frame increasing in duration with 
escalating dose. Locomotive AIMs were exhibited from 15-30 min onwards lasting for a time period 
which increased dose-dependently, and all doses resulted in a peak score of 1.5 except for the highest 
dose which peaked similarly at 2.  In comparison, vehicle treatment induced minimal ALO AIMs at 
intermittent time periods lasting for no longer than two consecutive scoring sessions and peaking at a 
total score of 1, and locomotive AIMs  were not seen throughout the assessment period. Only L-dopa 
doses of 6.25, 9.375 and 12.5 mg/kg resulted in significant behavioural manifestation of ALO and 
locomotive AIMs compared to vehicle treatment.  
As seen in Figure 2-12 all ropinirole doses (0.1, 0.2, 0.3, 0.4 and 0.5 mg/kg) induced an increase in ALO 
AIMs as compared to vehicle treatment manifesting at the 15 min score period and lasting up until 75 
min after drug treatment for the lowest ropinirole dose (0.1 mg/kg) and until 145 min for the highest 
dose (0.5 mg/kg). ALO AIMs reached a peak after 15-30 min and duration of effect ranged from between 
90-150 min. All doses from 0.2 mg/kg upwards resulted in peak ALO AIMs scoring 6-7, whilst at 0.1 
mg/kg a peak score of 4 was exhibited. Meanwhile locomotive AIMs peaked at a score of 1-2 for all 
ropinirole doses and at 0.4 mg/kg lasted for a maximum period of 60 min. Compared to vehicle only 
treated animals, ropinirole doses from 0.2-0.5 mg/kg caused significant ALO AIMs and 0.4-0.5 mg/kg 
caused significant locomotive AIMs. Vehicle treatment did not appear to induce ALO or locomotive AIMs 
overall. 
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Conclusion Both L-dopa and ropinirole administration induce AIMs in 6-OHDA-lesioned primed rats over 
a time-course which lengthens with escalating dose. Peak AIMs scores show less dependence on dose. 
Compared to L-dopa, ropinirole is seen to be shorter acting with a smaller window of dyskinesia. L-dopa 
6.25 mg/kg and ropinirole 0.2 mg/kg were selected for further investigations based on these data and in 
keeping with doses employed in the literature (Cenci et al., 1998; Ravenscroft et al., 2004; Marin et al., 




Figure 2-11 L-dopa dose-response ALO and locomotive AIMs data following L-dopa (LD) 3.125, 6.25, 
9.375, or 12.5 mg/kg (plus benserazide 15 mg/kg i.p.) treatment. Data are presented as medians (n=8); 
Time-course of AIMs (a) ALO  (b) locomotive, and also individual values; Total AIMs (a’) ALO and (b’) 
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Figure 2-12 Ropinirole dose-response ALO and locomotive AIMs data following ropinirole (Rop) 0.1, 
0.2, 0.3, 0.4 or 0.5 mg/kg i.p. treatment. Data are presented as medians (n=7); Time-course of AIMs (a) 
ALO  and (b) locomotive, and also individual values; Total AIMs (a’) ALO and (b’) locomotive; 
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2.4  The MPTP-treated primate model:   
2.4.1 Introduction 
MPTP is a neurotoxin serendipitously found to cause a form of parkinsonism in humans indistinguishable 
in appearance from idiopathic PD (Langston et al., 1983). Administration of MPTP to non-human 
primates induces a syndrome of parkinsonism closely resembling the human form. MPTP induces 
selective nigral dopaminergic cell loss via action of the metabolite 1-methyl-4-phenylpyridinium on 
mitochondria thus impairing energy production (Singer et al., 1988). Dopaminergic agents commonly 
used in PD patients, including L-dopa and dopamine agonists, are able to reverse symptoms of motor 
disability seen in MPTP-treated primates. Priming of these animals with dopaminergic drugs leads to the 
characteristic display of dyskinesia with chorea and dystonia manifesting in a time-dependent manner 
(Pearce et al., 1995). These uncontrollable motor movements are not disimilar to those seen in PD 
patients, indeed dyskinesia in primates is commonly assessed using scoring criteria with only minor 
modification from clinical ratings (Pearce et al., 1995; Langston et al., 2000). The model provides a very 
valuable measure for preclinical investigations, especially for translation of beneficial anti-dyskinetic 
agents into the clinic.    
 
2.4.2  Animal husbandary 
Adult common marmosets (callithrax jacchus) of either sex (n=15; 9 female and 6 male; weight 320 to 
450 g; University of Manchester/Harlan UK) were used in this study. Animals were housed singly or in 
pairs at a temperature of 25±1 °C with 50 % relative humidity on a 12 h light/dark cycle. All animals were 
fed fresh fruit once daily and had ad libitum access to Mazuri food pellets (Mazuri Primate Diet, Special 
Diet Services Ltd., UK) and water. All animals were drug naïve prior to commencing this study. All 
experiments were carried out in accordance with Home Office regulations under the Animals (Scientific 
Procedures) Act 1986 and project license number 70/6345.   
 
2.4.3 MPTP-lesion induction 
Following an acclimatisation period of a minimum of 8 weeks marmosets were treated with 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP-HCL; 2.0 mg/kg, in sterile saline 0.9 %, s.c.) 
(Sigma, UK/ Research Biochemicals International) daily for 5 consecutive days.   
 
2.4.4 Post-MPTP care 
For 10-16 weeks animals were hand-fed once-twice daily on a high protein/carbohydrate liquid diet 
(Marmoset jelly, Special Diet Services Ltd., UK and Complan, Complan Foods Ltd., UK) until they were 
able to feed independently and body weight had stabilised. Approximately 2 weeks after the end of 
treatment some animals developed a hyper-activity syndrome and home cages were padded with soft 
bedding materials to reduce risk of injury. Animals were monitored closely at all times to ensure 
recovery from the acute effects of the toxin and stabilisation of motor deficits.  
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2.4.5 Behavioural effects of MPTP administration 
Within one week following the initiation of MPTP treatment animals developed symptoms akin to 
Parkinson’s disease including bradykinesia, akinesia, rigidity and hypophonia. These were accompanied 
by a prominent loss of vocalisation, diminished blinking, incoordination and action tremor. A period of 
aphagia and adipsia lasting approximately 4 weeks also occurred. Gradual recovery followed and 
behavioural assessment indicated all animals had similar levels of motor deficits. The MPTP-treatment 
regimen, as described in section 2.4.3, routinely leads to a syndrome where behavioural deficiencies 
remain stable over several years (Jenner et al., 1984).   
 
2.5  The MPTP-treated primate model: Behavioural assessment 
All animals were formally monitored for locomotor activity, motor disability and dyskinesia in specially 
designed aluminium test units (50 x 60 x 70 cm) with perspex doors (50 x 70 cm). All primate 
behavioural assessments were carried out between the hours of 7.00 am and 4.00 pm Animals were 
placed in individual test units and initially acclimatised for a 1 h period prior to drug treatment, and at 
50-60 min a baseline score was taken. In addition to the three measurements outlined below general 
observational comments on the animal’s behaviours were also recorded.  
 
2.5.1 Priming for dyskinesia 
Following recovery from the acute effects of MPTP a group of MPTP-treated primates (n=6) were 
treated daily with L-dopa methyl ester (12.5 mg/kg + carbidopa 12.5 mg/kg p.o.) for a period of 8 weeks, 
to establish stable dyskinesia levels as measured by behavioural rating scales.  Animals were scored for 
dyskinesia (as shown in Figure 2-13) and motor disability, and locomotor activity data assessed, at 
baseline (day 0) and once-twice weekly thereon (see sections 2.5.2 - 2.5.4). Beyond the priming period 
animals were dosed weekly with L-dopa (12.5 mg/kg + carbidopa 12.5 mg/kg p.o.) to ensure a persistent 
dyskinetic response until subsequent studies commenced.     
 





Figure 2-13 Dyskinesia development during L-dopa priming of MPTP-treated marmosets; animals (n=5) 
were treated with L-dopa methyl ester (12.5 mg/kg + carbidopa 12.5 mg/kg p.o.) on a daily basis for 8 
weeks and scored for dyskinesia once-twice per week; total dyskinesia (for a 4 h scoring period) is 
presented as medians for each week and interquartile ranges were typically 6 dyskinesia units. ++p<0.01 
for time; data were analysed by Friedman’s test. (Data taken from Chapter 5). 
 
60                                                                                   
            
 Chapter 2 
2.5.2 Locomotor activity measurement 
Test units were fitted with eight horizontally orientated infrared beams so as to detect movement of the 
marmosets. Three beams were localised to the cage floor, two along the perches (one per perch), one 
centrally on the front door and a further two directed perpendicular to each of the perches. Beam 
interruptions were relayed to computer software (DASYLab data acquisition system, laboratory version 
11) throughout the test period and accumulated in 1, 10, and 30 min intervals. Data were set to 
download directly into an excel file for analysis.  
 
2.5.3  Motor disability assessment 
Motor disability was scored simultaneously to locomotor activity measurement through a one-way 
mirror during the last 10 min of consecutive 30 min time intervals. Initial baseline scores were made at 
50-60 min after animals had been placed into the test units, at the end of the acclimatisation period. 
Scoring continued for a maximum 7 h period in total.  Scores were based on the established motor 
disability rating scale (Pearce et al., 1995), as detailed in Table 2-3, and the score for each period was 
taken as a total of the sub-scores ascribed to each of the individual criterion. A maximum motor 
disability score of 18 was possible, indicating a severely disabled marmoset. Typically an MPTP-treated 
marmoset will have a motor disability score of 10-14 for each assessment period without drug 
treatment. Meanwhile, naïve marmosets rarely score beyond 2 for motor disability.  
Table 2-3 Motor disability scoring classification 
Assessment criteria Score 
Alertness 0=normal, 1=reduced, 2=sleepy 
Checking movements 0=present, 1=reduced, 2 =absent 
Posture 0=normal, +1=abnormal trunk, +1=abnormal limbs, +1=abnormal tail, 
4=grossly abnormal   
Balance 0=normal, 1=impaired, 2=unstable, 3=spontaneous falling 
Reactions 0=normal, 1=reduced, 2=slow, 3= absent 
Vocalisation 0=normal, 1=reduced, 2=absent 
Motility 0=normal, 1=bradykinesia, 2=akinesia 
 
2.5.4 Dyskinesia assessment 
Dyskinesia was rated at the same time as motor disability using an established dyskinesia rating scale 
(Pearce et al., 1995) as summarised below (see Table 2-4). Chorea is characterised by rapid, dance-like 
movements predominantly of the limbs, and dystonia manifests as abnormal sustained posturing. Total 
dyskinesia takes into account both of these parameters. The score recorded for dystonia, chorea and 
also total dyskinesia is reflective of the quality and quantity of dyskinetic activity over the full 10 min 
observation period. Score increments of 0.5 were used where behaviour exhibited fell between 
assessment criteria. 
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Table 2-4 Dyskinesia scoring classification 
Assessment criteria Score 
Absent 0 
Mild fleeting and rare dyskinetic postures and movements 1 
Moderate; more prominent abnormal movements but not significantly affecting 
normal behaviour 
2 
Marked; frequent and at times continuous dyskinesia affecting normal repertory 
of behaviour 
3 




2.5.5 Establishing doses for L-Dopa and ropinirole  
Introduction As for 6-OHDA-lesioned rats both L-dopa and dopamine agonists such as ropinirole lead to 
dyskinesia expression in MPTP-treated marmosets after long-term use. To investigate the potential 
effects of nNOS inhibitors on resulting dyskinetic behaviour it was necessary to determine the optimal 
doses of dopaminergic agents to be used in subsequent marmoset investigations.  
Method A group of primed MPTP-treated marmosets (n=6) exhibiting stable dyskinesia (as described in 
section 2.5.1) was administered a range of doses of L-dopa methyl-ester or ropinirole to provide a dose-
response curve for both drugs. A cross-over study with a modified latin-square design was employed 
including a minimum 2-day drug washout between challenges. Initially animals were treated with L-dopa 
methyl-ester (+ carbidopa 12.5 mg/kg) (3.125, 6.25, 9.375, 12.5 or 25.0 mg/kg p.o.) or sucrose (10 %, 
p.o.) at 2 ml/kg and assessed for locomotor activity, motor disability and dyskinesia in test units 
(described in section 2.5.2 - 2.5.4). In the next set of experiments animals were treated with ropinirole 
(+ domperidone 2 mg/kg) (0.1, 0.2, 0.3 or 0.4 mg/kg p.o.) or sucrose (10 %, p.o.) at 2 ml/kg and assessed 
as before. Behavioural time-course graphs and totals, calculated from the time courses by AUC 
(Graphpad Prism version 5.0) using the trapezoid method where each successive 30 min was labelled as 
a single time-bin, were plotted as medians (n=6).  All total counts/score data were analysed by 
Friedman’s test followed by post hoc Dunn’s test. 
 Results As shown in Figure 2-14 all doses of L-dopa administered to MPTP-treated marmosets increased 
locomotor activity with peak effects at approximately 90 min and gradually returning towards baseline 
levels thereafter in a dose-dependent manner.  Locomotor activity increased in a dose-dependent 
manner as the L-dopa dose was increased up to 12.5 mg/kg above which there was a slight reduction in 
counts following L-dopa 25 mg/kg. The total locomotor activity was significantly increased compared to 
vehicle following L-dopa 12.5 and 25 mg/kg. L-dopa reversed motor disability in a dose-dependent 
manner peaking at 60 min after L-dopa administration. L-dopa increased motor disability reversal in 
terms of both severity and duration, as compared to vehicle treatment, although this effect did not 
reach statistical significance. Dyskinesia was only expressed at L-dopa doses of 6.25 mg/kg and above, 
with severity and duration increasing dose-dependently, reaching a peak at 60-90 min and stabilising for 
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30-60 min more and/or gradually returning towards baseline levels. Total dyskinesia increased with 
increasing L-dopa dose plateauing at 12.5 mg/kg. Both L-dopa doses of 12.5 and 25 mg/kg caused a 
significant increase in dyskinesia compared with vehicle treated animals.   
As shown in Figure 2-15 all ropinirole doses increased locomotor activity which peaked at 90-120 min 
after treatment, gradually returning to baseline levels by a maximum of 360 min in a dose-dependent 
time-frame. A significant increase in total locomotor activity was observed for ropinirole 0.2-0.4 mg/kg 
compared to vehicle treatment. The reversal of motor disability reached maximal levels by 60 min for 
ropinirole 0.2-0.4 mg/kg and 120 min for 0.1 mg/kg with a duration of effect increasing with dose. Total 
motor disability reversal was significantly increased at ropinirole doses of 0.2-0.4 mg/kg compared to 
vehicle. Animals expressed dyskinesia at all ropinirole doses peaking between 30-90 min after treatment 
and returning to baseline levels by 240 min. Peak dyskinesia scores also increased as a function of the 
ropinirole dose administered plateauing at 0.3 mg/kg. Ropinirole doses of 0.2-0.4 mg/kg resulted in 
significant levels of dyskinesia expression as compared to vehicle treatment. 
Conclusion In primed MPTP-treated marmosets both L-dopa and ropinirole cause dyskinetic behaviour 
with a severity and time-course which increases with escalating dose. Compared to L-dopa, ropinirole 
appears to be longer acting although both drugs result in similar levels of dyskinesia at the doses 
employed.  L-dopa 12.5 mg/kg and ropinirole 0.2 mg/kg were selected for further investigations based 
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Figure 2-14 Behavioural assessment in MPTP-treated marmosets following L-dopa (LD) 3.125, 6.25, 
9.375, or 12.5 or 25.0 mg/kg p.o. (+ carbidopa 12.5 mg/kg p.o.) treatment. Data are presented as 
medians (n=6);  Time-course data for (a) Locomotor activity, (b) Motor Disability and (c) Dyskinesia, and 
also individual values; Total counts/score for (a’) Locomotor activity, (b’) Motor Disability and (c’) 
Dyskinesia; *p<0.05  ,**p<0.01, compared to vehicle treatment; Friedman’s test followed by Dunn’s 
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Figure 2-15 Behavioural assessment in MPTP-treated marmosets following ropinirole (Rop) 0.1, 0.2, 
0.3 or 0.4 mg/kg p.o. (+ domperidone 2 mg/kg p.o.) treatment. Data are presented as medians (n=6); 
Time-course data for (a) Locomotor activity, (b) Motor Disability and (c) Dyskinesia, and also individual 
values; Total counts/score for; (a’) Locomotor activity, (b’) Motor Disability and (c’) Dyskinesia; *p<0.05, 
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2.6   Biochemical Techniques 
2.6.1 Radioenzymatic measurement of NOS activity in brain tissue 
2.6.1.1 Collection of brain tissue 
To determine activity levels of nNOS naïve male Wistar rats (250-275 g; Harlan) were used in ex vivo 
studies, and at the time point of interest post-dosing animals were killed by decapitation using a 
guillotene. Both the cerebellum and striatum were dissected out according to the atlas of Paxinos and 
Watson (1986) , snap frozen and stored at -70 ˚C until further use. 
 
2.6.1.2 nNOS radioactivity assay 
nNOS activity was measured by monitoring radioactivity levels following the enzymatic conversion of 
[³H]-arginine to [³H]-citrulline as described by Bredt and Snyder (1989). The radioenzymatic assay is 
described below. 
The NOS assay was performed in a 96 well-plate and all reagents apart from the reaction mixture 
prepared in advance (Table 2-5) and kept on ice until use. Brain tissue samples were weighed and 5 x 
volume of 1 x homogenisation buffer (Table 2-5) containing Protease inhibitor cocktail set III (1:20 
dilution) was added. Tissue samples (plus homogenisation mix) were then homogenised, using a 
cordless motor pellet pestle homogeniser (Kontes), and centrifuged (for 1 h at 1000 g at 4 °C). 
Supernatant was transferred into newly labelled eppindorfs and aliquots (20 μl) were transferred into a 
96 well plate in triplicate. The same volume of boiled supernatant (10 min at 100 °C) was used as a 
control. Next the reaction mixture (30  μl) (as described in Table 2-5) was added to each well and the 
plate placed in an incubator at 30 °C while gently shaking.  
After 1 h of incubation the reaction was terminated by adding 50 μl stop buffer to each well. 
Additionally 100  μl of equilibrated resin (Biorad AG 50W Cation Resin, see Table 2-5) was added to each 
sample and subsequently incubated for 45 min at 30 °C while gently shaking. Then the reactions were 
pipetted into Multiscreen HTS DV 0.65 μM filtration plates (Millipore) and filtered using a chemical duty 
vacuum pump (Millipore). The [³H]-citrulline, being ionically neutral, flowed through the filter whilst the 
positively charged [³H]-arginine stayed bound to the resin. Finally eluate (10  μl/well) was transferred 
into a 96-well microplate containing 100 μl Scintillant (Ultima Gold, Perkin-Elmer) per well. NOS activity 
was quantified by using a Wallac Beta-liquid scintillation counter yielding measurements in counts per 
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Table 2-5 Reagents for radioenzymatic NOS assay 
Reagent Components  
10 x Homogenisation Buffer 250 mM Tris-HCL (pH 7.4) 
10 mM ethylenediaminetetraacetic acid (EDTA) disodium salt 




50 mM Tris-HCl (pH 7.4) 
6 μM tetrahydrobiopterin (BH4) 
2 μM flavin adenine dinucleotide (FAD) 
2 μM flavin adenine mononucleotide (FMN) 
Stop buffer 50 mM N-2-hydroxyethylpiperazine- 
N´-2-ethanesulfonic acid (HEPES) (pH 5.5) 
5 mM EDTA disodium salt 
Equilibrated Resin 12.5 % cation resin (w/v) suspended in sodium hydroxide for 1hr at RT, 
wash with dH2O to pH7-10. Eqilibrate with 10mM HEPES to pH 6.5 
Reaction mixture 1 x reaction buffer (as above) 
6 mM CaCl2 (3.6 mM/well) 
10 mM reduced nicotinamide adenine dinucleotide phosphate (β-
NADPH) 
16.7 μM  L-[2,3,4-3H] arginine monohydrochloride 
 
 
2.6.1.3 Protein content determination 
Protein content of tissue homogenate was measured using a NanoDrop spectrophotometer (ND-1000) 
in conjunction with ND-1000 3.5.1 software. Samples of homogenate (2 μl) were loaded on to the lower 
measurement pedestal of the NanoDrop and light absorbance measured at 280 nm (A280) (See Figure 
2-16); samples were analysed in triplicate. Measurements of absorbance are directly proportional to 
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Figure 2-17 Protein content standard curve from Nanodrop. Protein standards were prepared in 
triplicate and the absorbance of 2 μl BSA samples read at 280 nm; the graph demonstrates the linear 
relationship between absorbance and protein concentration.    
Figure 2-16 Example of protein measurement using the NanoDrop spectrophotometer. Protein 
content of cerebellar and striatal samples were determined in triplicate using this equipment. Light 
absorbance was measured for the sample and compared to internal standards. 
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Figure 2-18 Example of radioenzymatic measurement of nNOS activity in brain homogenates. Samples 
taken from naïve rats treated with saline (0.9 %) and culled by decapitation at 1hr (a) Striatal and 
cerebellar samples assayed following standard protocol (n=4), (b) Cerebellar samples assayed with (+) 
(standard protocol) and without (―) CaCl2 in the reaction mixture (n=3)  Data are presented as mean ± 
SEM.    
2.6.1.4 Data and statistical analysis 
To evaluate nNOS activity the average cpm from the boiled control was subtracted from the average 
cpm of the tissue sample. Dividing by the average tissue sample protein measurement (mg/ml) obtained 
from the Nanodrop (as described in section 2.6.1.3) this cpm figure was converted into cpm per mg of 
protein. Statistical analysis was carried out using a one-way ANOVA followed by post hoc Newman-Keuls 
test. Results as exemplified in Figure 2-18a were expressed as L-[3H]-citrulline formation (cpm per mg 
protein; specific activity is 47.9 cpm/fmol) . Calcium-independent NOS activity accounts for less than 3 % 
of the overall activity as measured when samples were assayed using a reaction mixture where CaCl2 
was replaced by deionised water (Figure 2-18 b). iNOS activity is therefore negligible in comparison to 
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2.6.2 Determination of tyrosine hydroxylase 
In order to confirm the lesion size in 6-OHDA rats, immunohistochemical analysis of tyrosine 
hydroxylase (TH) positive cells was used to quantify dopamine neurones in the substantia nigra pars 
compacta.    
 
2.6.2.1 Collection of brain tissue 
At the conclusion of behavioural studies (see section 2.3) 6-OHDA-lesioned rats were administered a 
lethal dose of sodium pentobarbitol (100 mg/kg ip). Once animals had lost reflex reactions the thorax 
was opened to expose the heart and perfused with 100 ml of ice-cold 0.1 M phosphate buffered saline 
(PBS; pH 7.4) followed by 100 ml ice-cold paraformaldehyde (PFA; 4 % in 0.1 M PBS). Animal were then 
decapitated and brains dissected from the skull and transferred to 4 % PFA for post-fixation at 4 ˚C. 
After 2-3 days brains were moved to 30 % sucrose (with 0.05 % sodium azide) for cryoprotection and 
stored at 4 ˚C until they sunk. Brains were maintained in these conditions until cutting commenced.      
 
2.6.2.2 Processing of brain tissue 
Brains were cut on a Leica freezing microtome (SM2000R) and collected as coronal sections of 30 µm 
thickness in 24-well plates. The cerebellum was initially removed with a blade and the remaining brain 
tissue mounted on a cold metal stage with Cryo-M-bed, embedding compound. The brain was cooled to 
-30 ˚C, using cryospray to assist, and adjoining sections of tissue throughout the level of the substantia 
nigra were collected in series. Sections were stored, 4 per well, in 0.1 M PBS (with 0.05 % sodium azide)  
at 4 ˚C until further use.  
 
2.6.2.3 Immunohistochemistry 
In preparation for TH staining, sections were incubated in 1 % H2O2 in 0.1 M PBS for 35 min to block 
endogenous peroxidase activity. They were then permeabilised by washing twice for 10 min in 0.05 %  
Triton-X in 0.1 M PBS (PBS-TX). Sections were blocked for 1 h with 20 % normal goat serum (NGS) in PBS-
TX followed by incubation in primary antibody (rabbit TH diluted 1:500, in 2 % NGS in PBS-TX) overnight 
at room temperature. 
 
After primary antibody incubation sections were washed twice for 10 min in PBS-TX and subsequently 
incubated with biotinylated secondary antibody (anti-rabbit TH diluted 1:200, in PBS-TX) for 1.5 h at 
room temperature. Next, sections were again washed twice for 10 min in PBS-TX and incubated for 1 h 
with Avidin biotin complex (ABC), as prepared during the secondary antibody incubation. Sections were 
then washed twice for 10 min in Tris-HCL buffer (0.1 M; pH 7.4) before incubating with DAB (0.05 % in 
Tris-HCL buffer) plus H2O2 (0.03 %) for 30-60 seconds. The reaction was terminated by transferring 
sections through a Tris-HCl buffer rinse and two distilled water rinses. Sections were then mounted onto 
polylysine coated slides (VWR International) and left to dry overnight. 
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The next day sections were rinsed in distilled water and dehydrated through an escalating series of 
ethanol solutions (2 min each in 70, 98 & 100 %). Sections were subsequently delipidated in histoclear 
for 10 min and cover slipped using DePeX mounting medium. Slides were left to dry overnight before 
viewing under the microscope.   
 
2.6.2.4 Cell counts 
TH positive cells stained by immunohistochemistry as described in 2.6.2.3 were counted using an 
Olympus (BX61) Light Microscope. For each coronal brain section all stained cells appearing in the SNpc 
at the level of the third nerve were included in the count which was conducted on both lesioned (left) 
and non-lesioned (right) sides to allow comparison (see Figure 2-19). An Olympus (DP70) digital camera 
in combination with Cell D Analysis imaging software were used to capture photographs of sections 










Figure 2-19 TH Immunohistochemistry of 6-OHDA-lesioned rat brain section; substantia nigra shown at 
the level of third nerve following a lesion in the medial forebrain bundle. Brown stained areas depict 
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2.7  General materials used 
Table 2-6 List of drugs  
Item Supplier 
L-DOPA methyl ester Sigma 
Benserazide Sigma 
Carbidopa Sigma 
Ropinirole hydrochloride Sigma 
7-Nitroindazole (7-NI) Tocris Bioscience, Bristol, UK 
ARR17477 HCL salt Mercachem, The Netherlands / WuxiAppTec, 
China 
(+)-MK-801 hydrogen maleate Sigma 
(+)-8-Hydroxy-2-(dipropylamino)tetralin(8 
OHDPAT) 
Tocris Bioscience, Bristol, UK 
Amantadine hydrochloride Sigma 
 
Table 2-7 List of chemicals and reagents  
Item Supplier 
Avidin biotin complex (ABC) Vector Laboratories, Peterborough, UK 
Biotinylated goat anti-rabbit IgG Vector Laboratories, Peterborough, UK 
Calcium chloride Applichem, Biochemica 
Cryo-M-bed, embedding compound  Bright Instrument Co Ltd, Cambridgeshire, UK 
DAB kit Vector Laboratories, Peterborough, UK 
DePeX mounting medium BDH, VWR International, Lutterworth, UK 
Cryospray Bright Instrument Co Ltd, Cambridgeshire, UK 
EMLA cream AstraZeneca, UK 
Ethanol Fisher Scientific, Leicestershire, UK 
Goat serum Vector Laboratories, Peterborough, UK 
Histoclear VWR International, Lutterworth, UK 
Homogenisation Buffer (x10) Stratagene, Leicester, UK 
Isofluorane Abbott Laboratories Ltd, Berkshire, UK 
L-[2,3,4-3H] Arginine Monohydrochloride GE Healthcare, Amersham, UK / Perkin-Elmer, 
Beaconsfield, UK 
Protease Inhibitor cocktail set III Calbiochem, Nottingham, UK 
Resin AG50W-X8  (100-200 dry mesh, 106-250 µm 
wet bead) 
Bio-Rad Laboratories Ltd. Hertfordshire, UK 
Rimadyl Pfizer Animal Health, Kent, UK 
Sodium Chloride BDH, VWR International, Lutterworth, UK 
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Sodium Pentobarbitol (Euthanal) Merial, Dundee, UK 
Tyrosine hydroxylase antibody (rabbit) Pel-Freez, USA 
Tris (hydroxylmethyl) methylammonium chloride 
(Tris-HCL) 
BDH, VWR International, Lutterworth, UK 
Ultima gold scintillant Perkin-Elmer, Beaconsfield, UK 
Chemicals and reagents not listed were acquired from Sigma-Aldrich, Dorset, UK 
Table 2-8 List of equipment and consumables 
Item Supplier 
12- and 24-Well Plates Nunc, Roskilde, Denmark 
AIMs cages Workshop, King’s College London 
Centrifuge Meadowrose Scientific Ltd., Oxfordshire, UK  
Chemical duty vacuum/pressure pump 220 vol 
(WP6122050) 
Millipore, Livingston, UK 
Cover slips VWR International, Lutterworth, UK 
DASYLab data acquisition system, laboratory 
version 11 
Adept Scientific plc, Herts, UK 
Ethovision software Tracksys Ltd., Nottingham, UK 
Hamilton syringe 10 µl (701RN)  Hamilton Company, Nevada, USA 
Micro-injector syringe pump ‘Nanomite’  Harvard Apparatus, Kent, UK 
Microplate, Corning 96-well plate Fisher Scientific, Leicestershire, UK 
Microscope (BX61) Olympus, Essex, UK 
Microscope digital camera (DP70) Olympus, Essex, UK 
Microtome SM 2000R Leica Microsystems, Milton Keynes, UK 
Motor pellet pestle homogeniser Fisher Scientific, Leicestershire, UK 
Multiscreen HTS DV 0.65 µM filter plates Millipore, Livingston, UK 
Nanodrop ND-1000 Spectrophotometer Labtech International, East Sussex, UK 
Pipette tips Starlab Ltd., Milton Keynes, UK 
Polysine-coated slides VWR International, Lutterworth, UK 
Primate behavioural test units Workshop, King’s College London 
Rotometry arenas Workshop, King’s College London 
Stereotaxic Frame Kopf Instruments 
Sutures Ethicon, Johnson & Johnson 
Swabs (70 % isopropyl alcohol) Uhs, Enfield, UK 
Tracksys Video monitoring Software and 
Equipment 
Tracksys Ltd., Nottingham, UK 
Wallac MicroBeta Liquid scintillation counter Perkin Elmer, Beaconsfield, UK 
Wide orifice filter pipet tips VWR international, Lutterworth, UK 
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Chapter 3 :  The effects of nNOS inhibitor treatment on 























 Chapter 3 
3.1 Introduction 
Dyskinesia presents a significant clinical problem in PD surfacing where long-term dopaminergic 
medication becomes necessary to reverse the characteristic motor symptoms of the disease. Indeed PD 
patients have a 40 % likelihood of developing dyskinesia following 4-6 years of L-dopa therapy, although 
it is notable that their levels are not troublesome in all cases (Ahlskog & Muenter, 2001). To date the 
only agent which appears to reduce the severity of established dyskinesia, without worsening of 
parkinsonian symptoms, is amantadine (Luginger et al., 2000; Snow et al., 2000), but it is only effective 
in a small proportion of patients and is poorly tolerated with benefits often transient (Stocchi et al., 
2008). Importantly the beneficial effects of amantadine suggest that it is possible to attenuate 
dyskinesia once it has emerged but there is a clear requirement for more effective anti-dyskinetic 
interventions. 
Targeting the nitrergic sytem has received little attention as a therapy option for dyskinesia despite the 
key role of nitric oxide as a neuromodulator in the CNS. There exists a strong rationale for investigating 
nNOS inhibitors in the management of dyskinesia, as discussed in further detail in Chapter 1 (see section 
1.4). This opportunity is supported by changes in nitric oxide, nNOS and nNOS mRNA in PD patients and 
animal models of PD (Eve et al., 1998; Gatto et al., 2000).  
The nNOS inhibitor 7-NI has been utilised in a range of in vivo studies to date, and therefore provides an 
opportune probe, although its selectivity for nNOS over other NOS isoforms is arguable (Moore et al., 
1993a; Zagvazdin et al., 1996). The more recently discovered AstraZeneca compound ARR17477 (Zhang 
et al., 1996) is described as a comparatively potent and selective inhibitor of nNOS relative to other NOS 
isoforms, and whilst there are limited experimental data examining its use in vivo especially concerning 
routes of administration beyond i.v. (O'Neill et al., 2000; Reif et al., 2000), further characterisation 
would be a worthwhile endeavour owing to its favourable properties. By employing both of these 
compounds as tools, it is logical that their combined advantages could lead to findings regarding the 
specific effects of nNOS inhibition.   
Furthermore, the established 6-OHDA-lesioned rat offers a validated and accessible model in which to 
test for the potential benefits of nNOS inhibitors in PD. Following chronic dosing with L-dopa, animals 
rapidly develop abnormal movements which can be rated by a trained observer. The abnormal 
involuntary movement (AIMs) model as established by Cenci and colleagues (1998) has been extensively 
characterised in the published literature to date and is widely used for testing therapeutic agents in PD 
(Lundblad et al., 2002; Dekundy et al., 2007; Dupre et al., 2008). Although the model may not be entirely 
representative of the progressive nature of dyskinesia manifestation in man, drugs reported to reduce 
dyskinesia in the clinic such as amantadine and clozapine have been confirmed effective in this model 
(Lundblad et al., 2002; Dekundy et al., 2007). Thus the 6-OHDA-lesioned rat was selected for studies to 
investigate dyskinesia via AIMs assessment.  
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Once dyskinesia manifests, there is some evidence in PD patients, MPTP-treated primates and 6-OHDA-
lesioned rats suggesting its expression tends to be lower with dopamine agonists as opposed to L-dopa 
(Kapoon et al., 1989; Facca & Sanchez-Ramos, 1996; Hadj Tahar et al., 2000; Jackson et al., 2007; 
Papathanou et al., 2011). In severe cases, patients may be switched to dopamine agonist monotherapy 
in an attempt to alleviate the dyskinesia or more commonly a combination of L-dopa and dopamine 
agonists may allow the L-dopa dose to be reduced (Rascol et al., 2002b). Anti-dyskinetic agents may 
therefore have differing degrees of effect on the control of motor abnormalities, dependent upon 
whether L-dopa or a dopamine agonist e.g. ropinirole is being administered. Thus the chosen 
dopaminergic drug is an important factor to consider when assessing the potential of any anti-dyskinetic 
adjunct therapy. 
Thus the purpose of these studies was to further explore the link between NO and dyskinesia expression 
following dopaminergic treatment in PD. To this end it was necessary to extend the characterisation of 
ARR17477 and 7-NI inhibition of neuronal NOS to then enable investigation into the expression of 
dyskinesia in the 6-OHDA-lesioned rat model of PD.   
 
3.1.1 Hypothesis 
It is hypothesised that inhibibition of nNOS will reduce the expression of established dyskinesia induced 
by dopaminergic drugs in 6-OHDA-lesioned rats.  
 
3.1.2 Aims 
The aim of these studies was to determine whether nNOS inhibitors can reduce the expression of 
dyskinesia following acute challenges of dopaminergic treatment in L-dopa primed-6-OHDA-lesioned 
rats, and specifically to investigate; 
1. The effect of the selective nNOS inhibitors ARR17477 and 7-NI on nNOS activity ex vivo following a 
range of doses. 
2. The acute behavioural effect of ARR17477 and 7-NI administered in combination with L-dopa on 
dyskinesia expression in L-dopa-primed 6-OHDA-lesioned rats. 
3.  The acute behavioural effect of ARR17477 and 7-NI administered in combination with ropinirole on 
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3.2 Materials and methods 
3.2.1 Introduction 
Initially ex vivo studies were carried out in order to establish the dose of nNOS inhibitors for in vivo 
studies. Secondly the effect of nNOS inhibitors was investigated in rats with a 6-OHDA lesion and primed 
to express AIMS (dyskinesia), by chronic dosing with L-dopa. Acute studies, with the pre-selected doses 
of nNOS inhibitors were carried out to determine the effect on both L-dopa- and ropinirole-induced 
AIMs. The methods for these studies are described below. 
3.2.2 Animals 
For all studies male Wistar rats (200-250 g; Harlan, UK or B & K, UK) were housed 2-3 per cage in the 
Biological Service Unit, King’s College London. Room temperatures were maintained at 19-21 ˚C at 55 % 
humidity with a 12 h light-dark cycle and animals had free access to pelleted food and water, as 
described in section 2.2.2. Experiments were performed in accordance with the UK Animals (Scientific 
Procedures) Act, 1986 under Home Office project licence no. 70/6019 or 70/6898.      
3.2.3 Ex vivo NOS assay 
To determine the effect of the nNOS inhibitors ARR17477 and 7-NI on nNOS activity in rat brain, enzyme 
activity was assessed in rats by measuring the conversion of L-arginine to L-citrulline ex vivo following 
administration of a range of doses. 
3.2.3.1 Establishing nNOS inhibitor doses for acute AIMs studies 
The doses of the nNOS inhibitors ARR17477 and 7NI to be used in these studies were determined in 
experiments measuring the inhibition of nNOS activity ex vivo following systemic administration. 
3.2.3.1.1 Determination of ARR17477 doses  
Naïve male Wistar rats (n=4/group; 200-250 g) were treated with ARR17477 (3, 6 or 12 mg/kg in 0.9 % 
saline s.c.) or vehicle (saline 0.9 %; 1 ml/kg s.c.). These doses were chosen based on published studies 
(O'Neill et al., 2000; Reif et al., 2000) and preliminary data from our laboratory showing that ARR17477 
(10 mg/kg i.p.) reduced striatal nNOS activity by 67 % at 1 h.  
Animals were culled at one hour after ARR17477 treatment by decapitation. Both the cerebellum and 
striatum were dissected out (as described in 2.6.1.1), snap frozen and stored at -70 ˚C for measurement 
of nNOS activity by radioenzymatic assay. 
3.2.3.1.2 Determination of 7NI doses  
Naïve male Wistar rats (n=4/group; 200-250 g) were treated with 7NI (12.5, 25 or 50 mg/kg dissolved in 
DMSO:saline 0.9 %, 50:50, i.p.) or vehicle (DMSO:saline 0.9 %, 50:50 i.p.). These doses were selected on 
the basis of dose ranges utilised in published literature (Mackenzie et al., 1994; Moore & Bland-Ward, 
1996; Bush & Pollack, 2000). 
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Animals were culled after 1 h by decapitation. Both the cerebellum and striatum were dissected out (as 
described in section 2.6.1.1), snap frozen and stored at -70 ˚C for measurement of nNOS activity by 
radioenzymatic assay.  
3.2.3.2 Radioenzymatic measurement of NOS activity 
nNOS activity was determined in brain homogenates by measuring enzymatic conversion of L-[³H]-
arginine to L-[³H]-citrulline as fully described in section 2.6.1. Briefly homogenised tissue samples were 
centrifuged (as detailed in section 2.6.1.2), and supernatants transferred to a 96-well plate in triplicate. 
Boiled supernatant was used as a negative control. A pre-prepared reaction mixture containing L-[2,3,4-
3H] arginine monohydrochloride (1 mCi/ml; 16.7 μM) and CaCl2 (6 mM) was added (30 μl/well) and the 
plates incubated for 1 h at 30 °C. The reaction was terminated and the reaction mixture further 
processed to measure L-[³H]-citrulline formation, by the addition of resin and subsequent filtration of 
the samples as described in section 2.6.1.2. L-[³H]-citrulline was determineded in a Beta-liquid 
scintiallation counter (see section 2.6.1.2) whilst protein content of samples was quantifieded with a 
NanoDrop spectrophotometer (see section 2.6.1.3). Data were analysed as described in section 2.6.1.4 
expressing nNOS activity as L-[³H]-citrulline formation per mg of protein per hour. 
3.2.3.2.1 ARR17477 results 
ARR17477 (6 and 12 mg/kg) significantly reduced nNOS activity by 41 % and 56 % respectively in the 
cerebellum (Figure 3-1a).  Similarly, ARR17477 (3, 6 and 12 mg/kg) significantly reduced nNOS activity in 
a dose-dependent manner ranging from 34-60 % inhibition in striatal tissue (Figure 3-1b) and were 
hence chosen for further study. 
3.2.3.2.2 7-NI results 
7-NI (12.5, 25 and 50 mg/kg) significantly reduced nNOS activity by 30 % at the lowest dose 
administered, 58 % at 25 mg/kg and 49 % at 50 mg/kg in cerebellar tissue (Figure 3-2a). 7-NI (12.5, 25 
and 50 mg/kg) also significantly reduced nNOS activity in the striatum by 41-43 % at the lower two doses 
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Figure 3-1 Radioenzymatic measurement of the effect of ARR17477 (3, 6 or 12 mg/kg s.c.) on nNOS 
activity in cerebellum and striatum. Naïve male Wistar rats were treated with ARR17477 or vehicle 
(saline 0.9 % s.c.) and culled by decapitation at 1hr. Tissue samples were obtained from (a) cerebellum 
and (b) striatum. nNOS activity is displayed as L-[3H]-citrulline formation (cpm/mg protein); Data are 
presented as means ± SEM (n=4/group); *P<0.05, ** P<0.01  compared to vehicle treatment. Data were 
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Figure 3-2 Radioenzymatic measurement of the effect of 7-NI (12.5, 25 or 50 mg/kg i.p.) on nNOS 
activity in cerebellum and striatum. Naïve male Wistar rats were treated with 7-NI or vehicle 
(DMSO:saline 0.9 %, 50:50 i.p.) and culled by decapitation at 1hr. Tissue samples were obtained from (a) 
cerebellum and (b) striatum; nNOS activity is displayed as L-[3H]-citrulline formation (cpm/mg protein); 
Data are presented as means ± SEM (n=4/group); *P<0.05, ** P<0.01 compared to vehicle treatment. 
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3.2.4 Assessment of the effect of nNOS inhibition on AIMs in L-dopa primed 6-OHDA-
lesioned rats 
 
3.2.4.1 Unilateral 6-OHDA lesion 
Male Wistar rats (see section 3.2.2) were unilaterally lesioned with 6-OHDA under general anaesthesia 
(as described fully in section 2.2.3) using standard stereotaxic techniques. In brief, 6-OHDA 
hydrochloride (8 µg free base in 4µl 0.9 % saline containing 0.05 % ascorbic acid) was injected at a rate 
of 1 µl per minute with a Hamilton syringe and 26S gauge needle into the left MFB (according to the 
coordinates of Paxinos and Watson, 1986; A-P:-2.6 mm, M-L: +2.0 mm, V:-8.8 mm as measured from 
bregma). The needle was left in place for 4 min to allow for the 6-OHDA to diffuse into the surrounding 
region and then slowly withdrawn before cleaning and suturing the wound. Animals were cared for 
post-operatively as described in section 2.2.4. 
Three to four weeks after surgery rats were treated with amphetamine sulphate (2.5 mg/kg i.p. in 0.9 % 
saline) and rotational behaviour was monitored as described in section 2.3.1. Only rats exhibiting 7 or 
more ipsilateral turns per minute at peak activity were used for further studies.  
 
3.2.4.2 Establishing AIMs 
Rats were primed for dyskinesia, as assessed by AIMs expression (see 3.2.4.4), by daily treatment with L-
dopa methyl ester (6.25 mg/kg free base + benserazide 15 mg/kg, dissolved in 0.9 % saline i.p.) for a 
period of 22 days as described in section 2.3.2.1. Figure 2-4 graphically depicts the development of AIMs 
in rats over this priming period. All drugs were administered at a volume of 1 ml/kg. After the priming 
period animals were assessed for AIMs on two subsequent occasions and only rats exhibiting a mean 
ALO AUC AIMS score >30 were taken forward to the acute challenges.  
 
3.2.4.3 Acute dopaminergic drug challenges in combination with nNOS inhibitors 
L-dopa- primed 6-OHDA-lesioned rats were divided into two groups (n=8/group), each balanced for 
mean AIMs scores based on dyskinesia assessment at the end of the priming period, as described in 
section 3.2.4.4. In each of the expression studies all drugs were administered according to a modified 
latin-square design (see Appendix, Figure 0-1) so that each animal received each treatment, and a 3-7 
days drug washout period was employed between studies as outlined below (and summarised in Figure 
3-3).  
 
L-dopa AIMs expression studies 
-Study i. Animals were treated with L-dopa methyl ester (6.25 mg/kg free base + benserazide 15 mg/kg, 
in saline 0.9 %, i.p.) plus, at the same time, either ARR17477 (3, 6 or 12 mg/kg in 0.9 % saline s.c.) or 
saline 0.9 %. AIMs were scored as described in section 3.2.4.4 below. A drug washout period of 1 week 
was employed between each treatment. 
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-Study ii. Animals were treated with L-dopa methyl ester (6.25 mg/kg + benserazide 15 mg/kg, in saline 
0.9 %, i.p.) plus, 30 min earlier, 7-NI (12.5, 25 or 50 mg/kg in DMSO: saline 0.9 %, 50:50, i.p.) or DMSO: 
saline (0.9 %, 50:50, i.p.). Baseline AIMs were scored as described in section 3.2.4.4, and dopaminergic 
drugs were administered with scoring continuing from here on.  A drug washout period of 3 days was 
employed between each treatment. 
 
Ropinirole AIMs expression studies 
-Study iii. Animals were treated with ropinirole (0.2 mg/kg, in saline 0.9 %, i.p.) plus, 30 min beforehand, 
7-NI (12.5, 25 or 50 mg/kg in DMSO: saline 0.9 %, 50:50, i.p.) or DMSO: saline (0.9 %, 50:50, i.p.). 
Baseline AIMs were scored as described in section 3.2.4.4, and dopaminergic drugs were administered 
with scoring continuing from here on. A drug washout period of 3 days was employed between each 
treatment. 
-Study iv. Animals were treated with ropinirole (0.2 mg/kg, in saline 0.9 %, i.p.) plus, at the same time, 
either ARR17477 (3, 6 or 12 mg/kg in 0.9 % saline s.c.) or saline 0.9 %. AIMs were scored as described in 
section 3.2.4.4 below. A drug washout period of 1 week was employed between each treatment. 
 
3.2.4.4 AIMs assessment 
Dyskinesia was assessed in rats based on the observation of four subtypes of AIM’s; locomotive, axial, 
limb and orolingual (originally described by Cenci et al., 1998), each rated on a scale of 0-4 dependent 
on frequency and intensity (see section 2.3.2.2). Rats were placed in transparent cages one hour before 
drug treatment commenced to enable acclimatisation (as described in section 2.3.2.2). Baseline AIMs as 
described in section 2.3.2.2 were scored 20 min and 5 min prior to dosing. Following drug treatment 
AIMs were assessed for 5 min every 15 min for up to 210 min.   
 
Figure 3-3 Summary diagram of animal groups and treatments used in L-dopa (LD) and ropinirole (Rop) 
AIMs expression studies in combination with the nNOS inhibitor ARR17477 (ARR) or 7-NI, following 
priming and selection of 6-OHDA-lesioned rats. 
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3.2.5 Data and statistical analysis 
Time-course data were plotted as the median AIMs score and a mean of the two baseline scores was 
taken on each assessment day to give a single baseline score plotted at t=0. Data for totals, peaks and 
duration of activity were plotted as medians and also individual values. Total scores over the assessment 
period were calculated by AUC (Graphpad Prism version 5.0) using the trapezoid method where each 
successive 15 min was labelled as a single time-bin and peak score was taken as the maximum AIMs 
score achieved per 15 min. The duration of AIMs was calculated taking into account all score periods 
gaining above 0 and in the case of orolingual AIMs included those gaining above 1.  
Time-course data were analysed by 2-way-ANOVA followed by Friedman’s test and Dunn’s post hoc test 
where appropriate. Total scores, peak scores, and duration of activity were analysed by Friedman’s test 
and Dunn’s post hoc test. Statistical significance was set at p<0.05 and analyses were carried out in 
Graphpad Prism 5. Additionally a ’trend’ was described in the data where there was greater than a 75 % 
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3.3 Results  
3.3.1 Locomotive AIMs in L-dopa-primed 6-OHDA-lesioned rats treated acutely with 
L-dopa plus nNOS inhibitor 
 
3.3.1.1 nNOS inhibitor + vehicle.  
Neither ARR17477 (12 mg/kg) plus vehicle (saline), nor 7-NI (50 mg/kg) plus vehicle (saline) produced 
locomotive AIMs in 6-OHDA-lesioned rats primed with L-dopa (Figure 3-4a & Figure 3-5a).  
3.3.1.2 Vehicle + L-dopa. 
L-dopa alone induced locomotive AIMs in Group 1 and 2 for between 15-135 min (Figure 3-4a & Figure 
3-5a) with a peak score of 2 (Figure 3-4c & Figure 3-5c), and a duration of locomotive AIMs activity of 
between 120-135 min (Figure 3-4d & Figure 3-5d). The total AIMs score for the session was 12-14 
(Figure 3-4b & Figure 3-5b). 
3.3.1.3 nNOS inhibitor + L-dopa.  
There was no significant effect of ARR17477 (3, 6 or 12 mg/kg) or 7-NI (12.5, 25, or 50 mg/kg) on L-dopa-
induced locomotive AIMs in either group as measured by peak (Figure 3-4c & Figure 3-5c), duration of 
activity (Figure 3-4d & Figure 3-5d) or total AIMs score (Figure 3-4b & Figure 3-5b).   
 
3.3.2 Locomotive AIMs in L-dopa-primed 6-OHDA-lesioned rats treated acutely with 
ropinirole plus nNOS inhibitor 
 
3.3.2.1 nNOS inhibitor + vehicle  
As previously described neither ARR17477 (12 mg/kg) plus vehicle (saline), or 7-NI (50 mg/kg) plus 
vehicle (saline) produced locomotive AIMs in L-dopa-primed 6-OHDA-lesioned rats (Figure 3-6a & Figure 
3-7a).  
3.3.2.2 Vehicle + ropinirole 
Ropinirole alone induced locomotive AIMs from between 15-60 min (Figure 3-6a & Figure 3-7a) with a 
peak score of 1.5-2.5 (Figure 3-6c & Figure 3-7c) and duration of activity of between 20-60 min (Figure 
3-6d & Figure 3-7d). Ropinirole produced locomotive AIMs of a similar severity level to L-dopa, but 
these lasted for a shorter time period. The total AIMs score was 2-5 (Figure 3-6b & Figure 3-7b). 
3.3.2.3 nNOS inhibitor + ropinirole 
No significant effect of ARR17477 (3, 6 or 12 mg/kg) was observed on ropinirole induced locomotive 
AIMs as measured by peak scores (Figure 3-6c), duration of activity (Figure 3-6d), or totals (Figure 3-6b). 
Surprisingly 7-NI caused a significant increase in the duration of ropinirole-induced locomotive AIMs at 
specific time points (Figure 3-7a). AIMs scores were significantly greater than for ropinirole alone at 45 
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min (7-NI 12.5 mg/kg), at 60 min (7-NI 25 mg/kg) and at 60-90 min (7-NI 50 mg/kg), translating into an 
extension in the duration of ropinirole-induced AIMs. No overall significant effect of 7-NI (12.5, 25, or 50 
mg/kg) was observed on peak AIMs (Figure 3-7c). However, the duration of locomotive AIMs was 
significantly extended by 7-NI 12.5 mg/kg, although the change did not reach statistical significance with 
higher doses of the nNOS inhibitor (Figure 3-7d). Meanwhile this pattern was not reflected in the total 
AIMs score which was not significantly affected by 7-NI at any dose, although total AIMs did tend to be 
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Figure 3-4 Locomotive AIMs expression following ARR17477 plus L-dopa treatment. ARR17477 (ARR; 3, 
6 or 12 mg/kg s.c) and L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) treatment in L-dopa-
primed 6-OHDA-lesioned rats. Data are presented as medians (n=8); (a) Time-course, and also individual 
values (b) Total, (c) Peak and (d) Duration of activity. ++p<0.01 compared to vehicle + ARR 12 mg/kg s.c. 
treatment. Time-course data were analysed by 2-way-ANOVA and Friedman’s test followed by Dunn’s 
post hoc test, and all other data were analysed by Friedman’s test followed by Dunn’s post hoc test. 
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Figure 3-5 Locomotive AIMs expression following 7-NI plus L-dopa treatment. 7-NI (12.5, 25.0 or 50.0 
mg/kg i.p) and L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) treatment in L-dopa-primed 6-
OHDA-lesioned rats. Data are presented as medians (n=8); (a) Time-course, and also individual values  
(b) Total, (c) Peak and (d) Duration of activity. +p<0.05, ++p<0.01 compared to vehicle + 7-NI 50 mg/kg 
i.p. treatment. Time-course data were analysed by 2-way-ANOVA and Friedman’s test followed by 
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Figure 3-6 Locomotive AIMs expression following ARR17477 plus ropinirole treatment. ARR17477  
(ARR; 3, 6 or 12 mg/kg s.c) and ropinirole (Rop; 0.2 mg/kg s.c.) treatment in L-dopa-primed 6-OHDA-
lesioned rats. Data are presented as medians (n=8); (a) Time-course, and also individual values (b) Total, 
(c) Peak and (d) Duration of activity. +p<0.05 compared to vehicle + ARR 12 mg/kg s.c. treatment. Time-
course data were analysed by 2-way-ANOVA and Friedman’s test followed by Dunn’s post hoc test, and 
all other data were analysed by Friedman’s test followed by Dunn’s post hoc test. 
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Figure 3-7 Locomotive AIMs expression following 7-NI treatment plus ropinirole. 7-NI (12.5, 25.0 or 
50.0 mg/kg mg/kg i.p.) and ropinirole (Rop; 0.2 mg/kg s.c.) treatment in L-dopa-primed 6-OHDA-
lesioned rats. Data are presented as medians (n=8); (a) Time-course, and also individual values (b) Total, 
(c) Peak and (d) Duration of activity. *p<0.05, **p<0.01 compared to rop + vehicle treatment (colours 
used in (a) refer to key). Time-course data were analysed by 2-way-ANOVA and Friedman’s test followed 
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3.3.3 Axial, limb, orolingual and ALO AIMs in L-dopa-primed 6-OHDA-lesioned rats 
treated acutely with L-dopa plus nNOS inhibitor 
 
3.3.3.1 nNOS inhibitor + vehicle 
Rats treated with ARR17477 (12mg/kg) plus vehicle (saline), or 7-NI (50 mg/kg) plus vehicle (saline) did 
not produce any axial or limb AIMs, and exhibited little or no orolingual and ALO AIMs (Figure 3-8a-d & 
Figure 3-10a-d).  
3.3.3.2 Vehicle + L-dopa  
L-dopa alone induced axial AIMs from 15-165 min predominantly of a moderate to marked nature 
(Figure 3-8a & Figure 3-10a), with a peak score of 3-3.5 across both groups (Figure 3-9a & Figure 3-11a). 
Both groups also showed axial AIMs for an average duration of 160 min (Figure 3-9a’ & Figure 3-11a’) 
with a total AIMs score of 23-27 (Figure 3-8a’ & Figure 3-10a’).  
Limb AIMs were induced over the same time frame as axial AIMs (Figure 3-8b & Figure 3-10b), were 
mainly of moderate intensity peaking at a score of 2.5-2.75 (Figure 3-9b & Figure 3-11b) with a duration 
of activity of 160-165 min (Figure 3-9b’ & Figure 3-11b’). Limb AIMs totalled 22-24 (Figure 3-8b’ & 
Figure 3-10b’).  
Meanwhile orolingual AIMs of mild to marked intensity were predominantly induced between 15-180 
min and observed fleetingly at later time points (Figure 3-8c & Figure 3-10c), with an overall peak score 
of 3-4 (Figure 3-9c & Figure 3-11c) and duration of activity of 130-165 min (Figure 3-9c’ & Figure 3-11c’). 
Orolingual AIMs totalled 20-28 (Figure 3-8c’ & Figure 3-10c’). 
ALO AIMs scores reflected individual AIMs categories for L-dopa alone with animals expressing 
moderate to marked ALO AIMs from 15-165 min (Figure 3-8d & Figure 3-10d). Both groups showed a 
peak ALO AIMs score of 8-8.5 (Figure 3-9d & Figure 3-11d) and marked AIMs were maintained for a 
period of at least 90 min before gradually declining to baseline levels by 180-195 min (Figure 3-8d & 
Figure 3-10d). ALO AIMs were expressed for an overall duration of 165 min (Figure 3-9d’ & Figure 
3-11d’) with a total AIMs score of 70-77 (Figure 3-8d’ & Figure 3-10d’). 
3.3.3.3 nNOS inhibitor + L-dopa 
There was no significant effect of ARR17477 (3, 6 or 12mg/kg) on axial, limb, orolingual or ALO AIMs 
induced by L-dopa as measured by peak score (Figure 3-9a-d), duration of activity (Figure 3-9a’-d’) or 
total AIMs (Figure 3-8a’-d’).  
By contrast 7-NI (50 mg/kg) significantly increased the duration of L-dopa-induced axial AIMs as 
measured at individual time points without increasing severity (Figure 3-10a). Axial AIMs remained 
raised at moderate-marked intensity levels at 165 and 180 min following L-dopa plus 7-NI (50 mg/kg) 
treatment, compared to L-dopa alone which resulted in axial AIMs that were mild or absent by these 
respective time points (Figure 3-10a). However there was no statistically significant effect of 7-NI (50 
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mg/kg or 12.5 and 25 mg/kg) on overall axial AIMs as measured by duration (Figure 3-11a’), peak (Figure 
3-11a) or total AIMs score (Figure 3-10a’).   
7-NI (25 and 50 mg/kg) significantly increased the duration of L-dopa-induced limb AIMs at 180 min with 
moderate levels still observable compared to L-dopa only treatment for which limb AIMs were absent at 
this same time point (Figure 3-10b). However there was no overall effect of 7-NI treatment on peak 
score (Figure 3-11b), duration (Figure 3-11b’) or total limb AIMs (Figure 3-10b’). 
7-NI (12.5 mg/kg) significantly extended the duration of moderate orolingual AIMs at 180 min and this 
was also the case for 7-NI (50 mg/kg) at 195 min compared to L-dopa alone (Figure 3-10c). Again, there 
was no overall effect of 7-NI treatment on orolingual peak score (Figure 3-11c), duration (Figure 3-11c’) 
or total AIMs (Figure 3-10c’).  
7-NI (12.5 mg/kg) significantly extended the duration of moderate ALO AIMs at 180 and 195 min, and 
this was also true for 7-NI 50 mg/kg at 180-210 min, compared to L-dopa alone (Figure 3-10d).  7-NI (50 
mg/kg) also caused a significant increase in the overall duration of activity of ALO AIMs by 45 min 
compared to treatment with L-dopa alone (Figure 3-11d’). However there was no significant effect of 7-
NI (12.5, 25, or 50 mg/kg) on L-dopa induced ALO AIMs as measured by peak scores or total AIMs 
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Figure 3-8 Time-course and Total score for axial (a & a’), limb (b & b’), orolingual (c & c’) and ALO AIMs 
(d & d’) expression following ARR17477 plus L-dopa treatment. ARR17477 (ARR); 3, 6 or 12 mg/kg s.c) 
and L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) treatment in L-dopa-primed 6-OHDA-
lesioned rats. Data are presented as medians (n=8); (a-d) Time-course, and also individual values (a’-d’) 
Total; +p<0.05, ++p<0.01, +++ p<0.001 compared to vehicle + ARR 12 mg/kg s.c. treatment. Time-course 
data were analysed by 2-way-ANOVA and Friedman’s test followed by Dunn’s post hoc test, and all 
other data were analysed by Friedman’s test followed by Dunn’s post hoc test. 
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Figure 3-9 Peak scores and Duration of activity for axial (a & a’), limb (b & b’), orolingual (c & c’) and 
ALO AIMs (d & d’) expression following ARR17477 plus L-dopa treatment. ARR17477 (ARR; 3, 6 or 12 
mg/kg s.c) and L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) treatment in L-dopa-primed 6-
OHDA-lesioned rats. Data are presented as medians and individual values (n=8); (a-d) Peak score and 
(a’-d’) Duration of activity; +p<0.05, ++p<0.01 compared to vehicle + ARR 12 mg/kg s.c. treatment. Data 
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Figure 3-10 Time-course and Total score for axial (a & a’), limb (b & b’), orolingual (c & c’) and ALO 
AIMs (d & d’) expression following 7-NI plus L-dopa treatment. 7-NI (12.5, 25.0 or 50.0 mg/kg i.p.) and 
L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) treatment in L-dopa-primed 6-OHDA-lesioned 
rats.  Data are presented as medians (n=8); (a-d) Time-course, and also individual values (a’-d’) Total; 
*p<0.05, **p<0.01 compared to LD + vehicle treatment (colours used in (a-d) refer to key), ++p<0.01 
compared to vehicle + 7-NI 50 mg/kg i.p. treatment. Time-course data were analysed by 2-way-ANOVA 
and Friedman’s test followed by Dunn’s post hoc test, and all other data were analysed by Friedman’s 
test followed by Dunn’s post hoc test. 
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Figure 3-11 Peak scores and Duration of activity for axial (a & a’), limb (b & b’), orolingual (c & c’) and 
ALO AIMs (d & d’) expression following 7-NI plus L-dopa treatment. 7-NI (12.5, 25.0 or 50.0 mg/kg i.p.) 
and L-dopa (LD; 6.25 mg/kg mg/kg plus benserazide 15 mg/kg i.p.) treatment in L-dopa-primed 6-OHDA-
lesioned rats. Data are presented as medians and individual values (n=8); (a-d) Peak score and (a’-d’) 
Duration of activity; *p<0.05 compared to LD + vehicle treatment, +p<0.05, ++p<0.01 compared to 








 Chapter 3 
3.3.4 Axial, limb, orolingual and ALO AIMs in L-dopa-primed 6-OHDA-lesioned rats 
treated acutely with ropinirole plus nNOS inhibitor 
 
3.3.4.1 nNOS inhibitor + vehicle 
Animals treated with ARR17477 (12mg/kg) plus vehicle (saline) did not exhibit any axial, limb, or 
orolingual AIMs and consequently no ALO AIMs were evident (Figure 3-12a-d). By contrast animals 
treated with 7-NI (50 mg/kg) and vehicle (saline) showed occasional mild and fleeting axial AIMs 
between 30-135 min (Figure 3-14a) with a peak score of 1 (Figure 3-15a) and median duration of 30 min 
(Figure 3-15a’) and were observed in 7 out of 8 of the animals. However limb AIMs were not observed 
(Figure 3-14b) and mild orolingual AIMs appeared only briefly (Figure 3-14c) with a peak score of 1 
(Figure 3-15c). Mild and fleeting ALO AIMs were therefore observed between 15 and 135 min and did 
not exceed a score of 1 at any individual time point (Figure 3-14d). It is noteworthy that comparison of 
the total AIMs scores for this group of animals treated with 7-NI (50 mg/kg) plus vehicle and the other 
group used for the L-dopa plus nNOS inhibitor study receiving the same treatment (see Figure 3-14a’ & 
d’, & Figure 3-10a’ & d’) shows that there is no significant difference overall in axial or ALO AIMS (Mann 
Whitney test; data not shown).    
3.3.4.2 Vehicle + ropinirole 
Ropinirole alone induced axial AIMs from 15-75 min (Figure 3-12a & Figure 3-14a) with a peak score at 
15 min of 2.5-3 (Figure 3-13a & Figure 3-15a) and declining thereafter. The total duration of axial AIMs 
was between 60-70 min and these were moderate to marked in severity (Figure 3-13a’ & Figure 3-15a’), 
with a total AIM’s score of 8-12 (Figure 3-12a’ & Figure 3-14a’).  
Moderate to marked limb AIMs were induced in animals from 15 min onwards declining to baseline 
levels by between 45 and 75 min (Figure 3-12b & Figure 3-14b), showing a peak score of 2-3 (Figure 
3-13b & Figure 3-15b) and duration of activity ranging from 25-60 min (Figure 3-13b’ & Figure 3-15b’). 
Overall limb AIMs totalled 4-10 (Figure 3-12b’ & Figure 3-14b’). 
Mild and intermittent orolingual AIMs were induced between 15 and 120 min (Figure 3-12c & Figure 
3-14c) after ropinirole treatment, peaking at a score of 1.5-2 (Figure 3-13c & Figure 3-15c) and lasting 
for a median duration of between 25-30 min (Figure 3-13c’ & Figure 3-15c’). Overall orolingual AIMs 
totalled 4-5 (Figure 3-12c’ &Figure 3-14c’). 
Ropinirole treated rats exhibited moderate to marked ALO AIMs between 15 and 90 min (Figure 3-12d 
& Figure 3-14d). Scores peaked at 4.5-6.5 (Figure 3-13d & Figure 3-15d), and gradually returned to 
baseline levels by 105 min with a minor fluctuation after this time. ALO AIMS were exhibited for an 
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3.3.4.3 nNOS inhibitor + ropinirole 
Overall there was no significant effect of ARR17477 (3, 6 or 12mg/kg) on peak score (Figure 3-13a-d), 
duration of activity (Figure 3-13a’- d’) or total AIMs (Figure 3-12a’-d’), for axial, limb, orolingual or ALO 
AIMs.  
By contrast, 7-NI (50 mg/kg) produced a significant increase in duration of ropinirole-induced axial AIMs 
of moderate-marked levels at individual assessment periods between 75-105 min compared to 
ropinirole treatment alone (Figure 3-14a). 7-NI (50 mg/kg) also caused a significant increase in axial 
overall duration of activity by 75 min (Figure 3-15a’) and total AIMs of 11 (Figure 3-14a’). There was no 
significant effect of 7-NI (12.5-50 mg/kg) on peak axial AIMs score (Figure 3-15a), hence 7-NI had no 
effect on severity of axial AIMs, or of 7-NI at the lower two doses (12.5 and 25 mg/kg) on overall 
duration (Figure 3-15a’) or total axial AIMs (Figure 3-14a’).   
 7-NI (25 and 50 mg/kg) caused a significant increase in duration of moderate limb AIMs at 45 min, 7-NI 
(25 mg/kg) at 60min and 7-NI (50 mg/kg) at 75 and 90 min (Figure 3-14b) compared to ropinirole 
treatment alone. 7-NI (50 mg/kg) also caused a significant increase in total limb AIMs of 10 (Figure 
3-14). There was no significant effect of 7-NI (12.5-50 mg/kg) on peak limb AIMs (Figure 3-15b), or 
overall duration of limb AIMs (Figure 3-15b’) and also no effect of 7-NI (12.5 and 25 mg/kg) on total limb 
AIMs (Figure 3-14b’) as compared to ropinirole alone.  
Orolingual AIMs were unaffected by 7-NI treatment at individual time points (Figure 3-14c) and also in 
terms of overall peak, duration and total AIMs (Figure 3-14c’, Figure 3-15 c & c’). 
7-NI (25 mg/kg) caused a significant increase in the duration of moderate ALO AIMs at individual 
assessment periods of 45 and 75 min compared to treatment with ropinirole alone (Figure 3-14d).  This 
increased duration was similarly the case for 7-NI (50 mg/kg) at 75-105 min and also at 135 min (Figure 
3-14d). Treatment with the highest dose of 7-NI (50 mg/kg) plus ropinirole caused a significant increase 
in ALO AIMs overall as measured by duration of activity (Figure 3-15d’) and total AIMs (Figure 3-14d’). 
The duration of activity of ALO AIMs following 7-NI (50 mg/kg) was extended by 75 min as compared to 
treatment with ropinirole alone (Figure 3-15d’) and total AIMs were increased by a score of 20 (Figure 
3-14d’). No significant effects of lower doses of 7NI (12.5 and 25 mg/kg) were observed on ALO AIMs as 
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Figure 3-12 Time-course and Total score for axial (a & a’), limb (b & b’), orolingual (c & c’) and ALO 
AIMs (d & d’) expression following ARR17477 plus ropinirole treatment. ARR17477 (ARR; 3, 6 or 12 
mg/kg s.c) and ropinirole (Rop; 0.2 mg/kg i.p.) treatment in L-dopa-primed 6-OHDA-lesioned rats.  Data 
are presented as medians (n=8); (a-d) Time-course, and also individual values (a’-d’) Total; ++p<0.01, 
+++p<0.001 compared to vehicle + ARR 12 mg/kg s.c. Time-course data were analysed by 2-way-ANOVA 
and Friedman’s test followed by Dunn’s post hoc test, and all other data were analysed by Friedman’s 
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Figure 3-13 Peak scores and Duration of activity for axial (a & a’), limb (b & b’), orolingual (c & c’) and 
ALO AIMs (d & d’) expression following ARR17477 plus ropinirole treatment. ARR17477 (ARR; 3, 6 or 
12 mg/kg s.c) and ropinirole (Rop; 0.2 mg/kg i.p.) treatment in L-dopa-primed 6-OHDA-lesioned rats. 
Data are presented as medians and individual values (n=8); (a-d) Peak score and (a’-d’) Duration of 
activity;. +p<0.05, ++p<0.01, +++ p<0.001 compared to vehicle + ARR 12 mg/kg s.c treatment. Data were 
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Figure 3-14 Time-course and Total score for axial (a & a’), limb (b & b’), orolingual (c & c’) and ALO 
AIMs (d & d’) expression following 7-NI plus ropinirole treatment. 7-NI (12.5, 25.0 or 50.0 mg/kg i.p.) 
and ropinirole (Rop; 0.2 mg/kg i.p.) treatment in L-dopa-primed 6-OHDA-lesioned rats. Data are 
presented as medians (n=8); (a-d) Time-course, and also individual values (a’-d’) Total; *p<0.05, 
**p<0.01 compared to rop + vehicle treatment (colours used in (a-d) refer to key). Time-course data 
were analysed by 2-way-ANOVA and Friedman’s test followed by Dunn’s post hoc test, and all other 





















































                                                                                  




                                                                                  




                                                                                   




                                                                                 




                                                                                 




                                                                                  




                                                                         




                                                                         




                                                                          




                                                                          




Figure 3-15 Peak scores and Duration of activity for axial (a & a’), limb (b & b’), orolingual (c & c’) and 
ALO AIMs (d & d’) expression following 7-NI plus ropinirole treatment. 7-NI (12.5, 25.0 or 50.0 mg/kg 
i.p.) and ropinirole (Rop; 0.2 mg/kg i.p.) treatment in L-dopa-primed 6-OHDA-lesioned rats. Data are 
presented as medians and individual values (n=8); (a-d) Peak score and (a’-d’) Duration of activity; 
*p<0.05 compared to rop + vehicle treatment.  +p<0.05 compared to vehicle + 7-NI treatment. Data 
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3.4 Discussion 
The studies described in this chapter set out to establish how nNOS activity in the brain is affected by 
two inhibitors ARR17477 and 7-NI described in the literature, and subsequently to evaluate their 
capacity to treat established dyskinesia in PD. It was hypothesised that the selective inhibition of 
neuronal NOS would reduce the expression of dyskinesia by L-dopa or the dopamine agonist ropinirole, 
and this was tested in the 6-OHDA-lesioned rat primed to express dyskinesia by chronic L-dopa 
treatment. 
3.4.1 Inhibition of nNOS by ARR17477 and 7-NI 
Initial ex vivo studies confirmed that both ARR17477 and 7-NI could reduce nNOS activity in the striatum 
and cerebellum at 1 h following systemic administration. ARR17477 caused increasing inhibition with 
escalating doses, achieving a maximum reduction in nNOS activity at 12 mg/kg (56-60 %). Such inhibition 
of nNOS is consistent with Zhang et al. (1996), O'Neill et al. (2000) and Reif et al. (2000) who showed a 
significant reduction of nNOS activity following ARR17477 (1- 10 mg/kg i.v.) treatment at 2-3 h in rat 
cortex and cerebellum, although higher levels of inhibition were seen under these circumstances 
presumably owing to i.v. administration. Only Johansson et al. (1999) have employed ARR17477 
subcutaneously at comparable doses, showing positive behavioural effects attributed to nNOS inhibition 
at 0.5-5.0 mg/kg, but no ex vivo investigation was included. Thus the present study further verifies the 
utilisation of ARR17477 by a subcutaneous route of administration coupled with evidence for nNOS 
inhibition at an earlier (1hr) time point than previously described.  
The reduction of nNOS activity by 7-NI was maximal at 12.5-25.0 mg/kg and lessened as the dose was 
increased to 50 mg/kg i.p., which may be indicative of non-specific activity at the highest dose (see later 
discussion). Lack of a concentration effect on nNOS inhibition with increasing dose of 7-NI may also be 
explained by a reduction in solubility of the drug with increasing dose, whereas ARR17477 
demonstrated full solubility and a dose-response effect. The findings corroborate work by Moore et al. 
(1993b) who showed 7-NI (25 mg/kg i.p.) produces significant inhibition of nNOS in mouse cerebellum at 
15 min without affecting mean arterial blood pressure, and Mackenzie et al. (1994) who found 7-NI (30 
mg/kg i.p.) significantly reduced nNOS activity in rat cerebellum, striatum and cortex within 30 min, 
lasting for at least 4hrs. nNOS inhibition may be underestimated by the ex vivo as some dissociation of 
the inhibitor may have occurred during the assay, especially in the case of 7-NI which has reversible, 
relatively short-lasting effects (Moore & Bland-Ward, 1996). Indeed Salter et al. (1995), showed that 
there is a decrease in accuracy of a NOS assay in reflecting in vivo NOS activity as incubation time is 
increased, especially where inhibitors dissociate within a short time-frame. Again these discrepancies, 
suggest inhibitory activity would have been greater in reality.  
In conclusion the doses of nNOS inhibitors used in the ex vivo rat studies, specifically ARR17477 (3, 6 and 
12 mg/kg s.c.) and 7-NI (12.5, 25 and 50 mg/kg ip), were sufficient to cause a reduction in central nNOS 
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3.4.2 The effect of nNOS inhibition on L-dopa-induced AIMS expression  
Neither of the nNOS inhibitors ARR17477 or 7-NI, administered at brain penetrable doses to reduce 
nNOS activity, significantly attenuated L-dopa induced axial, limb, orolingual or locomotive AIMs 
expression in the L-dopa-primed 6-OHDA-lesioned rat. Indeed, contrary to the original hypothesis, 7-NI 
in combination with L-dopa extended the duration of ALO AIM’s expression.  
The extension in duration of L-dopa-induced ALO AIMs observed in these studies following 7-NI (50 
mg/kg) may be accounted for by non-nitrergic effects of the nNOS inhibitor as they were not observed 
following ARR17477 treatment. Non-nitrergic effects are further supported by the ex vivo data showing 
a small decrease in nNOS inhibition by 7-NI as the dose was increased from 25 mg/kg to 50 mg/kg. In 
addition to its nNOS activity there is evidence to suggest that 7-NI is also a potent MAOB inhibitor in 
vitro, where Ki = 4 μM, and also in vivo (Castagnoli et al., 1997; Di Monte et al., 1997; Desvignes et al., 
1999; Thomas et al., 2008). 7-NI administration alone was seen to induce some mild AIMs in 6-OHDA-
lesioned rats, above those of ARR17477 alone (although not significantly so) suggesting an inbalance in 
dopaminergic activity occurred in the 7-NI group which may have been caused by MAOB inhibitory 
effects. As well as inhibiting any upregulation of nNOS resulting from exposure to L-dopa, 7-NI could also 
prolong the duration of L-dopa effects by inhibiting the enzymatic breakdown of dopamine by MAOB 
(LeWitt, 1992). MAOB inhibition would account for an increased duration of L-dopa activity in the 
presence of 7-NI and hence the accompanying AIMS, without a worsening in their severity, as was 
indeed seen for axial, limb, orolingual and ALO AIMs at later time points. It should be noted that 
ARR17477 shows a mild interaction with MAOB in vitro (see Appendix, Table 0-1) although whether its 
activity is inhibitory or excitatory and would hold true in vivo is unknown. MAOB inhibitory effects may 
therefore not fully explain these differences between the duration of AIMs expression by L-dopa in 
combination with 7-NI and with ARR17477. 
It has also been reported that 7-NI may not be as selective for nNOS in vivo as originally described by 
Moore and colleagues (1993a). Zagvazdin et al. (1996) showed 7-NI (50 mg/kg) administration to cause a 
significant increase in mean arterial blood pressure suggesting eNOS activity may also be affected. In 
vitro data also support the relative lack of isoform selectivity with Babbedge et al. (1993) showing little 
difference in selectivity for nNOS over eNOS, and Vallance and Leiper (2002) reporting that 7-NI shows 
only 1.4-fold selectivity for nNOS over eNOS whereas ARR17477 shows 23-fold selectivity for nNOS over 
eNOS. Therefore at the highest dose of 7-NI where the duration of ALO AIMs is most extended 
compared to activity following L-dopa alone eNOS related effects could certainly account for this 
difference. Notably Padovan-Neto et al. (2009) did not report any increase in AIMs with 7-NI in 
combination with L-dopa and this may be due to their utilisation of a lower maximal dose of the nNOS 
inhibitor of only 30 mg/kg. The regulation of vascular smooth muscle by eNOS enables circulatory 
modulation of brain microvessels and consequently the inhibition of eNOS by 7-NI could result in 
vasoconstriction (Rees et al., 1989) which may interfere with the rate of L-dopa clearance hence 
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cerebral blood flow by 7NI (25 & 50 mg/kg). However further investigations would be necessary to 
confirm an effect of 7NI on dopaminergic pharmacokinetics as no data exist in the literature concerning 
eNOS-induced vasoconstriction and L-dopa clearance.   
It is noteworthy that although ARR17477 is more potent and nNOS-selective than 7-NI, it is still not ideal 
as an nNOS inhibitor showing a maximum 100-fold selectivity for nNOS over eNOS in the published 
literature (Reif et al. 2000; Johansson et al., 1999). However it is the best nNOS inhibitor available to 
date that can be systemically administered.     
Why do nNOS inhibitors not reduce the expression of dyskinesia in this study? Dyskinesia was 
undoubtedly present in all groups of animals used for these studies as demonstrated by the moderate to 
severe AIMs scores evident across the groups and dyskinesia clearly has the potential to be relieved as 
seen in the characterisation studies of Chapter 2 (section 2.3.2.3) where MK-801, 8-OHDPAT and 
amantadine all reduce expression of L-dopa-induced AIMs. Furthermore the AIMs model employed as 
established by Cenci and colleagues (1998) has been extensively characterised in the published 
literature and drugs reported to cause a reduction in dyskinesia in the clinic such as amantadine and 
clozapine have also been confirmed effective in this model (Lundblad et al., 2002; Dekundy et al., 2007).  
The most obvious explanation for the lack of efficacy in reducing AIMs by nNOS inhibition is that 
increased nNOS activity in itself is not a key factor underlying the expression of dyskinetic behaviour or 
perhaps the modulation of nNOS alone is insufficient to reduce dyskinesia in this model. However, this 
finding is in contrast to the finding of Padovan-Neto et al. (2009) who reported that 7-NI (30 mg/kg i.p.) 
reduced ALO and locomotive AIMs scores in the 6-OHDA-lesioned rat model. However there were a 
number of differences between these two studies – Padovan-Neto et al. (2009) initially primed animals 
with an exceptionally high dose of L-dopa (100 mg/kg p.o.), far beyond that required to reverse 
unilateral asymmetry and also routinely used to prime and induce AIMs (Cenci et al., 1998; Westin et al., 
2001; Picconi et al., 2003). This difference in dosage could have had various implications on underlying 
molecular changes occurring within the brain during the priming process, as supported by the fact that 
even naïve primates may develop dyskinesia following repeated high dose L-dopa administration 
(Pearce et al., 2001).  
Additionally the dose of L-dopa used by Padovan-Neto et al. (2009) to express AIMs was also 
considerably high (30 mg/kg p.o.) compared to the dose used for the studies presented in this chapter 
(6.25 mg/kg i.p.), and in comparison with the literature (Cenci et al., 1998; Putterman et al., 2007; Dupre 
et al., 2008; Monville et al., 2009). Indeed such higher doses of L-dopa greatly enhance rotational 
behaviour to the extent that they may obscure dyskinesia expressed in the trunk and limbs (Marin et al., 
2006). It is therefore possible that some dyskinesia may have gone unnoticed in these experiments. The 
difference in route of administration of L-dopa must be borne in mind, as oral bioavailability of L-dopa is 
lower than for systemic administration (Rose et al., 1993; Bredberg et al., 1994), although this 
discrepency does not fully explain the need for employing such high doses. Additionally, AIMS were only 
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in behaviour occurring at time points in between these observations. The findings presented within this 
chapter are in keeping with the AIMs model as developed by Cenci and collegues (1998), and 
pharmacologically relevant doses of dopaminergic drugs used to control motor symptoms in PD 
patients.  
These studies show that nNOS inhibition by ARR17477 or 7-NI does not reduce L-dopa-induced 
dyskinesia in the 6-OHDA-lesioned rat model.   
 
3.4.3 The effect of nNOS inhibition on ropinirole-induced AIMS expression  
As expected, the dopamine agonist ropinirole induced less severe dyskinesia overall, as measured by 
AIMs, compared to L-dopa. This supports the literature where ropinirole is described to induce more 
naturalistic behaviours without stereotopies, whilst L-dopa causes stereotypic behaviour and 
compulsive grooming in the 6-OHDA-lesioned rat (Eden et al., 1991; Ravenscroft et al., 2004). However, 
only descriptions of behaviour were published and AIMs were not measured per se. The present finding 
corroborates a more recent study showing ropinirole to cause a significant reduction in both overall 
duration and total ALO AIMs expression compared to L-dopa (Papathanou et al., 2011). As mentioned 
previously, some evidence suggests that relatively lower dyskinesia expression may occur after 
switching from L-dopa to dopamine agonists in animal models and PD patients further validating the 
observed difference, although it is uncertain whether benefits are long-lasting (Kapoon et al., 1989; 
Facca & Sanchez-Ramos, 1996; Hadj Tahar et al., 2000; Jackson et al., 2007).     
No significant reduction in AIMs subcategories by the nNOS inhibitors ARR17477 or 7-NI was observed 
when animals were treated with ropinirole in place of L-dopa. Similar to the effects seen on L-dopa-
induced AIMS, 7-NI in combination with ropinirole increased the duration of ALO AIMs in addition to 
increasing the duration of axial and locomotive AIMs expression. The overall total ALO AIMs expression 
was also increased by 7-NI administration.  
7-NI (50 mg/kg) significantly extended the overall duration of both ropinirole-induced axial and ALO 
AIMs activity by 75 min and total AIMS scores were also significantly higher for axial, limb and ALO AIMs 
meanwhile L-dopa-induced ALO AIMS were significantly extended by only 45 min without affecting 
totals or other AIMs subcategories. The general rationale for nNOS inhibitors not reducing ropinirole-
induced AIMs expression are equally valid as for L-dopa effects as described in section 3.4.2. In 
particular ropinirole-induced AIMs extension by 7-NI may be related to its MAOB associated activity, 
especially considering no such increase in duration of AIMs was induced by ARR17477. However MAOB 
effects are unexpected with a dopamine agonist acting post-synaptically. A possible explanation is that 
MAOB inhibition could enhance levels of any remaining endogenous dopamine which would act on both 
D1 and D2 receptors. There is evidence to suggest that a small amount of D1 activity coupled with D2-
specific agonism results in synergistic effects potentiating dopamine levels and associated behaviour in 
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the effect of 7-NI on AIMs appears more exaggerated with ropinirole (D2 selective) than L-dopa (D1 & 
D2). Additionally this phenomenon may relate to eNOS inhibition as already described in terms of the 
extension of the L-dopa response (see section 3.4.2).  
Furthermore, the shorter duration of AIMs expression in the 6-OHDA-lesioned L-dopa-primed rat 
observed following ropinirole compared to L-dopa, as corroborated by Papathanou et al. (2011),  would 
afford an increased period over which to potentially extend AIMs. This difference may provide a 
practical explanation as to why 7-NI in combination with ropinirole appeared to have a greater impact 
on dyskinesia expression both prolonging the duration over a wider time frame and also affecting more 
subtypes of overall AIMS than 7-NI in combination with L-dopa. Had AIMs been assessed over a longer 
time period following L-dopa treatment then less differences may have been apparent. This observation 
may also be dose-dependent and were a higher dose of ropinirole chosen it is possible that effects 
would not be dissimilar between the two types of dopaminergic agents.   
These studies show that nNOS inhibition by ARR17477 or 7-NI does not reduce ropinirole-induced 
dyskinesia in the 6-OHDA-lesioned rat model. 
   
3.4.4 Conclusion 
In summary, no significantly beneficial effect of nNOS inhibition on L-dopa-or ropinirole-induced AIMs 
expression has been demonstrated in L-dopa-primed 6-OHDA-lesioned rats within the studies discussed 
so far. Neither ARR17477 nor 7-NI significantly attenuated AIMs expression by dopaminergic drugs, and 
indeed the highest dose of 7-NI was shown to extend the duration of AIMs expression in combination 
with L-dopa and ropinirole, which is likely to be due to non-nNOS-specific effects of 7-NI.  
There may be key differences between mechanisms underlying the expression of AIMs by single acute 
challenges with dopaminergic agents and those changes occurring during the initial priming process 
where dyskinesia is induced in otherwise drug naïve animals. It is important to determine whether nNOS 
inhibitors may be effective in reducing or even preventing AIMs if administered in combination with 
dopaminergic drugs from the outset. The next chapter will investigate the role of nNOS inhibitors within 
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4.1 Introduction 
In the preceding chapter the inhibition of nNOS did not reduce the expression of AIMs generated by L-
dopa or ropinirole in L-dopa-primed 6-OHDA-lesioned rats. This finding suggests that neuronal nitric 
oxide may not be a critical factor underlying the expression of pre-established dyskinesia in rats 
following long-term dopaminergic treatment. Prior to nNOS inhibitor administration the animals 
employed within these previous studies had already received chronic treatment with L-dopa to induce 
behavioural changes, and accordingly the underlying molecular changes responsible for dyskinesia 
expression. By this stage irreversible adaptations may have taken place within the basal ganglia circuitry, 
which could no longer be impeded by nNOS inhibition, such as long-term changes in synaptic 
transmission (Belujon et al., 2010).  
The  manifestation of abnormal movements is considered a two-step process whereby ‘expression’ of 
dyskinetic behaviour is brought about by an induction, or so-called ‘priming’, phase (Brotchie, 2005).  
Thus, expression studies tend to mimic the later stages of PD therapeutics where dyskinesia is fully 
established and therefore exhibited with each subsequent dose of dopaminergic medication. The 
molecular changes underlying the induction of dyskinesia may well differ from those responsible for the 
execution of involuntary movements (Jenner, 2008b). Additionally due to the large extent of dopamine 
neurone degeneration necessary for the 6-OHDA-lesioned rat to potentially demonstrate dyskinesia 
(Cenci, 2007), the model pathologically mimics advanced PD when it may be markedly more challenging 
to influence molecular changes. The mechanisms underlying priming are yet to be fully elucidated but a 
variety of long-term pre- and post-synaptic changes undoubtedly accompany the appearance of 
dyskinesia both in animal models and in patients with PD, as described in detail in Chapter 1 (Cenci & 
Lundblad, 2006; Jenner, 2008b; Santini et al., 2008).  
The malfunction of corticostriatal plasticity (modified transmission efficacy occurring at synapses), has 
been closely linked to the manifestation of dyskinesia particularly due to its persistent nature and a 
correlation with severity of abnormal movements (Calabresi et al., 2000; Picconi et al., 2003; Prescott et 
al., 2008). Furthermore, nitric oxide (NO) acts as a critical messenger capable of initiating molecular 
alterations leading to changes in synaptic plasticity such as long-term potentiation and long-term 
depression (LTP/LTD) in the CNS and more specifically the striatum (Calabresi et al., 1999; Prast & 
Philippu, 2001; West et al., 2002).  Aside from the extent of striatal dopamine loss, the onset of 
dyskinesia is inextricably related to the use of dopaminergic medication (Crossman, 1990), thus 
intervention occurring before these long-term alterations or synaptic changes are induced could 
potentially prevent dyskinesia.  
Implications of timing raise the question, if drug naïve 6-OHDA-lesioned rats were co-administered 
nNOS inhibitors from first exposure to dopaminergic treatment, is it possible that the priming 
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4.1.1 Hypothesis 
It is hypothesised that inhibition of nNOS will prevent the induction of dyskinesia by dopaminergic drug 
treatment in 6-OHDA-lesioned rats.  
 
4.1.2 Aims 
The aim of the studies reported in this chapter was to determine whether nNOS inhibitors can prevent 
the induction of dyskinesia (priming) following administration of dopaminergic treatment to drug naive 
6-OHDA-lesioned rats, more specifically to investigate; 
1. The effect of chronic treatment with the selective and irreversible nNOS inhibitor ARR17477 on nNOS 
activity at a range of doses ex vivo. 
2. The effect of the nNOS inhibitors ARR17477 and 7-NI on the induction of AIMs by chronic L-dopa 
administration in 6-OHDA-lesioned rats. 
3. The effect of the nNOS inhibitors ARR17477 and 7-NI on the induction of AIMs by chronic ropinirole 
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4.2 Materials and methods 
4.2.1 Introduction 
These studies aimed to investigate the effect of chronic administration of nNOS inhibitors on the 
priming for AIMs by L-dopa and ropinirole in 6-OHDA-lesioned rats. Although 7-NI has already been used 
widely in chronic treatment studies it was first necessary to establish the dose of ARR17477 required in 
order to inhibit nNOS for the chronic in vivo studies. Subsequently the effect of chronic administration 
of nNOS inhibitors was investigated on dopaminergic-mediated induction of AIMs, in drug-naïve 6-
OHDA-lesioned rats. AIMs were assessed regularly throughout the course of long term treatment to 
ascertain the effects of nNOS inhibition. The methods for these studies are described below.  
4.2.2 Animals  
For all experiments male Wistar rats (200-250 g; Harlan, UK or B & K, UK) were housed 2-3 per cage in 
the Biological Service Unit, King’s College London. Room temperatures were maintained at 19-21 ˚C at 
55 % humidity with a 12 h light-dark cycle and animals had free access to pelleted food and water, as 
described in section 2.2.2. Experiments were performed in accordance with the UK Animals (Scientific 
Procedures) Act, 1986 under Home Office project licence no. 70/6019 or 70/6898.      
4.2.3 Determination of the dose of nNOS inhibitor  
4.2.3.1 7-NI 
A dose of 7-NI (25 mg/kg dissolved in DMSO:saline 0.9 %, 50:50, i.p.) was chosen based on previous 
chronic studies performed in these laboratories and was in agreement with the published literature, 
(Mackenzie et al., 1994; Przedborski et al., 1996; Bush & Pollack, 2001; Li et al., 2002). This same dose 
(25 mg/kg i.p.) was also employed in the ex vivo and acute study of effects of nNOS inhibitors on 
dyskinesia expression (See Chapter 3, section 3.2.3). Taking into account the reversible nature of the 
inhibitor and its short half life (Moore et al., 1993b) as well as its use in numerous chronic studies to 
date, there was no concern over the effects of long-term 7-NI treatment in rats, hence no further ex vivo 
was warranted with this drug. Additionally studies have also shown there to be no adverse effects of 
dosing repeatedly with 7-NI at a similar dose (Przedborski et al., 1996; Li et al., 2002; Wangensteen et 
al., 2006).  
4.2.3.2 ARR17477 
It was desirable to reduce the dose of ARR17477 as far as possible from that employed in the acute 
studies of Chapter 3, to eliminate non-specific drug effects owing to drug accumulation during chronic 
treatment, due to its long lasting inhibition and irreversible nature (Zhang et al., 1996; Reif et al., 2000). 
These could include activity at adrenergic receptors, vesicular monoamine, norepinephrine or dopamine 
transporters (see Appendix, Table 0-1), or effects on eNOS activity. 
Therefore to determine the chronic effect of the nNOS inhibitor ARR17477 in rat brain, enzyme activity 
was assessed in rats by measuring the conversion of L-arginine to L-citrulline ex vivo following chronic 
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these studies was determined in experiments measuring the inhibition of nNOS activity ex vivo following 
chronic systemic administration. 
4.2.3.2.1 Ex vivo determination of ARR17477 dose 
Naïve male Wistar rats (n=4/group; 200-250 g) were treated daily with ARR17477 (0.5, 1, 3 or 6 mg/kg 
s.c.) or vehicle (saline 0.9 %; 1 ml/kg s.c.) for four consecutive days and culled by decapitation at 12 h 
after the final dose. These doses were chosen based on those selected for acute studies (see Chapter 3), 
taking into consideration the implications of irreversible binding properties of ARR17477 (personal 
communication with R.Silverman, Northwestern University, Chicago) on a chronic treatment regime. 
The cerebellum was dissected out, snap frozen and stored at -70 ˚C for measurement of nNOS activity 
by radioenzymatic assay. 
In order to confirm nNOS inhibition at an earlier time point the ex vivo study was repeated with animals 
treated with ARR17477 1 mg/kg s.c. or vehicle (saline 0.9 %; 1 ml/kg s.c.) for four consecutive days and 
then culled by decapitation at a 1 h time point after the final dose. Tissue was then dissected out as 
described above. 
4.2.3.2.2 Radioenzymatic measurement of NOS activity 
nNOS activity was determined in brain homogenates by measuring enzymatic conversion of L-[³H]-
arginine to L-[³H]-citrulline as fully described in section 2.6.1. Briefly homogenised tissue samples were 
centrifuged (as detailed in section 2.6.1.2), and supernatants transferred to a 96-well plate in triplicate. 
Boiled supernatant was used as a negative control. A pre-prepared reaction mixture containing L-[2,3,4-
3H] arginine monohydrochloride (1 mCi/ml; 16.7 μM) and CaCl2 (6 mM) was added (30 μl/well) and the 
plates incubated for 1 h at 30 °C. The reaction was terminated and the reaction mixture further 
processed to measure L-[³H]-citrulline formation, by the addition of resin and subsequent filtration of 
the samples as described in section 2.6.1.2. L-[³H]-citrulline was determined in a Beta-liquid 
scintiallation counter (see section 2.6.1.2) whilst protein content of samples was quantified with a 
NanoDrop spectrophotometer (see 2.6.1.3). Data were analysed as described in section 2.6.1.4 
expressing nNOS activity as L-[³H]-citrulline formation per mg of protein per hour. 
4.2.3.2.3 ARR17477 results 
ARR17477 lowered nNOS activity in a dose-related manner with a significant reduction of 56, 61 and 73 
% following doses of 1, 3 and 6 mg/kg s.c. respectively in the cerebellum at 12 h following 4 days of 
chronic treatment (Figure 4-1). A further ex vivo study of ARR17477 (1 mg/kg s.c.) dosed for 4 
consecutive days showed a 95 % reduction in nNOS activity at 1 h (Figure 4-2). This time point would 
coincide with peak plasma levels of dopaminergic treatment and therefore ARR17477 (1 mg/kg s.c.) was 



























Figure 4-2 Radioenzymatic measurement of the effect of repeated ARR17477 (1 mg/kg s.c.) treatment 
on nNOS activity in cerebellum. Naïve rats were treated with ARR17477 or vehicle (0.9 % saline s.c.) for 
four consecutive days and culled by decapitation at 1 h after the final dose. nNOS activity is displayed as 
L-[3H]-citrulline formation (cpm/mg protein); Data are presented as means ± SEM (n=4/group); *** 
P<0.001 compared to vehicle treatment. Data wereanalysed by t-test.  
 
Figure 4-1 Radioenzymatic measurement of the effect of repeated ARR17477 (0.5, 1, 3 or 6 mg/kg s.c.) 
treatment on nNOS activity in cerebellum. Naïve rats were treated with ARR17477 or vehicle (0.9 % 
saline s.c.) for four consecutive days and culled by decapitation at 12 h after the final dose. nNOS 
activity is displayed as L-[3H]-citrulline formation (cpm/mg protein); Data are presented as means ± SEM 
(n=4/group); **P<0.01 *** P<0.001 compared to vehicle treatment. Data were analysed by one-way 
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4.2.4 Behavioural Studies 
4.2.4.1 Unilateral 6-OHDA lesion 
Male Wistar rats (see section 4.2.2) maintained under general anaesthesia (2-3 % isofluorane in 95 % O2 
and 5 % CO2) were unilaterally lesioned with 6-OHDA in the left MFB using standard stereotaxic 
techniques, as described fully in section 2.2.3. In brief, 6-OHDA hydrochloride (8 µg free base in 4 µl 0.9 
% saline containing 0.05 % ascorbic acid) was injected at a rate of 1 µl per minute into the medial 
forebrain bundle (according to the coordinates of Paxinos and Watson, 1986; A-P:-2.6 mm, M-L: +2.0 
mm, V:-8.8 mm as measured from bregma). The needle was left in place for 4 min to allow for the 6-
OHDA to diffuse into the surrounding region and then slowly withdrawn before cleaning and suturing 
the wound. Animals were cared for post-operatively as described in section 2.2.4. 
Three-four weeks after surgery rats were treated with amphetamine sulphate (2.5 mg/kg i.p. in 0.9 % 
saline) and rotational behaviour was monitored as described in section 2.3.1. Only rats exhibiting 7 or 
more ipsilateral turns per minute at peak activity were used for further studies.  
4.2.4.2 Chronic drug challenges in combination with nNOS inhibitors 
Untreated 6-OHDA-lesioned rats were divided into seven treatment groups (n=8-10/group), as shown in 
Table 4-1, each balanced for mean total rotations following amphetamine screening as described in 
4.2.4.1. Preliminary studies were performed to establish whether ARR17477/7-NI induced dyskinesia 
with chronic treatment (Groups 1a & 1b, Table 4-1). Subsequently priming studies with L-dopa or 
ropinirole alone or in combination with nNOS inhibitors were carried out (Groups 2-7, Table 4-1). These 
studies employed a staggered design where representative animals from each treatment group were 
assessed for AIMs daily. 
Animals (Groups 2-7) were treated once daily with nNOS inhibitors ARR17477 (1 mg/kg in saline 0.9 %  
s.c.) or 7-NI (25 mg/kg in DMSO: saline 0.9 %, 50:50 i.p), or vehicle (1 ml/kg; saline 0.9 % s.c. or DMSO: 
saline, 0.9 %, 50:50 i.p.) for 3 days prior to co-administration of nNOS inhibitors with L-dopa methyl 
ester (6.25 mg/kg free base + benserazide 15 mg/kg, in saline 0.9 %, i.p.) or ropinirole (0.2 mg/kg, in 
saline 0.9 %, i.p.) daily for 22 days. Group 1 animals received nNOS inhibitors alone for the pre-
treatment and treatment phases amounting to 25 days in total. See Table 4-1 for individual treatment 
groups and course of drug administration. 
At the end of the chronic treatment phase following a 1 week drug washout animals were challenged 
acutely with L-dopa methyl ester (6.25 mg/kg free base + benserazide 15 mg/kg i.p.) or ropinirole (0.2 
mg/kg i.p.) on two separate occasions 1 week apart. 
4.2.4.3 AIMs assessment 
Dyskinesia was assessed based on the observation of four subtypes of AIM’s; locomotive, axial, limb and 
orolingual (originally described by Cenci et al., 1998), each rated on a scale of 0-4 dependent on 
frequency and intensity (see section 2.3.2.2). AIMs were assessed one day prior to the start of nNOS 
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pretreatment (Day -2; baseline2 ‘B2’) and then every third day starting from Day 1-22 of chronic 
treatment. AIMs were also assessed in the two final acute challenges described above (see Figure 4-3).  
On each assessment day rats were placed in transparent cages (set up as shown in Figure 2.5, Chapter 2) 
one hour before drug treatment commenced to enable acclimatisation (as described in section 2.3.2.2). 
Baseline AIMs for each session were scored 20 min and 5 min prior to dosing as described in section 
2.3.2.2. Following drug treatment AIMs were assessed for 5 min every 15 min for a total of 210 min in 
the L-dopa priming studies and 180 min in the ropinirole priming studies.  
 
Table 4-1 AIMs assessment treatment groups and drug administration during initial habituation (day      
-3), pre-treatment (days -2-0), treatment (days 1-22) and final acute challenges. Groups 1a&b were 
nNOS inhibitor controls, 2-4 were nNOS inhibitor + L-dopa treatment groups and 5-7 were nNOS 
inhibitor + ropinirole treatment groups. L-dopa was always administered with benserazide (15 mg/kg 
i.p.). 














ARR17477 (1 mg/kg s.c.) 
7-NI (25 mg/kg i.p.) 
ARR17477 (1 mg/kg s.c) 
7-NI (25 mg/kg i.p.) 
- 
- 
2 10 - Vehicle 
L-dopa (6.25 mg/kg i.p.) 
 + vehicle 
L-dopa  
(6.25 mg/kg i.p.) 
3 10 - ARR17477 (1 mg/kg s.c) 
L-dopa (6.25 mg/kg i.p.) 
 + ARR17477 (1 mg/kg s.c) 
L-dopa 
 (6.25 mg/kg i.p.) 
4 10 - 7-NI (25 mg/kg i.p.) 
L-dopa (6.25 mg/kg i.p.) 
 + 7-NI (25 mg/kg i.p.) 
L-dopa  
(6.25 mg/kg i.p.) 
5 10 - Vehicle 




6 10 - ARR17477 (1 mg/kg s.c) 
ropinirole (0.2 mg/kg i.p.)  
+ ARR17477 (1 mg/kg s.c) 
ropinirole (0.2 
mg/kg i.p.) 
7 10 - 7-NI (25 mg/kg i.p.) 
ropinirole (0.2 mg/kg i.p.)  





4.2.5 Data and statistical analysis 
Total and peak AIMs scores, and duration of AIMs activity were plotted as medians, throughout the 
chronic treatment phase, using data collected from individual test days. Any animals showing <90 % 
dopaminergic cell loss in SNpc at the lesioned compared to non-lesioned hemishphere, determined 
post-behavioural experiments by TH immunohistochemistry (See Chapter 2; section 2.6.2), were 
excluded from data analysis. Total AIMs scores for each assessment day were calculated by AUC 
(Graphpad Prism version 5.0) using the trapezoid method where each successive 15 min was labelled as 
a single time-bin and peak score was taken as the maximum AIMs score achieved per 15 min. The 
duration of AIMs was calculated taking into account all score periods gaining above 0 and in the case of 
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and Friedman’s test, and additionally Kruskal-Wallis test followed by Dunn’s post hoc test where 
appropriate. Summed data were also plotted for the full priming period using AUC (Graphpad Prism 
version 5.0) of 22 day total and peak AIMs scores, and duration of AIMs activity. Additionally final 
challenge data were plotted as a mean of the two final acute L-dopa challenges for total and peak AIMs 
scores, and duration of AIMs activity. Kruskall Wallis tests were used to compare the effect of treatment 
on summed AIMs scores for the priming period and also the subsequent L-dopa challenges. In all cases 
statistical significance was set at p<0.05 and analyses were carried out in Graphpad Prism 5. Additionally 
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4.3 Results 
4.3.1 AIMs in 6-OHDA-lesioned rats primed with nNOS inhibitor alone 
No significant effect of chronic treatment with ARR17477 or 7-NI on the induction of locomotive, axial, 
limb, orolingual or ALO AIMs (Two-way ANOVA and Friedman’s test on total, peak and duration of AIMs; 
data not shown). Therefore the two groups were combined to give an nNOS inhibitor control group. 
There was no effect of chronic nNOS inhibitor treatment alone on any AIMs subcategory, as exemplified 
in Figure 4-4 showing total locomotive or ALO AIMs scores throughout the 22 days (individual AIMs 
















Figure 4-4 Locomotive (a) and ALO Total AIMs (b) following chronic treatment with ARR17477 or 7-NI. 
ARR17477 (ARR; 1 mg/kg s.c) or 7-NI (25 mg/kg i.p.) in 6-OHDA-lesioned rats. Data are combined for the 
two nNOS inhibitors and presented as medians (n=8); (a) locomotive, (b) ALO AIMs. Data were analysed 
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4.3.2 Locomotive AIMs in 6-OHDA-lesioned rats chronically treated with L-dopa plus 
nNOS inhibitor 
4.3.2.1 Vehicle + L-dopa chronic treatment 
L-dopa alone induced locomotive AIMs scoring 2 on day 7 of chronic treatment increasing to a total of 5 
by day 10 (Figure 4-5a). A maximum peak locomotive score of mild levels scoring 1 was achieved by day 
10 continuing at a similar level through to day 22 (Figure 4-5b). The duration of locomotive AIMs activity 
increased from 25 min on day 7 to a maximal 90 min duration on day 10 and fluctuated between 25 and 
80 min on assessment days thereafter (Figure 4-5c). As expected locomotive AIMs significantly changed 
over the priming period as measured by all three parameters, increasing from baseline levels prior to 
initiation of L-dopa treatment.     
4.3.2.2 nNOS inhibitor + L-dopa chronic treatment 
There was no significant effect of ARR17477 or 7-NI on L-dopa-induced locomotive AIMs as measured by 
total AIMs score (Figure 4-5a), peak (Figure 4-5b), or duration of activity (Figure 4-5c). Although 
ARR17477 induced mild AIMs peaking at 1 and lasting for 45 min at the earlier time point of day 4 as 
compared to the L-dopa alone where animals showed no AIMs at this stage, and locomotive AIMs 
tended to be reduced from day 7 onwards, these differences did not reach statistical significance (Figure 
4-5a-c). The summed totals, and peaks graphs (Figure 4-5a’-b’) all showed a tendency for ARR17477 to 
reduce L-dopa-induced locomotive AIMs but again there was no statistical significance between the 
treatment groups.      
4.3.2.3 L-dopa final acute challenges  
Following chronic treatment with L-dopa alone, subsequent acute treatment with L-dopa alone induced 
a median total locomotive AIMs score of 5 (Figure 4-6a), with a peak score of 1 (Figure 4-6b) and a 
duration of 65 min (Figure 4-6c). There was no significant effect of chronic 7-NI plus L-dopa treatment 
on subsequent L-dopa-induced locomotive AIMs as measured by total or peak AIMs scores or durations 
of activity (Figure 4-6a-c). Chronic ARR17477 treatment tended to reduce total and peak AIMs scores 
and duration of activity, although these effects did not reach statistical significance (Figure 4-6a-c).  
 
4.3.3 Locomotive AIMs in 6-OHDA-lesioned rats with ropinirole plus nNOS inhibitor 
4.3.3.1 Vehicle + ropinirole 
Ropinirole alone induced mild locomotive AIMs which significantly increased across the treatment 
period with a total score of 1.5 on day 13 steadily increasing to 4 by day 22 (Figure 4-7a). A peak score of 
1.5 was achieved by day 22 (Figure 4-7b), and the average duration of activity increased from 15 min on 
day 13 to 45 min on day 22 (Figure 4-7c). Ropinirole produced locomotive AIMs of a similar severity level 
to L-dopa, but these were not expressed until a later time point and lasted for a shorter duration on 




 Chapter 4 
4.3.3.2 nNOS inhibitor + ropinirole 
No significant effect of ARR17477 or 7-NI was observed on ropinirole-induced locomotive AIMs as 
measured by total AIMs (Figure 4-7a), peak scores (Figure 4-7b) or duration of activity (Figure 4-7c). 7-NI 
appeared to induce AIMs at an earlier time point than ropinirole alone although this effect was not 
significant. The summed totals, peaks and duration graphs (Figure 4-7a’-c’) further confirmed there was 
a trend for increased locomotive AIMs but no overall significant effect of treatment. There was also a 
trend for ARR17477 increasing summed total locomotive AIMs, although this effect did not reach 
statistical significance (Figure 4-7a’).  
4.3.3.3 Ropinirole final acute challenges  
Acute treatment with ropinirole alone induced an average total locomotive AIMs score of 4 (Figure 
4-8a), with a peak of 1.75 (Figure 4-8b) and duration of activity of 45 min (Figure 4-8c) in animals 
previously chronically treated with ropinirole alone. There was no significant effect of ARR17477 or 7-NI 
plus ropinirole chronic treatment on subsequent ropinirole induced locomotive AIMs in terms of total 























Figure 4-5 Locomotive AIMs following chronic treatment with ARR17477 or 7-NI plus L-dopa. 
ARR17477 (ARR; 1 mg/kg s.c), 7-NI (25 mg/kg i.p.) and L-dopa (LD; 6.25 mg/kg plus benserazide 15 
mg/kg i.p.) in 6-OHDA-lesioned rats. Data are all presented as medians and also a’-c’ as interquartile 
ranges, (n=9-10); (a) Total score, (b) Peak score, (c) Duration of activity and (a’-c’) Summed data over all 
treatment days for graphs a-c respectively. +p<0.05, ++p<0.01, +++p<0.001 for time (colours used in (a-
c) refer to key). Data (a-c) were analysed by 2-way-ANOVA and Friedman’s test or (a’-c’) by Kruskal-
















Figure 4-6 Locomotive AIMs following final L-dopa challenges. L-dopa (LD; 6.25 mg/kg plus benserazide 
15 mg/kg i.p.). Data are presented as medians and individual values (n=9-10) and groups are labelled 
according to their prior chronic treatment; (a) Total score, (b) Peak and (c) Duration of activity. Data 








Figure 4-7 Locomotive AIMs following chronic treatment with ARR17477 or 7-NI plus ropinirole. 
ARR17477 (ARR; 1 mg/kg s.c), 7-NI (25 mg/kg i.p.) and ropinirole (Rop; 0.2 mg/kg i.p.) in 6-OHDA-
lesioned rats. Data are all presented as medians and also a’-c’ as interquartile ranges, (n=9-10); (a) Total 
score, (b) Peak score, (c) Duration of activity and (a’-c’) Summed data over all treatment days for graphs 
a-c respectively. +++p<0.001 for time (colours used in (a-c) refer to key). Data (a-c) were analysed by 2-





























Figure 4-8 Locomotive AIMs following final ropinirole challenges. Ropinirole (Rop; 0.2 mg/kg i.p.). Data 
are presented as medians and individual values (n=9-10) and groups are labelled according to their prior 
chronic treatment; (a) Total score, (b) Peak and (c) Duration of activity. Data were analysed by Kruskal-
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4.3.4 Axial, limb, orolingual and ALO AIMs in 6-OHDA-lesioned rats chronically 
treated with L-dopa plus nNOS inhibitor 
4.3.4.1 Vehicle + L-dopa 
L-dopa alone induced axial AIMs which significantly increased over the treatment period with total score 
reaching levels of 10 by day 7 and further escalating until reaching a maximum total of 24 on day 16 and 
then showing a small decrease thereafter (Figure 4-9a). On day 1 axial AIMs peaked at mild levels of 1 
and then showed a similar pattern as total scores, reaching a maximal marked peak score of 3 on day 16 
and continuing at moderate to marked levels until the final day of chronic treatment (Figure 4-10a). The 
median duration of axial AIMs increased from 55 min on day 1 to 120 min by day 13 and continued over 
a similar length of time up until day 22 (Figure 4-11a). 
Limb AIMs also significantly increased over time growing from a total score of 9 on day 4 to 17 by day 7 
and similar levels were maintained from here onwards and a maximal total score on 19 was observed on 
day 16 (Figure 4-9b). Peak limb AIMs increased from a mild-moderate score of 1.5 on day 4 to a 
moderate-marked 2.5 on day 7 which was also the maximal peak score and fluctuated between 2 and 
2.5 over the remaining days of chronic treatment (Figure 4-10b). The duration of limb AIMs also 
increased from 90 min on day 4 to 130 min on day 7 and persisted for a comparable duration thereon 
(Figure 4-11b).     
Orolingual AIMs showed a total score of 6 on day 1 and gradually increased reaching a maximum total of 
18 on day 13 and continuing at similar levels until day 22 (Figure 4-9c), significantly escalating over time. 
Peak orolingual AIMs did not increase above median baseline levels until day 4 when a maximal peak 
score of 2 was exhibited and maintained until the final day of chronic treatment (Figure 4-10c). 
Following a similar trend as total scores the duration of orolingual AIMs increased from 8 min on day 1 
to a maximum length of 100 min on day 13 and continued at similar mildly fluctuating levels thereafter 
(Figure 4-11c).     
ALO AIMs reflected individual AIMs categories for L-dopa alone steadily increasing from a total score of 
14 on day 1 reaching a maximum total score of 55 on day 16, and showing a small decline to 40 by day 
22 (Figure 4-9d). Peak scores began mildly from above baseline on day 1 of L-dopa treatment showing 
moderate peak scores of 5 by day 7 and increasing to a maximum marked peak of 7 by day 16 and 
declining back to a similar peak of 6 by day 22 (Figure 4-10d). The duration of ALO AIMs increased from 
60 min on day 1 to a maximum duration of 135 min by day 7 and persisted over a very similar time 
frame up until day 22 (Figure 4-11d).   
 
4.3.4.2 nNOS inhibitor + L-dopa  
7-NI significantly increased the duration of limb AIMs on day 4 compared to L-dopa alone and also the 
duration of ALO AIMs on days 4 and 22 of chronic treatment (Figure 4-11b & d). These findings were 
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limb AIMs and ALO AIMs following 7-NI treatment (Figure 4-11b’ & d’). There was some tendency for 7-
NI to increase the total score and duration of axial AIMs, although there was no statistical effect (Figure 
4-9a-b & Figure 4-11a-b). 
There was no significant effect of ARR17477 on L-dopa-induced axial, limb, orolingual or ALO AIMs over 
the 22 day chronic treatment phase, as measured by totals, peaks or duration, compared to L-dopa 
alone (Figure 4-9a-d, Figure 4-10a-d & Figure 4-11a-d). There was also no significant effect of ARR17477 
on summed total, peak or duration of axial, limb, orolingual or ALO AIMs (Figure 4-9a’-d’, Figure 4-10a’-
d’ & Figure 4-11a’-d’). 
 
4.3.4.3 L-dopa final acute challenges  
Acute treatment with L-dopa alone induced a median total axial score of 17 (Figure 4-12a), with a 
moderate peak score of 2 (Figure 4-12a’) and duration of activity of 65 min (Figure 4-12a’’) in animals 
which had been chronically treated with L-dopa alone. 
Limb AIMs showed a total score of 14 (Figure 4-12b), a moderate peak score of 2 (Figure 4-12b’) and 
were expressed for 120 min (Figure 4-12b’’). 
Orolingual AIMs showed a total score of 9 (Figure 4-12c), a moderate peak score just below 2 (Figure 
4-12c’) and were expressed for 45 min (Figure 4-12c’’). 
ALO AIMs showed a total score of 35 (Figure 4-12d), a moderate peak score of 6 (Figure 4-12d’) and 
were expressed for 125 min (Figure 4-12d’’). 
There was no significant effect of ARR17477 or 7-NI plus L-dopa chronic treatment on subsequent L-
dopa-induced axial, limb, orolingual or ALO AIMs in terms of total scores, peaks or durations of activity 
(Figure 4-12a-d, a’-d’ & a’’-d’’). However ARR17477 tended to reduce axial AIMs as measured by total 
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Figure 4-9 Total and Summed total scores for axial (a-a’), limb (b-b’), orolingual (c-c’) and ALO AIMs (d-
d’) following chronic treatment with ARR17477 or 7-NI plus L-dopa. ARR17477 (ARR; 3, 6 or 12 mg/kg 
s.c), 7-NI (25 mg/kg i.p.) and L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) treatment in 6-
OHDA-lesioned rats. Data are all presented as medians and also a’-d’ as interquartile ranges, (n=9-10); 
(a-d) Total scores and (a’-d’) Summed data over all treatment days. +++p<0.001 for time (colours used in 
(a-d) refer to key). Data (a-d) were analysed by 2-way-ANOVA and Friedman’s test or (a’-d’) by Kruskal-
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Figure 4-10 Peak and Summed peak scores for axial (a-a’), limb (b-b’), orolingual (c-c’) and ALO AIMs 
(d-d’) following chronic treatment with ARR17477 or 7-NI plus L-dopa. ARR17477 (ARR; 3, 6 or 12 
mg/kg s.c), 7-NI (25 mg/kg i.p.) and L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.) treatment in 
6-OHDA-lesioned rats. Data are all presented as medians and also a’-d’ as interquartile ranges, (n=9-10); 
(a-d) Total scores and (a’-d’) Summed data over all treatment days. +++p<0.001 for time (colours used in 
(a-d) refer to key). Data (a-d) were analysed by 2-way-ANOVA and Friedman’s test or (a’-d’) by Kruskal-
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Figure 4-11 Duration and Summed duration of activity scores for axial (a-a’), limb (b-b’), orolingual (c-
c’) and ALO AIMs (d-d’) following chronic treatment with ARR17477 or 7-NI plus L-dopa. ARR17477 
(ARR; 3, 6 or 12 mg/kg s.c), 7-NI (25 mg/kg i.p.) and L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg 
i.p.) treatment in 6-OHDA-lesioned rats. Data are all presented as medians and also a’-d’ as interquartile 
ranges, (n=9-10); (a-d) Total scores and (a’-d’) Summed data over all treatment days. +++p<0.001 for 
time; *p<0.05 **p<0.01 for treatment compared to rop + vehicle (colours used in (a-d) refer to key). 
Data (a-d) were analysed by 2-way-ANOVA and Friedman’s test, or Kruskal-Wallis test followed by 
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Figure 4-12 Final L-dopa challenge data for axial (a-a’’), limb (b-b’’), orolingual (c-c’’) and ALO AIMs (d-
d’’). L-dopa (LD; 6.25 mg/kg plus benserazide 15 mg/kg i.p.). Data are presented as medians and 
individual values (n=9-10) and groups are labelled according to their prior chronic treatment; (a-d) Total 
score, (a’-d’) Peak score and (a’’-d’’) Duration of activity. Data were analysed by Kruskal-Wallis test. The 
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4.3.5 Axial, limb, orolingual and ALO AIMs in 6-OHDA-lesioned rats chronically 
treated with ropinirole plus nNOS inhibitor 
4.3.5.1 Vehicle + ropinirole  
Ropinirole alone induced axial AIMs which significantly increased over the chronic treatment period 
resulting in a total score of 3 on day 7 very gradually increasing to 5 by day 13 and 7.5 by day 22 (Figure 
4-13a). On day 7 axial AIMs had a moderate peak score of 2, which was also the maximum peak score 
seen over the 22 day of chronic treatment (Figure 4-14a). By day 10 animals showed a reduced peak 
axial score of just above 1 and these mild AIMs gradually increased back up to 2 by day 22.  The duration 
of axial AIMs was 30 min on day 7, extending to 60 min by day 10 with minor fluctuations from here on 
and finally showing axial activity for 70 min on day 22 (Figure 4-15a). 
Limb AIMs significantly increased over the chronic treatment period where a total score of 1 was 
recorded on day 16, decreasing to give a median total score of 0.5 on all subsequent assessment days 
(Figure 4-13b). The peak limb AIMs score for day 16-22 was a very mild 0.5 (Figure 4-14b), whilst the 
duration of activity was 15 min on day 16 shortening to just under 10 min on the remaining days (Figure 
4-15b). 
Orolingual AIMs scored a total of 2 on day 10 and showed a gradual increase over time reaching 5.5 on 
day 22 (Figure 4-13c), significantly rising over the full treatment period.  Peak orolingual AIMs scored 1 
at baseline and did not rise beyond this level until day 19 when the score was a mild-moderate 1.75, 
being displayed similarly on day 22 (Figure 4-14c). The duration of orolingual AIMs activity was 15 min 
on day 19 increasing to 25 min on day 22 (note only periods with scores above 1 are used to calculate 
the duration of orolingual AIMs – see section 2.3.2.2) (Figure 4-15c).       
ALO AIMs showed a total score of only 2.5 on day 4, accounting for the orolingual AIMs observed early 
on, and gradually increased in keeping with the individual AIMs subtypes reaching a final total score of 
13 on day 22 (Figure 4-13d). Peak ALO AIMs of a mild score of 2 were seen from day 7 onwards 
increasing to more moderate levels of 4-4.5 over days 19-22 (Figure 4-14d). The duration of ALO AIMs 
was 30 min on day 7, increasing to 45 min by day 13 and reaching 60 min from day 19 onwards (Figure 
4-15d).    
4.3.5.2 nNOS inhibitor + ropinirole  
7-NI in combination with ropinirole induced axial AIMs on day 4 that were significantly higher scoring 
than ropinirole alone as measured by totals and peak scores (Figure 4-13a & Figure 4-14a), and also 
significantly longer lasting as measured by duration of activity (Figure 4-15a). Additionally on day 16, 7-
NI significantly increased the duration of activity of axial AIMs as compared to ropinirole treatment 
alone (Figure 4-15a). The display of axial AIMs was effectively extended by 7-NI treatment, first 
appearing on day 4 (with a total score of 7, peak score of 2 and duration of activity of 60 min compared 
to 0 for ropinirole alone treatment on the same day) rather than day 7 and continuing for 90 min rather 
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orolingual or ALO AIMs as measured by totals, peaks or duration throughout the 22 days of treatment 
(Figure 4-13b-d, Figure 4-14b-d & Figure 4-15b-d). Summed total scores over the chronic treatment 
phase also showed 7-NI significantly increased the duration of ropinirole-induced axial AIMs (Figure 
4-15a’), although these data did not reveal any other significant effects (Figure 4-13a’-d’, Figure 4-14a’-
d’ & Figure 4-15b’-d’). There was however a tendency for 7-NI to increase summed total axial AIMs in 
addition to summed total, peak and duration of limb AIMs (Figure 4-13b’ and d’ & Figure 4-15b’). 
ARR17477 plus ropinirole had no significant effect on axial, limb, orolingual or ALO AIMs activity over 
the chronic treatment period as measured by totals, peaks or duration, compared to ropinirole alone 
(Figure 4-13a-d, Figure 4-14a-d & Figure 4-15a-d). There was also no significant effect of ARR17477 on 
summed total, peak or duration of axial, limb, orolingual or ALO AIMs (Figure 4-13a’-d’, Figure 4-14a’-d’ 
& Figure 4-15b’-d’)       
4.3.5.3 Ropinirole final acute challenges  
Acute treatment with ropinirole alone induced axial AIMs totalling 8 (Figure 4-16a) with a moderate 
peak score of 2 (Figure 4-16a’) and duration of activity lasting 65 min (Figure 4-16a’’), in animals which 
had been chronically treated with ropinirole alone. 
Limb AIMs showed a total score of 1.5 (Figure 4-16b), a mild peak score of 1 (Figure 4-16b’) and were 
expressed for a period of 15 min (Figure 4-16b’’).  
Orolingual AIMs showed a total score of 2.5 (Figure 4-16c), a mild peak score just above 1 (Figure 4-16c’) 
and were expressed for 10 min (Figure 4-16c’’). 
ALO AIMs showed a total score of 12 (Figure 4-16d), a moderate peak score of 4 (Figure 4-16d’) and 
were expressed for 60 min (Figure 4-16d’’).  
There was no significant effect of ARR17477 or 7-NI plus ropinirole chronic treatment on subsequent 
ropinirole induced axial, limb, orolingual or ALO AIMs in terms of total scores, peaks or durations of 
activity (Figure 4-16a-d, Figure 4-16a’-d’ & Figure 4-16a’’-d’’). However ARR17477 tended to increase 
the duration of activity of orolingual AIMs (Figure 4-16c’’), and 7-NI tended to increase the total and 
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Figure 4-13 Total and Summed total scores for axial (a-a’), limb (b-b’), orolingual (c-c’) and ALO AIMs 
(d-d’) following chronic treatment with ARR17477 or 7-NI plus ropinirole. ARR17477 (ARR; 3, 6 or 12 
mg/kg s.c), 7-NI (25 mg/kg i.p.) and (Rop; 0.2 mg/kg i.p.) treatment in 6-OHDA-lesioned rats. Data are all 
presented as medians and also a’-d’ as interquartile ranges, (n=9-10); (a-d) Total scores and (a’-d’) 
Summed data over all treatment days. ++p<0.01, +++p<0.001 for time; *p<0.05 **p<0.01 for treatment 
compared to rop + vehicle (colours used in (a-d) refer to key). Data (a-d) were analysed by 2-way-
ANOVA and Friedman’s test, or Kruskal-Wallis test followed by Dunn’s, or (a’-d’) by Kruskal-Wallis test 
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Figure 4-14 Peak and Summed peak scores for axial (a-a’), limb (b-b’), orolingual (c-c’) and ALO AIMs 
(d-d’) following chronic treatment with ARR17477 or 7-NI plus ropinirole. ARR17477 (ARR; 3, 6 or 12 
mg/kg s.c), 7-NI (25 mg/kg i.p.) and (Rop; 0.2 mg/kg i.p.) treatment in 6-OHDA-lesioned rats. Data are all 
presented as medians and also a’-d’ as interquartile ranges, (n=9-10); (a-d) Total scores and (a’-d’) 
Summed data over all treatment days. ++p<0.01, +++p<0.001 for time; *p<0.05 for treatment compared 
to rop + vehicle (colours used in (a-d) refer to key). Data (a-d) were analysed by 2-way-ANOVA and 
Friedman’s test, or Kruskal-Wallis test followed by Dunn’s, or (a’-d’) by Kruskal-Wallis test (B1 :baseline 1 
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Figure 4-15 Duration and Summed duration of activity scores for axial (a-a’), limb (b-b’), orolingual (c-
c’) and ALO AIMs (d-d’) following chronic treatment with ARR17477 or 7-NI plus ropinirole. ARR17477 
(ARR; 3, 6 or 12 mg/kg s.c), 7-NI (25 mg/kg i.p.) and (Rop; 0.2 mg/kg i.p.) treatment in 6-OHDA-lesioned 
rats. Data are all presented as medians and also a’-d’ as interquartile ranges, (n=9-10); (a-d) Total scores 
and (a’-d’) Summed data over all treatment days. +++p<0.001 for time; *p<0.05 **p<0.01 for treatment 
compared to rop + vehicle (colours used in (a-d) refer to key). Data (a-d) were analysed by 2-way-
ANOVA and Friedman’s test, or Kruskal-Wallis test followed by Dunn’s, or (a’-d’) by Kruskal-Wallis test 



















































                                                                         




                                                                         




                                                                          




                                                                          




Figure 4-16 Final ropinirole challenge data for axial (a-a’’), limb (b-b’’), orolingual (c-c’’) and ALO AIMs 
(d-d’’). Ropinirole (Rop; 0.2 mg/kg i.p.) treatment. Data are presented as medians and individual values 
(n=9-10) and groups are labelled according to their prior chronic treatment; (a-d) Total score, (a’-d’) 
Peak score and (a’’-d’’) Duration of activity. Data were analysed by Kruskal-Wallis test. The data is a 
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4.4 Discussion 
These studies investigated whether the administration of nNOS inhibitors with early-symptomatic 
treatment of PD could potentially avoid the emergence of dyskinesia. It was hypothesised that the 
selective inhibition of neuronal NOS would prevent the induction of dyskinesia by L-dopa, or the 
dopamine agonist ropinirole, and these effects were tested in the drug naive 6-ODHDA-lesioned rat. 
Initial studies set out to establish the dose of the long-acting and irreversible nNOS inhibitor ARR17477 
appropriate for use on a chronic basis, owing to concerns of drug accumulation arising from daily 
treatment. The dose of the short-acting nNOS inhibitor 7-NI was selected based on ex vivo results from 
Chapter 3 supported by the literature. These doses were then taken forward to in vivo experiments to 
explore their effects on induction and development of AIMs from the first exposure of lesioned rats to 
dopaminergic treatment.     
4.4.1 Inhibition of nNOS by chronic treatment with 7-NI 
The dose of 7-NI (25 mg/kg i.p.) was chosen based on results from the ex vivo and acute study of effects 
of nNOS inhibitors on dyskinesia expression showing a significant reduction in nNOS activity in the 
cerebellum and striatum of 58 % and 41 % respectively  (See Chapter 3, section 3.2.3). This dose was 
also consistent with published chronic studies of 7-NI in rodents; Bush and Pollack (2001) showed 7-NI 
25 mg/kg i.p. every 2 h for 14 h lead to a sustained ~50 % decrease in hippocampal NO2
- and NO3
- as 
measured by microdialysis, whilst Schulz et al. (1995) and Przedborski et al. (1996) employed 7-NI 25 
mg/kg s.c. dosed every 8 h for 2-4 days to achieve ongoing nNOS inhibition, although ex vivo data were 
not presented. Additionally Mackenzie et al. (1994) showed repeated administration was necessary 
every 4 hfor 20 h for significant inhibiton of nNOS (51-60 %) at 24 h demonstrating that repeated dosing 
of rats with 7-NI does not lead to a cumulative inhibition of nNOS ,being similar to the inhibition 
measured at 4 h. Due to this evidence combined with the reversible nature and short half life of 7-NI 
confirmed by other investigations (Moore et al., 1993b), no adverse behavioural effects of chronic 7-NI 
treatment were anticipated using the once daily dosing regimen employed in the present study, or 
indeed observed. This outcome was in accordance with a study which employed 7-NI (25 mg/kg s.c.) 
daily treatment for 4 weeks in naïve rats without seeing any unexpected effects (Wangensteen et al., 
2006).  
4.4.2 Inhibition of nNOS by chronic treatment with ARR17477 
Initial studies showed that ARR17477 inhibited nNOS in a dose-related manner, with significant effects 
between 1 and 6 mg/kg (s.c.) at 12 h after four consecutive days of treatment. Following this study a 
dose of 1 mg/kg (s.c) was further investigated after the same dosing regimen to confirm nNOS inhibition 
was significant at a 1 h time point, where plasma levels of dopaminergic treatment to be used for in vivo 
studies would be expected to peak. After four days of treatment, ARR17477 (1 mg/kg s.c.) inhibited 
nNOS reducing its activity by 95 % at one hour following administration. Previous studies have shown 
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but this thesis represents the first time that the effects of chronic administration of ARR17477 on nNOS 
activity have been reported. Inhibition of nNOS following this repeated scheme of administration 
produced levels of inhibition almost twice the extent found following a single dose of ARR17477 at the 
highest dose (12 mg/kg s.c.) in comparable tissue, as measured in Chapter 3. Importantly after dosing 
with ARR17477 (1 mg/kg s.c.) nNOS activity was reduced by 95 % at peak effect of L-dopa and dopamine 
agonist activity, and clearly remained significantly decreased for the major duration of dopaminergic 
activity according to the persisting nNOS inhibition measured at a 12 h time-point. The cumulative effect 
seen following chronic treatment further supports the long-lasting and irreversible nature of NOS 
inhibition by ARR17477. As no side-effects were apparent in animals following the 4 days of treatment 
and high levels of nNOS inhibition were conferred by this dose (1 mg/kg s.c.) of ARR17477 it was 
considered appropriate to ensure chronic nNOS inhibition throughout the study.  
4.4.3 The effect of chronic nNOS inhibition on L-dopa-induced AIMS   
As expected, L-dopa caused a significant increase in the expression of all AIMS sub-types over the 
treatment period. The same was also true for L-dopa administered in combination with the nNOS 
inhibitors ARR17477 and 7-NI. Additionally chronic ARR17477 or 7-NI treatment alone was found to 
have no effect on AIMs suggesting that there may be no dopamine associated changes induced by either 
nNOS inhibitor in the absence of L-dopa or ropinirole, or indeed if there are they appear insufficient to 
result in AIMs.  
Although there was no significant reduction of L-dopa-induced AIMs by either nNOS inhibitor during 
chronic treatment, summed totals showed 7-NI significantly increased the duration of limb and ALO 
AIMs compared to vehicle treatment. Additionally 7-NI tended to increase axial AIMs but these effects 
did not reach statistical significance.  Meanwhile there was a trend for ARR17477 to reduce axial AIMs 
as measured by total scores in final L-dopa only challenges, and locomotive AIMS as measured by 
summed scores and final L-dopa only challenges.  
As discussed in Chapter 3, where 7-NI also caused an increase in certain AIMs categories, this may be 
due to MAOB inhibitor activity (Castagnoli et al., 1997; Di Monte et al., 1997; Desvignes et al., 1999) 
prolonging the presence of extracellular dopamine and also therefore the resulting dyskinesia 
(Lamensdorf et al., 1996; Kadieva & Mutsueva, 2005). Notably the resulting prolongation of 
antiparkinsonian action afforded by MAOB adjunct therapy in the clinic usually permits the levodopa 
dose to be reduced and hence the level of associated dyskinesia falls, but in this case where L-dopa dose 
is unchanged the opposite effect is likely (Fernandez et al., 2007).  Additionally possible eNOS effects of 
7-NI could impact on dyskinesia as a consequence of changes in vascular tone (Zagvazdin et al., 1996; 
Ayajiki et al., 2001), although this seems a less likely explanation as a sub-maximal dose of 7-NI was used 
in the present chronic studies.  
The tendency of ARR17477 to show some reduction in L-dopa-induced dyskinesia suggests that nNOS 
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against other properties of the compound acting to oppose this effect. ARR1477 shows significant 
binding affinity for the vesicular monoamine transporter (VMAT), the norepinephrine transporter (NET), 
the dopamine transporter (DAT) and adrenergic α2 receptors (see Appendix, Table 0-1). Inhibition of 
VMAT which controls vesicular storage of the monoamines including dopamine would likely exacerbate 
the fluctuations in extracellular dopamine levels associated with dyskinesia as would NET inhibition as 
this also clears excess dopamine in the denervated striatum (Lee et al., 2006; Arai et al., 2008). 
Inhibition of DAT has been associated with increased dyskinesia (Nutt et al., 2004) although a reduction 
in dyskinesia has also been reported (Pearce et al., 2002). Additionally antagonist activity at adrenergic 
α2 receptors has shown antidyskinetic effects pre-clinically (although notably clinical trials have been 
unsupportive) suggesting that α2 stimulation may promote dyskinesia (Fox et al., 2001; Savola et al., 
2003). ARR17477 may therefore have properties which can contribute to worsen dyskinesia in addition 
to its affinity to nNOS. This characteristic was supported by the final acute challenges with L-dopa alone, 
for axial and locomotive AIMs in the present study, showing a trend for a reduction in scores/duration, 
although this was not reflected by other AIMs subcategories. This discrepancy may be due to axial and 
locomotive AIMs being more resilient to further L-dopa exposure than the other forms as it is proposed 
that different anatomical brain regions underlie the varied AIMs (Winkler et al., 2002). For example 
studies concentrating on especially localised dopamine depletion have shown the ventrolateral caudate-
putamen is associated with forelimb control whilst medial caudate-putamen, is associated with 
development of rotations thus relating to limb and locomotive AIMs respectively, whilst dopaminergic 
receptor changes in the subthalamic nucleus are associated with orofacial dyskinesia (Salamone et al., 
1993; Mehta et al., 2000). Further evidence would be required to verify these differences, although 
changes in activity of the direct and indirect striatal pathways are considered to be predominantly 
involved with either choreic or dystonic sub-types of dyskinesia respectively (Bezard et al., 2001; 
Schuster et al., 2008).     
Lack of significant efficacy may be due to non-nNOS-specific effects of the inhibitors used in these 
studies. Currently, ARR17477 is the most potent and selective nNOS specific inhibitor described in the 
literature which can be administered systemically, as many more selective inhibitors are let down by an 
inability to penetrate the blood-brain barrier (Lawton et al., 2009). ARR17477 is also known to be more 
potent and nNOS-selective than 7-NI with an IC50 of 0.07 μM compared to 8.3 μM respectively (Vallance 
& Leiper, 2002), and these factors may explain its relatively more beneficial effects on AIMS in the rat 
model.  
Presented here is the first study to investigate the effect of chronic selective inhibition of nNOS in L-
dopa priming for AIMs/dyskinesia. Recently Padovan-Neto et al. (2011) showed the non-selective eNOS 
and nNOS inhibitor, NG-nitro-L-Arginine (L-NOARG), reduced limb and orolingual AIMs at 60 min after 
first L-dopa exposure and also reduced locomotive AIMS at 120 min in 6-OHDA-lesioned rats. However 
no subsequent days of L-dopa priming were considered in this case. Again animals were only assessed at 
60 and 120 min following L-dopa treatment and the dose of L-dopa administered was astonishingly 16x 
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experiments (e.g.Taylor et al., 2005; Dekundy et al., 2007; Monville et al., 2009). These differences 
suggest that in fact eNOS inhibition in addition to nNOS may indeed be advantageous in reducing AIMs 
specifically when a supra-therapeutic dose of L-dopa is employed. However the effect of such a high 
dose of L-dopa needs to be considered, and suggests a non-clinically relevant finding.  
There are a range of studies confirming that AIMs can indeed be reduced during the initial process of 
chronic L-dopa exposure in the 6-OHDA-lesioned rat model. There is considerable evidence for an 
important role of glutamate in AIMs priming. Most recently the metabotropic glutamate receptor type 5 
(mGluR5) antagonist Fenobam was shown to reduce the development of AIMs, measured at peak 
dopaminergic effect, when administered in combination with L-dopa from first exposure (Rylander et 
al., 2010). Importantly, this reduction in AIMS was not due to motor impairment effects of the drug. L-
dopa was used at a comparable dose (6 mg/kg) to that applied in the studies presented here and 
administered on a once daily basis resulting in a significant decrease in ALO AIMs during chronic 
treatment. Similarly the mGluR5 antagonist MTEP effectively inhibited AIMs development induced by L-
dopa (Mela et al., 2007; Rylander et al., 2009).  The AMPA receptor antagonist IEM 1460 also reduced L-
dopa induced priming for ALO AIMs in drug naïve 6-OHDA-lesioned rats suggesting a key involvement of 
AMPA receptors in the priming process (Kobylecki et al., 2010).  
Manipulation of additional neurotransmitter pathways in 6-OHDA-lesioned rats has also shown promise 
in treatment for dyskinesia. Chronic administration of a combination of 5-HT1A and 5-HT1B agonists (8-
OH-DPAT and CP-94253 respectively), in addition to L-dopa in the 6-OHDA-lesioned rat naïve to drug 
treatment, resulted in significantly lower levels of dyskinesia manifestation after two weeks of 
treatment compared to an L-dopa only treatment group (Munoz et al., 2008). This effect is likely due to 
an ability of 5-HT1 agonists to reduce dysregulated release of dopamine from serotonergic neurons and 
hence pre-synaptic action (Carta et al., 2007). Chronic treatment with L-Stepholidine, a naturally 
occurring D1 receptor agonist and D2 antagonist, significantly reduced axial, limb and ALO AIMs induced 
by L-dopa from day 4 of co-administration (Mo et al., 2010). A dual mechanism of D2 antagonistic 
activity and D1 partial agonistic activity is proposed to restore the balance between direct and indirect 
striatal output pathways inhibiting behavioural sensitization induced by chronic L-dopa treatment. L-
Stepholidine also shows 5-HT1A agonistic activity further contributing to an anti-dyskinetic effect. It is 
possible to reduce L-dopa priming for AIMs in the 6-OHDA-lesioned rat model and hence it would 
appear that the nNOS inhibitors ARR17477 and 7-NI are insufficient to attenuate L-dopa induced 
changes underlying dyskinesia. As such, it seems nNOS is not involved in L-dopa-induced priming for 
AIMs. 
4.4.4 The effect of chronic nNOS inhibition on ropinirole-induced AIMS 
Akin to results for the AIMs expression studies described in Chapter 3, ropinirole induced lower levels of 
AIMs during chronic treatment compared to L-dopa, and AIMS also developed more gradually over the 
22 day chronic treatment period often not emerging until later treatment days than for L-dopa.  These 
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showed no ALO AIMs to be induced by ropinirole on day 1 and only very mild AIMs by day 19 of 
repeated treatment, whilst L-dopa induced mild ALO AIMs already on day 1 severely worsening by day 
19. These are similar patterns  to those of the experiments presented here, although direct comparison 
is made difficult by a differing representation of AIMs scores and the dose of ropinirole being 
considerably higher at 5.0 mg/kg compared to the 0.2 mg/kg employed in the present study. However, 
this does suggest that increasing the ropinirole dose 25-fold has little bearing on priming for ropinirole-
induced AIMs.  Furthermore, Papathanou et al. (2011) showed a significantly shorter duration of ALO 
AIMs on the final day of chronic treatment with ropinirole compared to L-dopa and there was also a 
trend for a reduction in ALO total scores.  
In a study by Ravenscroft et al. (2004), measurement of contralateral rotations displayed by 6-OHDA-
lesioned rats following chronic ropinirole and L-dopa treatment were similar in intensity and duration, 
used at a comparable dose to that employed here. However comparison of these studies does depend 
on interpretation of rotational behaviour in the 6-OHDA-lesioned rat and whether it is truly 
representational of dyskinesia, as there is inconsistency between rotations and AIMs measured in 
response to dopaminergic treatment (Marin et al., 2006). A 6-OHDA-lesioned mouse model of AIMs 
showed chronic ropinirole administration induced no ALO AIMs whereas L-dopa induced a gradual 
increase in ALO AIMs over two weeks of treatment (Lundblad et al., 2005). This supports a greater 
dyskinesiogenic effect of L-dopa than ropinirole. There is a chance that ropinirole-induced AIMs may 
have further increased if chronic dosing was continued beyond 22 days in the present studies, although 
this duration is relatively long considering similar experiments using varied doses lasted between 15 and 
21 days (Lundblad et al., 2005; Carta et al., 2008c; Papathanou et al., 2011). Additionally scores on the 
final day of priming (day 22) are comparable to those seen in acute studies where animals were treated 
with ropinirole alone (See Chapter 3; section 3.3.4.2) despite the fact all animals were priorly primed 
with L-dopa in Chapter 3, suggesting continued priming with ropinirole would have had no significant 
effect.   
There was no significant effect of ARR17477 treatment on ropinirole-induced axial, limb, orolingual, ALO 
or locomotive AIMs throughout the 22 day priming period. Meanwhile 7-NI significantly increased axial 
AIMs compared to ropinirole alone as measured by total and peak scores as well as duration of AIMs on 
day 4, and totals were also significantly increased on day 16.  This tendency for 7-NI to increase AIMs 
was not observed in the final acute challenges, following drug washout, where all animals were treated 
with ropinirole alone. Hence combined with the fact that ARR17477 did not alter ropinirole-induced 
AIMs, this finding suggests that it is a property specific to 7-NI such as MAOB and/or eNOS effects 
leading to a relative increase in AIMs, as previously discussed (see sections 4.4.3 and 3.4.2). There was a 
trend for prior treatment with ARR17477 to increase the duration of orolingual AIMs in the final 
ropinirole challenges, which is difficult to explain but given the very low levels exhibited with vehicle the 
difference itself is minimal suggesting a non-important effect. No studies reported in the literature 
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However, as for L-dopa-induced priming for dyskinesia, nNOS is not critically involved in ropinirole-
induced development of dyskinesia.      
4.4.5 Conclusion 
The findings presented in this chapter suggest that nNOS does not play a key role in the induction of 
dyskinesia as assessed by AIMs in the 6-OHDA-lesioned rat. De novo chronic treatment with L-dopa or 
ropinirole in combination with either ARR17477 or 7-NI affords no significant improvement in dyskinesia 
during chronic treatment or indeed following acute dopaminergic treatment alone after drug-washout.  
Whilst nNOS inhibitors may not be advantageous in prevention or management of dyskinesia, another 
possibility is that the model itself is unsuitable. It is questionable how truly representative abnormal 
involuntary movements in the 6-OHDA-lesioned rat are of the complex choreic and dystonic elements of 
dyskinesia seen in the clinic (Bezard et al., 2001). The onset of AIMs also typically occurs immediately 
after initiation of dopaminergic treatment, unlike the clinical scenario, whilst interpretation of AIMs may 
be hindered by rotational activity. Additionally the unilateral 6-OHDA-model employed in these 
experiments does not show overt symptoms of PD in the absence of dopaminergic treatment. 
Meanwhile, the long-established MPTP-treated primate model of PD strongly mimics the parkinsonian 
state and is considered to display abnormal movements closely resembling those apparent in the human 
disorder upon dopaminergic treatment, and these can be assessed using clinical rating scales with only 
minor adaptation (Schneider, 1989; Imbert et al., 2000; Langston et al., 2000). With these differences 
between behavioural models in mind, the next chapter will examine the effects of nNOS inhibition on 
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5.1 Introduction 
In the previous chapter it was reported that nNOS inhibition was ineffective in reducing the induction of 
AIMs by de novo L-dopa or ropinirole treatment in 6-OHDA-lesioned rats, suggesting that nNOS is not 
involved in the development of dyskinesia in this model of PD. Additionally results from Chapter 3 
indicate that nNOS is not a key factor in the expression of established dyskinesia in this rodent model. 
Whilst these studies suggest nNOS and NO do not play an important role in these motor abnormalities, 
given the strong association between NO and basal ganglia function whereby glutamatergic activity can 
lead to NO synthesis and influence synaptic plasticity, the malfunctioning of which has already been 
linked to dyskinesia (Garthwaite et al., 1989; Calabresi et al., 2000; Chase & Oh, 2000; West & Grace, 
2000)(see Chapter 1, section 1.4.4), perhaps the 6-OHDA-lesioned rat is not the most appropriate model 
to be using.    
 
The assessment of AIMs as a measure of dyskinesia is a relatively recent advancement in animal 
modelling (Cenci et al., 1998), and the behavioural repertoire of 6-OHDA-lesioned rats treated with 
dopaminergic drugs falls short of the motor abnormalities demonstrated by the longer-standing MPTP-
treated primate (Jenner et al., 1984; Langston et al., 1984; Crossman, 1987). MPTP-treated primates 
commonly demonstrate chorea, dystonia, athetosis and akathisia following chronic dopaminergic 
treatment as well as rigidity, akinesia, bradykinesia and action tremor when off drug (Boyce et al., 1990; 
Pearce et al., 1995). Even the abnormal motor phenomena of an MPTP-treated primate off drug are 
easily noticeable whilst unilaterally 6-OHDA-lesioned rats show no overt symptoms of PD. The extent of 
motor disability can therefore be gauged simultaneously to dyskinesia in the primate model whereas 
this is not possible in the rat. Indeed rating scales for motor disability in primates tend to be based on 
clinical measures and have been developed in association with experienced neurologists in some 
laboratories including our own (Pearce et al., 1998; Imbert et al., 2000).     
 
Upon dopaminergic medication 6-OHDA-lesioned rats can exhibit rotations and AIMs but these are 
arguably far removed from the characteristics of clinical PD. Obviously this disparity is partly due to the 
unilateral nature of toxin administration in the rat, but a full bilateral lesion is rarely tolerated (Simola et 
al., 2007). Even the significance of rotations for anti-parkinsonian activity versus dyskinesiogenic 
potential of drugs is disputed (Lundblad et al., 2002; Marin et al., 2006). By contrast in the MPTP-treated 
primate locomotor activity is easily measured during treatment, which can provide additional insight 
into drug effects especially as it tends to positively correlate with dyskinesia (Kuoppamaki et al., 2007).  
 
The MPTP-treated primate model has been extensively investigated to date, with marmosets and other 
primates having basal ganglia anatomy more analogous to man than do rats, and displaying motor 
abnormalities frequently indistinguishable from those characterising idiopathic PD (Hardman et al., 
2002; Iravani & Jenner, 2011). Furthermore the MPTP model shows high predictive validity for 
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for treatment of PD have proven effective in this model (Duty & Jenner, 2011).  Thus this primate model 
certainly seems to mimic PD in many respects more closely than do rodents. 
 
No studies to date have investigated the effect of nNOS inhibitors on dyskinesia in the MPTP-treated 
primate. The distinct advantages of the model over the 6-OHDA-lesioned rat, including its symptomatic 
and neurophysiological similarities to man, broader behavioural repertoire, proven clinical translation, 
and long-established validity, combined with the evidence for changes in NO in PD, afforded further 
investigation. In contrast with the studies undertaken thus far (Chapters 3 & 4), it is possible that nNOS 
inhibitors may demonstrate beneficial effects on expression and priming for dyskinesia in the MPTP-
treated primate model. 
 
5.1.1 Hypothesis 
It is hypothesised that in MPTP-treated primates inhibition of nNOS will reduce the expression of 
established dyskinesia following dopaminergic drug treatment and also prevent the induction of 
dyskinesia from first L-dopa exposure.  
 
5.1.2 Aims 
The aim of the studies in this chapter was to determine whether, in MPTP-treated primates, nNOS 
inhibitors can attenuate the expression of dyskinesia following L-dopa or dopamine agonist treatment 
and also prevent development of dyskinesia following chronic L-dopa treatment. In order to achieve 
these aims the following shall be specifically investigated; 
1. The effect of acute administration of ARR17477 in combination with L-dopa on dyskinesia expression 
in L-dopa-primed MPTP-treated primates  
2. The effect of acute administration of ARR17477 in combination with ropinirole on dyskinesia 
expression in L-dopa-primed MPTP-treated primates 
3. The effect of chronic  nNOS inhibition on the induction of dyskinesia by L-dopa administration in 
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5.2 Materials and methods 
 
5.2.1 Introduction 
The doses of ARR17477 required for nNOS inhibition in the acute and subsequent chronic in vivo studies 
in primates were based on ex vivo rodent studies described in Chapters 3 and 4. Following recovery 
from MPTP treatment, marmosets were primed to express dyskinesia by chronic dosing with L-dopa. 
These animals were then treated acutely with the pre-selected doses of ARR17477 in combination with 
L-dopa or ropinirole and assessed for locomotive activity, motor disability and dyskinesia. Next using a 
group of naïve MPTP-treated marmosets the effect of nNOS inhibition on L-dopa-induced priming for 
dyskinesia was investigated. The methods for these studies are described below. 
 
5.2.2 Determination of the dose of nNOS inhibitor 
5.2.2.1 ARR17477 
For the dyskinesia expression studies the doses of ARR17477 (3, 6 and 12 mg/kg s.c.) selected were 
those employed in the rat studies of Chapter 3 (see section 3.2.3), which were all shown to significantly 
reduce nNOS activity ex vivo in agreement with published findings (O'Neill et al., 2000; Reif et al., 2000).  
5.2.2.2 7-NI 
Owing to home office requirements 7-NI could not be administered to marmosets using an i.p. route as 
previously used in the rat, hence a s.c. route was chosen and an ex vivo study was necessary to confirm 
inhibition of nNOS in the brain.   
5.2.2.2.1 Animals 
Male Wistar rats (200-250 g; Harlan, UK or B & K, UK) were housed 2-3 per cage in the Biological Service 
Unit, King’s College London. Room temperatures were maintained at 19-21 ˚C at 55 % humidity with a 
12 h light-dark cycle and animals had free access to pelleted food and water, as described in section 
2.2.2. Experiments were performed in accordance with the UK Animals (Scientific Procedures) Act, 1986 
under Home Office project licence no. 70/6019 or 70/6898.      
5.2.2.2.2 Ex vivo determination of 7-NI dose 
Naïve male Wistar rats (n=4/group; 200-250 g) were treated with 7NI (20 mg/kg, suspended in peanut 
oil, s.c.) or vehicle (peanut oil, 1 ml/kg, s.c.). This dose was selected on the basis of the doses tested ex 
vivo in Chapter 3 and also in the published literature (Hantraye et al., 1996; Przedborski et al., 1996). 
Animals were culled by decapitation at 1 h after treatment and striata and cerebellum were dissected 
out, snap frozen and stored at -70 ˚C for measurement of nNOS activity by radioenzymatic assay. 
5.2.2.2.3 Radioenzymatic measurement of NOS activity 
nNOS activity was determined in brain homogenates by measuring enzymatic conversion of L-[³H]-
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centrifuged (as detailed in section 2.6.1.2), and supernatants transferred to a 96-well plate in triplicate. 
Boiled supernatant was used as a negative control. A pre-prepared reaction mixture containing L-[2,3,4-
3H] arginine monohydrochloride (1 mCi/ml; 16.7 μM) and CaCl2 (6 mM) was added (30 μl/well) and the 
plates incubated for 1 h at 30 °C. The reaction was terminated and the reaction mixture further 
processed to measure L-[³H]-citrulline formation, by the addition of resin and subsequent filtration of 
the samples as described in 2.6.1.2. L-[³H]-citrulline was determined in a Beta-liquid scintiallation 
counter (see section 2.6.1.2) whilst protein content of samples was quantified with a NanoDrop 
spectrophotometer (see section 2.6.1.3). Data were analysed as described in section 2.6.1.4 expressing 
nNOS activity as L-[³H]-citrulline formation per mg of protein per hour. 
5.2.2.2.4 Effect of 7-NI on nNOS activity 
7-NI (20 mg/kg s.c.) significantly reduced nNOS activity by 20 % in the striatum compared to vehicle 
treatment alone (Figure 5-1b). Meanwhile there was no significant change in nNOS activity in the 
cerebellum (Figure 5-1a).  
 
5.2.3 Animals 
Animals and husbandry are described fully in section 2.4.2. In brief, 16 adult common marmosets 
(callithrax jacchus; 10 female and 6 male; weight 320 to 450 g) were housed at a temperature of 25±1 °C 
with 50 % relative humidity on a 12 h light/dark cycle. All animals were fed fresh fruit once daily and had 
ad libitum access to Mazuri food pellets (Mazuri Primate Diet, Special Diet Services Ltd., UK) and water. 
Experiments were all conducted in accordance with Home Office regulations under the Animals 
(Scientific Procedures) Act 1986 and project license number 70/6345.  
 
5.2.4 MPTP-treatment 
As described in section 2.4.3-2.4.5, after a minimum acclimatisation period of 8 weeks marmosets were 
administered MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride; 2.0 mg/kg, in saline 
0.9 %, s.c.) once daily for 5 consecutive days. Animals were then hand-fed for up to 4 months until able 
to feed independently and maintain a stable body weight. Following recovery from the acute effects of 
the toxin, MPTP-treatment induced a stable parkinsonian syndrome characterised by bradykinesia, 














































Figure 5-1 Radioenzymatic measurement of the effect of 7-NI (20 mg/kg s.c.) on nNOS activity in 
cerebellum and striatum. Naïve rats were treated with 7-NI or vehicle (peanut oil s.c.) and culled by 
decapitation at 1 h. Tissue samples were obtained from (a) cerebellum and (b) striatum. nNOS activity is 
displayed as L-[3H]-citrulline formation (cpm/mg protein); Data are presented as means ± SEM 
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5.2.5 Expression studies 
5.2.5.1 Establishing L-dopa-induced dyskinesia  
After recovery from the MPTP treatment, animals (n=6) were treated daily with L-dopa methyl ester 
(12.5 mg/kg + carbidopa 12.5 mg/kg p.o.) for a period of 8 weeks, to establish stable dyskinesia as 
described in section 2.5.1. Dyskinesia was assessed once-twice weekly in addition to other behavioural 
parameters (see section 5.2.7). Only animals displaying marked dyskinesia at the end of the priming 
period were taken forward to the expression studies. 
5.2.5.2 L-dopa - dyskinesia expression studies 
L-dopa-primed MPTP-treated marmosets (n=6) were pre-treated with carbidopa (12.5 mg/kg, in sucrose 
10 % as a suspension, p.o.) followed 1 h later by L-dopa methyl ester (12.5 mg/kg free base, in sucrose 
10 %, p.o.), plus concomitant ARR17477 (3, 6 or 12 mg/kg in 0.9 % saline s.c) or vehicle (0.9 % saline s.c). 
The L-dopa dose was chosen from preliminary studies showing 12.5 mg/kg p.o. gives a maximal 
response in terms of locomotor activity counts, motor disability reversal and dyskinesia scores (see 
section 2.5.5). ARR17477 or vehicle was administered according to a modified latin-square such that 
each animal received all treatments (repeated measures) in a randomised design (see Appendix, Figure 
0-2). Animals were assessed behaviourally on each treatment day, and a minimum 1 week washout 
period was allocated between each treatment.  
5.2.5.3 Ropinirole - dyskinesia expression studies 
L-dopa-primed MPTP-treated marmosets (n=6) were pre-treated with domperidone (2 mg/kg in sucrose 
10 %, p.o.) followed 1 h later by ropinirole (0.2 mg/kg, in sucrose 10 %, p.o.), plus concomitant 
ARR17477 (3, 6 or 12 mg/kg in 0.9 % saline s.c) or vehicle (0.9 % saline s.c). The ropinirole dose was 
chosen from preliminary studies showing 0.2 mg/kg p.o. is equipotent to the L-dopa dose employed 
with respect to locomotor activity counts, motor disability reversal and dyskinesia scores (see section 
2.5.5). ARR17477 or vehicle was administered according to a modified latin-square such that each 
animal received all treatments (repeated measures) in a randomised manner (see Appendix, Figure 0-2). 
Animals were assessed behaviourally on each treatment day, and a minimum 1 week washout period 
was allocated between each treatment. 
 
5.2.6 Priming study 
Following recovery from MPTP-treatment, animals (n=10) were assessed for basal locomotor activity 
(see section 2.5.2) and assigned to one of two treatment groups, each matched for mean basal 
locomotor activity. All animals were administered L-dopa methyl ester (12.5 mg/kg + carbidopa 12.5 
mg/kg, in sucrose 10 %, p.o.) once daily for 8 weeks except on behaviour assessment days where 
carbidopa was administered 1 h prior to L-dopa. Animals in Group 2 were also treated with 7-NI (20 
mg/kg; in peanut oil, s.c.) dosed 30 min before L-dopa during weeks 1-4 and ARR17477 (1mg/kg; in 0.9 
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with vehicle (1 ml/kg, s.c.; peanut oil, weeks 1-4 or 0.9 % saline, weeks 5-8). It became necessary to 
change the nNOS inhibitor from 7-NI to ARR17477 after the initial 4 weeks of chronic treatment as 
animals began to develop sores at the 7-NI/vehicle (s.c.) injection sites. ARR17477 has the advantage of 
being soluble in 0.9 % saline and produced no irritation. Animals were assessed behaviourally once or 
twice per week throughout the priming period (see Figure 5-2). 
One week following withdrawal of chronic drug treatment, animals were challenged on two separate 
occasions one week apart with L-dopa methyl ester (10 mg/kg + benserazide 10 mg/kg, in 0.9 % saline, 
s.c.), and assessed for behaviour.  
 
5.2.7 Behavioural assessment 
Animals were placed in the behavioural test units following administration of carbidopa where 
necessary. Behavioural assessment was performed for 1 h before and up to 6 h after L-
dopa/ropinirole/vehicle administration, as described in section 2.5.  In brief, locomotor activity, motor 
disability and dyskinesia were monitored. Locomotor activity was measured by infrared beam 
interruptions which accumulated and recorded electronically in 10 and 30 min time bins. Animals were 
also observed and scored for motor disability and dyskinesia during the last 10 min of consecutive 30 
min intervals. Full descriptions of assessment criteria are provided in sections 2.5.2 - 2.5.5.  
 
5.2.8 Data and statistical analysis 
For both expression and priming studies total activity/scores over the assessment period were 
calculated by AUC (Graphpad Prism version 5.0) using the trapezoid method where each successive 30 
min was labelled as a single time-bin. Peak activity/score was taken as the maximum count/score 
achieved per 30 min within the full assessment period. ‘On-time’ for locomotor activity was defined as 
the duration of the test period that an animal exhibited activity greater than 2x its mean baseline count 
calculated from 10 min time-bin data. ‘On-time’ for reversal of motor disability was defined as the 
duration of the test period that an animal scored below 8 on the motor disability scale and ‘on-time’ for 
dyskinesia was defined as the duration of the test period that an animal scored above 0 on the 
dyskinesia rating scale. In all cases statistical significance was set at p<0.05 and analyses were carried 
out in Graphpad Prism 5. Additionally a ’trend’ was described in the data where there was greater than 
a 75 % change from vehicle treated animals. 
For expression studies time-course data were plotted as medians at 30 min intervals over 6 h following 
drug administration, with pre-treatment baseline plotted at t=0. Drugs were administered at t=0 on 
graphs. Time-course data for locomotor activity, motor disability and dyskinesia were analysed by 2-way 
ANOVA followed by Friedman’s and Dunn’s post hoc test where appropriate. Total and peak 
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For the priming studies median total and peak activity/scores, and on-time, were plotted from weekly 
test days using data collected over a 4 h period following treatment. Pre-treatment baseline data were 
plotted at week 0 where animals were drug naïve. Data were analysed by 2-way ANOVA followed by 
Kruskall-Wallis or Friedman’s test and then Dunn’s post hoc test where appropriate. Summed data were 
also plotted for the full priming period using AUC (Graphpad Prism version 5.0) of 8 week total and peak 
activity/scores, and on-time. Mann-Whitney tests were used to compare the effect of treatment on 
summed total activity/scores for the priming period and also the subsequent L-dopa challenges.  
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5.3 Results 
5.3.1 The effect of ARR17477 on L-dopa-induced locomotor activity, motor disability 
and dyskinesia expression in L-dopa-primed MPTP-treated marmosets 
Vehicle-vehicle administration did not alter locomotor activity, motor disability or dykinesia expression 
over time (Figure 5-3a, Figure 5-4a & Figure 5-5a). 
 
5.3.1.1 Locomotor activity  
-nNOS inhibitor + vehicle  
ARR17477 (12 mg/kg s.c.) plus vehicle did not alter locomotor activity in MPTP-treated marmosets 
compared to vehicle-vehicle treatment (Figure 5-3a). This lack of effect was confirmed by unchanged 
total locomotor activity counts (median counts of 60 for both ARR17477 plus vehicle and vehicle-vehicle 
groups), peak locomotor activities (120 counts/30 min) and on-times (20 min) for ARR17477 plus vehicle 
and vehicle-vehicle groups (Figure 5-3b, c & d).  
-Vehicle + L-dopa 
L-dopa alone gradually increased locomotor activity from 30 min reaching a maximum of 400 counts/30 
min at 90 min, returning to baseline levels by 120 min (Figure 5-3a). Total locomotor activity over 6 h 
was 1100 counts which was significantly higher than vehicle-vehicle treated animals (Figure 5.2b). Peak 
locomotor activity of 500 counts and on-time of 140 min was achieved following L-dopa alone treatment 
(Figure 5-3b & c).  
-nNOS inhibitor + L-dopa 
Although there was no significant effect of ARR17477 (3, 6 or 12 mg/kg) on L-dopa-induced increase in 
locomotor activity as measured by total counts (Figure 5-3b), peak activity (Figure 5-3c) and on-time 
(Figure 5-3d), total activity tended to be greater following all doses of ARR17477, and peak activity 
tended to be greater after ARR17477 (12 mg/kg), compared to L-dopa alone.   
 
5.3.1.2 Motor disability  
-nNOS inhibitor + vehicle   
ARR17477 (12 mg/kg) alone did not reverse motor disability with scores not significantly different from 
vehicle-vehicle treatment (Figure 5-4a). Similarly there was no significant effect of ARR17477 alone on 
total motor disability score (ARR17477-vehicle=6, vehicle-vehicle=15), peak motor disability score 
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-Vehicle + L-dopa 
L-dopa alone induced an expected reversal of motor disability compared to vehicle-vehicle treatment 
with scores of 2 from 30-120 min after administration followed by a gradual return to baseline levels 
from 150-240 min (Figure 5-4a). Overall total reversal of motor disability had a median score of 75 
(Figure 5-4b), with a peak score of 2 and on-time of 180 min (Figure 5-4c & d). Both peak motor 
disability score and on-time were significantly greater than for vehicle-vehicle treatment. The total 
change in motor disability score over 6 h tended to be greater than vehicle-vehicle, although it was not 
statistically significant (Figure 5-4b). 
  
-nNOS inhibitor + L-dopa 
There was no significant effect of ARR17477 (3, 6 or 12 mg/kg) on L-dopa-induced reversal of motor 
disability as measured by total change in motor disability score (Figure 5-4b), peak score (Figure 5-4c) 
and on-time (Figure 5-4d).   
 
5.3.1.3 Dyskinesia  
-nNOS inhibitor + vehicle   
ARR17477 (12 mg/kg) plus vehicle treatment did not induce dyskinesia throughout the 6 h period of 
behavioural assessment, with scores not significantly different to vehicle-vehicle treatment (Figure 
5-5a). Total and peak dyskinesia both scored 0, and no on-time was recorded for ARR17477 plus vehicle 
similar to vehicle-vehicle treatment groups (Figure 5-5b-d).      
-Vehicle + L-dopa 
L-dopa alone immediately induced dyskinesia expression with a score of 2 at 30 min, increasing to 3 
between 90 and 120 min and returning to a score of 0 between 150-180 min (Figure 5-5a). Total 
dyskinesia scored was 10, with a peak score of 3 and on-time of 180 min (Figure 5-5b-d). Total and peak 
dyskinesia, and on-time all tended to be greater than for vehicle-vehicle treatment, although  these 
effects were not statistically significant.  
 
-nNOS inhibitor + L-dopa 
There was no significant effect of ARR17477 (3, 6 or 12 mg/kg) on L-dopa-induced dyskinesia as 
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Figure 5-3 Locomotor activity following ARR17477 plus L-dopa treatment. ARR17477 (ARR; 3, 6 or 12 
mg/kg s.c) and L-dopa (LD; 12.5 mg/kg plus carbidopa 12.5 mg/kg p.o.) treatment in L-dopa-primed 
MPTP-treated marmosets. Data are presented as medians (n=5); (a) Time-course, and also individual 
values (b) Total, (c) Peak and (d) On-time. +p<0.05 compared to vehicle + vehicle treatment. Time-
course data were analysed by 2-way-ANOVA and all other data were analysed by Friedman’s test 
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Figure 5-4 Motor disability following ARR17477 plus L-dopa treatment. ARR17477 (ARR; 3, 6 or 12 
mg/kg s.c) and L-dopa (LD; 12.5 mg/kg plus carbidopa 12.5 mg/kg p.o.) treatment in L-dopa-primed 
MPTP-treated marmosets. Data are presented as medians (n=5); (a) Time-course, and also individual 
values (b) Total, (c) Peak and (d) On-time. +p<0.05 compared to vehicle + vehicle treatment. Time-
course data were analysed by 2-way-ANOVA and all other data were analysed by Friedman’s test 
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Figure 5-5 Dyskinesia expression following ARR17477 plus L-dopa treatment. ARR17477 (ARR; 3, 6 or 
12 mg/kg s.c) and L-dopa (LD; 12.5 mg/kg plus carbidopa 12.5 mg/kg p.o.) treatment in L-dopa-primed 
MPTP-treated marmosets. Data are presented as medians (n=5); (a) Time-course, and also individual 
values (b) Total, (c) Peak and (d) On-time. +p<0.05 compared to vehicle + vehicle treatment. Time-
course data were analysed by 2-way-ANOVA and all other data were analysed by Friedman’s test 
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5.3.2 The effect of ARR17477 on ropinirole-induced locomotor activity, motor 
disability and dyskinesia expression in L-dopa-primed MPTP-treated marmosets 
Vehicle-vehicle administration did not alter locomotor activity, motor disability or dykinesia expression 
over time (Figure 5-6a, Figure 5-7a & Figure 5-8a). 
  
5.3.2.1 Locomotor acticity 
-nNOS inhibitor + vehicle   
ARR17477 (12 mg/kg) plus vehicle treatment did not alter locomotor activity in MPTP-treated 
marmosets compared to vehicle-vehicle treatment (Figure 5-6a). This was confirmed by matching total 
locomotor activity counts (median counts of 25 for both ARR17477 plus vehicle and vehicle-vehicle 
groups), peak locomotor activities (150 counts/30 min) and on-times (20 min) for ARR17477 alone and 
vehicle-vehicle groups (Figure 5-6b, c & d).         
-Vehicle + ropinirole 
Ropinirole alone increased locomotor activity from 30 min with a maximum effect of 700 counts/30 min 
at 90 min, returning to baseline levels by 150 min with small fleeting amounts of activity thereafter 
(Figure 5-6a). Total locomotor activity recorded over the 6 h was 2300 counts, with a peak activity of 
700counts/30 min and on-time measuring 150 min (Figure 5-6b, c & d). Total, peak and on-time for 
ropinirole-induced locomotor activity tended to be greater than in vehicle-vehicle treated animals, 
although the difference was not statistically significant.          
 
-nNOS inhibitor + ropinirole 
There was no significant effect of ARR17477 (3, 6 or 12 mg/kg) on ropinirole-induced increase in 
locomotor activity as measured by total counts (Figure 5-6b), peak activity (Figure 5-6c) and on-time 
(Figure 5-6d), compared to ropinirole alone.    
 
5.3.2.2 Motor disability 
-nNOS inhibitor + vehicle   
ARR17477 (12 mg/kg) alone did not reverse motor disability with scores not significantly different from 
vehicle-vehicle treatment (Figure 5-7a). ARR17477 alone produced no significant change in total motor 
disability score compared to vehicle-vehicle (both scored 8), the peak motor disability score (both 10), or 
on-time (both 0 min), (Figure 5-7b-d). 
-Vehicle + ropinirole 
Ropinirole alone significantly reversed motor disability compared to vehicle-vehicle treatment with 
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levels between 240 and 300 min (Figure 5-7a). Overall total reversal of motor disability had a median 
score of 65 (Figure 5-7b), with a peak motor disability score of 2 and on-time of 150 min (Figure 5-7c & 
d). Both peak motor disability score and on-time were significantly greater than for vehicle-vehicle 
treatment. 
 
-nNOS inhibitor + ropinirole 
ARR17477 (3, 6 or 12 mg/kg) had no significant effect on ropinirole-induced reversal of motor disability 
as measured by total score (Figure 5-7b), peak score (Figure 5-7c) and on-time (Figure 5-7d).   
 
5.3.2.3 Dyskinesia  
-nNOS inhibitor + vehicle   
ARR17477 (12 mg/kg) alone did not induce dyskinesia throughout the 6 h of behavioural assessment, 
showing no difference to vehicle-vehicle dyskinesia scores (Figure 5-8a). Total and peak dyskinesia both 
scored 0, and no on-time was recorded for the ARR17477 alone or vehicle-vehicle treatment groups 
(Figure 5-8b-d).      
-Vehicle + ropinirole 
Ropinirole alone induced dyskinesia expression with a score of 1.5 at 60 min, increasing to 2 at 90 min 
and declining thereafter reaching 0 by 180 min (Figure 5-8a). Total dyskinesia scored over the 6 h was 
6.5, with a peak score of 2 and on-time of 90 min (Figure 5-8b-d). Total and peak dyskinesia, and on-
time tended to be greater than for vehicle-vehicle treatment, although this difference was not 
statistically significant. 
-nNOS inhibitor + ropinirole 
There was no significant effect of ARR17477 (3, 6 or 12 mg/kg) on ropinirole-induced dyskinesia as 
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Figure 5-6 Locomotor activity following ARR17477 plus ropinirole treatment. ARR17477 (ARR; 3, 6 or 
12 mg/kg s.c) and ropinirole (Rop; 0.2 mg/kg plus domperidone 2 mg/kg p.o.) treatment in L-dopa-
primed MPTP-treated marmosets. Data are presented as medians (n=6); (a) Time-course, and also 
individual values (b) Total, (c) Peak and (d) On-time. Time-course data were analysed by 2-way-ANOVA 
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Figure 5-7 Motor disability following ARR17477 plus ropinirole treatment. ARR17477 (ARR; 3, 6 or 12 
mg/kg s.c) and ropinirole (Rop; 0.2 mg/kg plus domperidone 2 mg/kg p.o.) treatment in L-dopa-primed 
MPTP-treated marmosets. Data are presented as medians (n=6); (a) Time-course, and also individual 
values (b) Total, (c) Peak and (d) On-time. +p<0.05 compared to vehicle + vehicle treatment. Time-course 
data were analysed by 2-way-ANOVA and all other data were analysed by Friedman’s test followed by 
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Figure 5-8 Dyskinesia expression following ARR17477 plus ropinirole treatment. ARR17477 (ARR; 3, 6 or 
12 mg/kg s.c) and ropinirole (Rop; 0.2 mg/kg plus domperidone 2 mg/kg p.o.) treatment in L-dopa-
primed MPTP-treated marmosets. Data are presented as medians (n=6); (a) Time-course, and also 
individual values (b) Total, (c) Peak and (d) On-time. Time-course data were analysed by 2-way-ANOVA 
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5.3.3 The effect of nNOS inhibition on locomotor activity, motor disability and 
dyskinesia induction following de novo chronic treatment with L-dopa plus nNOS 
inhibitor in MPTP-treated marmosets 
 
5.3.3.1 Locomotor activity  
-Vehicle + L-dopa  
In week 1 of chronic treatment L-dopa-induced an expected increase in locomotor activity showing 800 
counts/4 h, increasing to a total of 2300 counts/4 h by week 3 (Figure 5-9a). Although activity did not 
reach this level again, locomotor activity remained raised around 700 counts/4 h from week 4 onwards. 
In week 1 peak locomotor activity was 450 counts/30 min increasing to a maximal peak in week 3 of 650 
counts/30 min after which levels remained stable with a peak activity of around 300 counts/30 min 
(Figure 5-9b). As expected all parameters significantly increased over the 8 week period (Figure 5-9a-b).     
-nNOS inhibitor + L-dopa  
There was no significant effect of nNOS inhibition on L-dopa-induced locomotor activity over the 8 week 
chronic administration phase as measured by total and peak activity (Figure 5-9a-b). These findings are 
further supported by the summed total and peak locomotor activity (Figure 5-9a’-b’) showing no 
significant difference between the two treatment groups.      
 
5.3.3.2 Motor disability  
-Vehicle + L-dopa  
L-dopa reversed motor disability giving a total score of 30 over 4 h in week 1 (Figure 5-10a). Total scores 
then remained stable between 30 (week 4) and 50 (week 7). Maximum reversal of motor disability was 
achieved in week 1 (score 2.5) and remained controlled throughout the chronic treatment period with 
maximum scores of 2.5-4 (Figure 5-10b). The on-time for motor disability reversal gradually increased 
from 1 h in week 1 to a maximal on-time of 3 h in weeks 6-8 (Figure 5-10c). Reversal of motor disability 
significantly increased over the course of the chronic treatment period in terms of total score, peak 
score and on-time (Figure 5-10a-c).        
-nNOS inhibitor + L-dopa  
There was no significant effect of nNOS inhibition on L-dopa-induced motor disability reversal over the 8 
week chronic administration phase as measured by total activity, peak activity and on-time (Figure 
5-10a-c). These findings are further supported by summed total, peak and on-time for motor diability 
(Figure 5-10a’-c’) showing no significant difference compared to L-dopa alone.      
 
5.3.3.3 Dyskinesia  
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Dyskinesia gradually increased over time with a total score of 2.5 during 4 h in week 1 and reaching a 
maximum total score of 9 by week 7 (Figure 5-11a). The peak dyskinesia score also gradually increased 
from 1 in week 1 to a maximum peak score of 2 in weeks 5, 7 and 8 (Figure 5-11b). The duration of 
dyskinesia also increased over the treatment period with on-times of 75 min in week 1 reaching a 
maximum of 120-150 min in weeks 5, 7 and 8 (Figure 5-11c).    
-nNOS inhibitor + L-dopa  
There was no significant effect of nNOS inhibition on L-dopa-induced dyskinesia over the chronic 
treatment period as measured by total scores, peak scores and on-time (Figure 5-11a-c). These findings 
are substantiated by summed total, peak and on-time for dyskinesia (Figure 5-11a’-c’), showing no 
significant difference between the two treatment groups. However there was a tendency for nNOS 
inhibition to increase total and peak summed L-dopa-induced dyskinesia over the 8 weeks despite a lack 
of statistical significance (Figure 5-11a’-b’). 
 
5.3.3.4 L-dopa final acute challenges  
Following withdrawal of chronic treatment with L-dopa plus vehicle, subsequent acute challenge with L-
dopa only induced an expected increase in locomotor activity with a median total of 1400 counts/4 h 
(Figure 5-12a), peak activity of 500 counts/30 min (Figure 5-12a’) and an on-time of 90 min (Figure 
5-12a’’). Similarly total motor disability scored 60 (Figure 5-12b), with a peak score of 2 (Figure 5-12b’) 
and on-time of 180 min (Figure 5-12b’’), and total dyskinesia scored 13.5 (Figure 5-12c), with a peak 
score of 3 (Figure 5-12c’) and duration of 180 min (Figure 5-12c’’).  
Following withdrawal of chronic treatment with L-dopa plus concomitant nNOS inhibitor, challenge with 
L-dopa alone also produced an increase in locomotor activity, reversal of motor disability and expression 
of dyskinesia (Figure 5-12a-c). There was no significant difference in acute L-dopa response in animals 
who had received prior chronic treatment with L-dopa in the presence of the nNOS inhibitor compared 
to L-dopa alone for locomotor activity, motor disability or dyskinesia as measured by total or peak 
















Figure 5-9 Locomotor activity following chronic treatment with nNOS inhibitor plus L-dopa. 7-NI (20 
mg/kg s.c.; weeks 1-4) or ARR17477 (ARR; 1 mg/kg s.c; weeks 5-8) and L-dopa (LD; 12.5 mg/kg plus 
carbidopa 12.5 mg/kg p.o.) treatment in MPTP-treated marmosets, L-dopa naïve at week 0 (t=0 indicates 
baseline activity). Data are presented as medians (n=5); (a) Total and (b) Peak, and also individual values 
(a’) Summed total and (b’) Summed peak +p<0.05, ++p<0.01 for time (colours representative as in key). 
Weekly behavioural data were analysed by 2-way-ANOVA followed by Friedman’s test for time. Summed 
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Figure 5-10 Motor Disability following chronic treatment with nNOS inhibitor plus L-dopa. 7-NI (20 
mg/kg s.c.; weeks 1-4) or ARR17477 (ARR; 1 mg/kg s.c; weeks 5-8) and L-dopa (LD; 12.5 mg/kg mg/kg 
plus carbidopa 12.5 mg/kg p.o.) treatment in MPTP-treated marmosets, L-dopa naïve at week 0 (t=0 
indicates baseline activity). Data are presented as medians (n=5); (a) Total, (b) Peak and (c) On-time, and 
also individual values (a’) Summed total, (b’) Summed peak and (c’) Summed on-time +p<0.05, 
++p<0.01, +++p<0.001 for time (colours representative as in key). Weekly behavioural data were 
analysed by 2-way-ANOVA followed by Friedman’s test for time. Summed data were analysed by Mann-
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Figure 5-11 Dyskinesia following chronic treatment with nNOS inhibitor plus L-dopa. 7-NI (20 mg/kg 
s.c.; weeks 1-4) or ARR17477 (ARR; 1 mg/kg s.c; weeks 5-8) and L-dopa (LD; 12.5 mg/kg plus carbidopa 
12.5 mg/kg p.o.) treatment in MPTP-treated marmosets, L-dopa naïve at week 0 (t=0 indicates baseline 
activity). Data are presented as medians (n=5); (a) Total, (b) Peak and (c) On-time, and also individual 
values (a’) Summed total, (b’) Summed peak and (c’) Summed on-time; +p<0.05, ++p<0.01 for time 
(colours representative as in key). Weekly behavioural data were analysed by 2-way-ANOVA followed by 
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Figure 5-12 Final L-dopa only challenge data subsequent to chronic nNOS inhibitor plus L-dopa 
treatment. L-dopa (LD; 12.5 mg/kg plus carbidopa 12.5 mg/kg p.o.) treatment in L-dopa plus nNOS 
inhibitor/vehicle primed MPTP-treated marmosets. Data are presented as medians and individual values 
(n=5) and groups are labelled according to their prior chronic treatment. Locomotor activity (a-a’’), 
motor disability (b-b’’) and dyskinesia (c-c’’); totals (a-c), peaks (a’-c’) and on-time (a’’-c’’). Data were 
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5.4 Discussion 
The studies described in this chapter explored the application of nNOS inhibitors in treatment of 
established dyskinesia and also in the process of dyskinesia development in MPTP-treated marmosets. It 
was hypothesised that nNOS inhibition would both reduce the expression of L-dopa- and ropinirole-
induced dyskinesia in L-dopa-primed MPTP-treated primates, and also prevent the induction of 
dyskinesia from first L-dopa exposure. 
Initially it was important to confirm that 7-NI promotes nNOS inhibition when administered via a s.c. 
route, as i.p. dosing is not approved in primates, whilst the doses of ARR17477 were chosen in line with 
previous rodent studies, where the treatment was already given s.c., and supported by the literature.  
These doses were then applied to in vivo investigations in MPTP-treated primates in a similar manner to 
those employed in 6-OHDA-lesioned rats in Chapters 3 and 4.        
5.4.1 Inhibition of nNOS by ARR17477 
In the dyskinesia expression studies, the doses of ARR17477 (3, 6 and 12 mg/kg s.c.) were selected on 
the basis of a previous study in rats showing nNOS activity was reduced in striatal tissue at all doses 
employed, in a dose-related manner and the highest two doses significantly reduced nNOS activity in 
cerebellar tissue (see Chapter 3, section 3.2.3). These findings were in agreement with published work 
on nNOS inhibition by ARR17477 (Zhang et al., 1996; O'Neill et al., 2000; Reif et al., 2000), as discussed 
in Chapter 3. For the priming study involving chronic treatment with nNOS inhibitor, the dose of 
ARR17477 (1 mg/kg s.c.) was chosen as previously described, showing a significant reduction in nNOS 
activity at 4 days, taken to be indicative of cumulative chronic treatment, without any overt side-effects 
(see Chapter 4, section 4.2.3.2). It was expected that these doses would be similarly effective in primate 
as rodent. It was important that the dose of ARR17477 should reduce nNOS activity without affecting 
basal motor function as sometimes noted with NOS inhibitors (Sandi et al., 1995; Dzoljic et al., 1997) and 
by lowering the dose as far as possible for the chronic study,  the chances of such an outcome would be 
minimised. 
5.4.2 Inhibition of nNOS by 7-NI 
The ex vivo study reported in this chapter showed that 7-NI (20 mg/kg s.c.) significantly reduced nNOS 
activity by 20 % in striatal tissue, although there was no significant effect in cerebellum. As the main site 
of interest for nNOS effects relating to motor output is the striatal interneurones where levels of nNOS 
expression per neuron are especially high (Bredt et al., 1991; Nisbet et al., 1994), the changes in striatal 
activity were considered most pertinent to these studies. Levels of inhibition were considerably lower 
following s.c. than  i.p. administration of a comparable dose, whereby the former route reduced striatal 
nNOS activity by 41 % (See Chapter 3). This variation may be due to the fact that 7-NI was given as a 
suspension in this case.  Measured at a later time point inhibition may have been higher, owing to 
continuous slow release of the nNOS inhibitor. It is also important to bear in mind that some enzyme-
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true levels of inhibition may well be higher and therefore 20 mg/kg s.c. should be an effective dose to 
use. Differences are also likely to be applicable to ex vivo studies in previous chapters (Chapters 3 & 4), 
where although not commented upon at the time, in retrospect may have had higher levels of nNOS 
inhibition owing to enzyme-inhibitor dissociation than strictly indicated by the measured changes in 
enzyme activity. Hantraye et al. (1996) indeed demonstrated that a similar dose of 7-NI (25 mg/kg s.c.), 
administered in peanut oil, prevented MPTP-induced neurotoxicity in primates. Although no nNOS ex 
vivo data for this route were presented, it suggests that this dose was effective at inhibiting NOS and the 
authors claim the findings were not due to any 7-NI related MAOB effects.  
 
5.4.3 The effect of acute nNOS inhibition on L-dopa-expressed behaviours in MPTP-
treated marmosets  
The highest dose of ARR17477 (12 mg/kg s.c.) had no significant effect on locomotor activity, motor 
disability or dyskinesia in MPTP-treated primates. These findings are  in agreement with effects seen in 
6-OHDA-lesioned rats also treated with ARR17477 alone (see Chapters 3 & 4), and in a study by 
Johansson et al. (1999) in rodents showing no change in locomotion or other gross behaviours following 
ARR17477 (0.5-20 mg/kg s.c.) administration. 
L-dopa alone induced an increase in locomotor activity, reversal of motor disability and onset of 
dyskinesia as expected from preliminary experiments (see dose-response, chapter 2, section 2.5.5) and 
as previously reported (Clarke et al., 1987; Pearce et al., 1995). Dyskinesia expression coincided with 
alleviation of motor disability both lasting for an equal duration and hence analogous to ‘peak-dose’ 
dyskinesia where abnormal movements are maximal where L-dopa plasma concentrations peak as seen 
in PD patients (Schneider, 1989).  
ARR17477 (3-12 mg/kg) treatment caused some potentiation of L-dopa-induced locomotor activity 
increasing total counts by 100 %, although statistically this did not prove significant compared to L-dopa 
alone likely to be due to due to the large variability evident in the animals’ responses. L-dopa-induced 
reversal of motor disability and dyskinesia were not significantly affected by ARR17477 treatment. 
Underlying this tendency for increasing locomotor activity may be non-nitergic effects of ARR17477, 
which has shown affinity to non-dopaminergic receptors, particularly α2, and the vesicular monoamine 
transporter (VMAT), dopamine transporter (DAT) and norepinephrine transporter (NET) in a ligand 
binding assay (See Appendix, Table 0-1). Although it is not possible to tell whether effects would be 
inhibitory or excitatory from these data, speculation on activity leading to an increased locomotor 
activity could be made. Inhibition of VMAT, involved in vesicular storage for regulation of sustained 
dopamine release, would be likely to increase locomotor activity as a result of higher levels of 
extracellular dopamine, and the inhibition of NET has been shown to enhance L-dopa-induced dopamine 
release which would be expected to have a similar effect (Liu & Edwards, 1997; Arai et al., 2008). 
Additionally inhibition of DAT and antagonist activity at adrenergic α2 receptors have both been 
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(Grondin et al., 2000; Madras et al., 2006). Inhibitory/antagonist activity of ARR17477 at these receptors 
or transporters could therefore potentially elevate locomotor activity. The activity is unlikely to be 
directly related to nNOS inhibitory properties of ARR17477 as NOS inhibitors would be expected to have 
the opposite effect having been shown to reduce spontaneous locomotion in animals (Stewart et al., 
1994; Sandi et al., 1995).  
Interestingly there was no significant effect or definitive trend for ARR17477 on L-dopa-induced reversal 
of motor disability suggesting it does not interfere with the antiparkinsonian action of L-dopa. One 
might expect an increase in motor disability reversal if extracellular dopamine levels are potentiated as 
suggested above, however motor disability scores are assessed using a finite scale and rarely exceed a 
peak score of 2, as most drugs do not completely normalise vocalisation in animals.. By contrast 
locomotor activity counts are continuous data with the potential to increase infinitely, hence there is no 
ceiling effect constraining measurement, which is likely to explain the apparent lack of further change 
seen in motor disability.   
According to the present results, nNOS inhibition does not reduce L-dopa expression of dyskinesia in the 
MPTP-treated primate. Meanwhile, various studies show that L-dopa-induced dyskinesia expression can 
indeed be reduced in this model. Amantadine, a weak NMDA receptor antagonist used in the clinic 
reduces dyskinesia (Blanchet et al., 1998a; Hill et al., 2004). Similarly other NMDA antagonists have been 
shown to alleviate dyskinesia in this model including LY235959 and the NR1A/NR2B subtype-specific 
antagonist Co 101244 (Papa & Chase, 1996; Blanchet et al., 1999). AMPA receptor antagonists 
topiramate and LY300164 (Konitsiotis et al., 2000; Silverdale et al., 2005) and metabotropic glutamate 
receptor type 5 (mGluR5) antagonists MTEP and MPEP (Johnston et al., 2010; Morin et al., 2010) also 
reduce dyskinesia in MPTP-treated primates, highlighting the important role of glutamate in the 
expression of abnormal motor effects.  
Modulation of other neurotransmitter pathways has also generated successful results with 5-HT1a 
agonists Sarizotan and (+)-8-OHDPAT reducing L-dopa-induced dyskinesia although the latter drug 
compromised reversal of motor disability Iravani et al., 2006b) (Bibbiani et al., 2001; Iravani et al., 2006). 
Combination of 5-HT1a and 5-HT1b agonists has also decreased L-dopa-induced dyskinesia in primates, 
as also seen with MDMA believed to act on these receptors (Iravani et al., 2003; Munoz et al., 2008). 
Quetiapine, having 5-HT2A/C and D2/3 antagonistic activity reduces expression of L-dopa-induced 
dyskinesia (Oh et al., 2002), whilst a partial D3 receptor agonist has similar effects (Bezard et al., 2003), 
hence the specific receptor sub-type targeted seems pertinent. The α2 adrenoreceptor antagonists 
idazoxan and fipamezole have also demonstrated anti-dyskinetic efficacy in this model (Henry et al., 
1999; Savola et al., 2003), although both of these compounds only delayed the onset of dyskinesia 
without reducing its overall expression in studies conducted in our laboratories (M. Jackson, 
unpublished data). Further targets for dyskinesia attenuation in MPTP-treated primates have included 
cannabinoid receptor agonists (Fox et al., 2002), opioid μ- and δ-receptor antagonists (Henry et al., 
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these dyskinesia-modifying drugs are relatively non-specific so it is difficult to know the exact mode of 
action or benefits may be due to multiple effects. However, the wide array of L-dopa adjuncts able to 
moderate motor complications demonstrate that it is certainly possible to reduce the expression of 
dyskinesia in MPTP-treated primates and hence suggests nNOS inhibitors are inappropriate agents for 
this purpose.     
Importantly, this study confirms the findings seen in the 6-OHDA-lesioned rat (Chapter 3) showing that 
nNOS is not critically involved in the expression of L-dopa-induced dyskinesia regardless of the model 
employed. 
 
5.4.4 The effect of acute nNOS inhibition on ropinirole-induced behaviour in MPTP-
treated primates  
Treatment with ropinirole caused an increase in locomotor activity, reversal of motor disability and 
onset of dyskinesia in L-dopa-primed MPTP-treated marmosets as seen in preliminary experiments (See 
dose-response, chapter 2). As expected, ropinirole resulted in lower levels of dyskinesia expression than 
produced by L-dopa. This contrast reflects published findings comparing the dyskinetic potential of 
ropinirole and L-dopa both in primates and 6-OHDA-lesioned rats (Jackson et al., 2007; Papathanou et 
al., 2011), and also earlier studies presented in this thesis (see Chapter 3, section 3.4.3). Whilst 
ropinirole is short-acting in rats, this study confirms that in primates it is longer acting, with effects on 
behavioural parameters lasting for a comparable time to L-dopa and beyond (Pearce et al., 1998; 
Fukuzaki et al., 2000b). This observed difference lends support to the similarity between drug responses 
in PD patients and the MPTP-treated primate, where ropinirole is also relatively long-acting. Meanwhile 
the extent of motor disability reversal was similar to that observed following L-dopa only treatment, 
although ropinirole appeared to induce higher total locomotor activity levels than L-dopa alone, despite 
an equivalent duration of locomotor activity. According to previous studies, locomotor activity levels in 
primed MPTP-treated marmosets tend to be comparable between L-dopa and ropinirole (Pearce et al., 
1998). Thus the difference found in the present study is likely to be attributable to the on-going low 
level activity, observable at 3-5 h after ropinirole dosing, only marginally above baseline levels which 
may not have counted towards median ‘on-time’ but would have contributed to totals for locomotor 
activity, owing to the nature of the different parameters.    
There was no significant effect of ARR17477 on ropinirole-induced locomotor activity, reversal of motor 
disability or dyskinesia. It is not surprising that ARR17477 did not show a similar trend for increasing 
locomotor activity as seen when administered in combination with L-dopa. As a dopamine agonist 
ropinirole’s effects are predominantly post-synaptic and therefore the non-nitrergic activity of the nNOS 
inhibitor, which would mainly affect pre-synaptic neurone terminals (as described in 5.4.3), is unlikely to 
interfere in this case. 
Although there are limited studies on the effects of adjuncts on ropinirole-induced dyskinesia 
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can be attenuated in the MPTP-treated primate. For example MDMA in combination with pramipexole, 
also a D2/D3 agonist, reduces the expression of dyskinesia and the moderation is likely to be due to 
interactions with 5-HT pathways (Iravani et al., 2003). This mechanism was further supported by work 
with (+)-8-OHDPAT, a selective agonist at 5-HT1a receptors, which also reduced dyskinesia expressed by 
pramipexole although only with a reduction in motor disability reversal (Iravani et al., 2006). 
Additionally morphine, an opioid agonist, attenuates dyskinesia expressed by the D2 receptor agonist, 
quinpirole (Samadi et al., 2004). Therefore the expression of dyskinesia by dopamine agonists with 
similar D2 affinity to ropinirole can be successfully reduced in the MPTP-treated primate model. The 
inability for ARR17477 to reduce dyskinesia expression by ropinirole undermines the use of nNOS 
inhibitors for treatment of motor complications in this model, and also the chances of benefit in man 
given the translational link between species (Fox et al., 2006; Porras et al., 2012). 
These findings further support the outcome seen for ARR17477 on L-dopa expressed dyskinesia. Again, 
the ineffectiveness of ARR17447 in this study confirms the results from the 6-OHDA-lesioned rat model 
of Chapter 3, and a lack of involvement of nNOS in ropinirole-induced dyskinesia expression.  
 
5.4.5 The effect of chronic nNOS inhibition on L-dopa-induced behaviour in MPTP-
treated primates 
The second set of experiments in this study investigated the effect of nNOS inhibition in the priming for 
dyskinesia by L-dopa. Priming could present an earlier opportunity to impede upon alterations in 
synaptic plasticity resulting from changes in nitric oxide, which may underlie the initial development of 
dyskinesia, and for which manipulating at the expression stage (sections 5.4.3 and 5.4.4) may have been 
too late on to confer benefit.  
Chronic administration of L-dopa raised locomotor activity, reversed motor disability and gradually 
induced dyskinesia over the treatment period. These findings were consistent with the effect of L-dopa 
reported in previous priming studies in MPTP-treated primates (Bedard et al., 1986; Boyce et al., 1990; 
Pearce et al., 1998; Smith et al., 2002). As expected, the reversal of motor disability and increase in 
locomotor activity was seen immediately after initiating treatment, although the duration of improved 
motor function tended to increase over the chronic treatment period. The onset of dyskinesia was more 
gradual with maximum scores not achieved until week 5. This is somewhat different to the onset of 
dyskinesia in rats which is almost immediate with maximal AIMs scores tending to be reached within the 
first week (See Chapter 4). However it does not completely reflect the delay in dyskinesia expression in 
man, where many years of dyskinesia free dopaminergic therapy are commonly experienced (Fahn, 
2000; Rascol et al., 2000; Ahlskog & Muenter, 2001). In primate and rodent models, in a similar manner 
to patients with PD, the severity of dyskinesia relates to the degree of parkinsonism and the dose and 
duration of levodopa therapy (Schneider et al., 2003; Smith et al., 2003). Both MPTP-treated primates 
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neuropathology evident in advanced stages of PD, which explains why dyskinesia is induced so rapidly in 
these models.  
Similar changes in motor behaviour were seen with L-dopa administered in combination with nNOS 
inhibitor compared to L-dopa alone. There was no difference in locomotor activity, reversal of motor 
disability or indeed dyskinesia between the two treatment regimes. Considering the lack of effect of 
nNOS inhibitors seen in 6-OHDA-lesioned rats the slower onset of dyskinesia in this model seemed more 
likely to allow for preventative therapy, but this difference in timing did not appear to alter the 
outcome. Furthermore after drug washout final acute challenges with L-dopa alone in both groups 
showed no effect of nNOS inhibitor on the priming process.  
It became necessary to change nNOS inhibitor during the course of chronic treatment due to skin lesions 
developing at 7-NI injection sites in several animals. 7-NI has poor solubility in polar solutions so it was 
not possible to use saline as vehicle and we had already anticipated that DMSO, as used in the rat 
studies involving 7-NI (Chapters 3 & 4), would cause skin problems. The decision was made to switch to 
ARR17477 which was the original choice of nNOS inhibitor owing to its more favourable properties of 
nNOS selectivity and potency, but was not employed initially in this primate model due to concerns over 
chronic implications of its long acting and irreversible nature. The switch occurred from one day to the 
next so it was ensured nNOS inhibition was consistent with subsequent L-dopa dosing.     
Although nNOS activity in rat striatum was shown to be reduced by subcutaneous administration of 7-NI 
in this chapter, there was no effect seen in the cerebellum. Whilst the striatum is considered the main 
site of interest for nNOS as discussed in section 5.4.2, the cerebellum is also known to be important in 
movement control and may contribute to the motor complications seen in PD (Hurley et al., 2003; Koch 
et al., 2009). Therefore it cannot be ruled out that 7-NI may have failed to lessen the development of 
dyskinesia owing to the fact it did not reduce cerebellar nNOS activity. Nevertheless when ARR17477 
treatment, already demonstrated to reduce nNOS activity in rat cerebellum (see Chapter 4), was 
introduced in week 4 dyskinesia levels were sub-maximal and there did not appear to be any prevention 
of dyskinesia progression in subsequent weeks. Potentially it could have been too late to resist 
underlying molecular changes by this stage of dopaminergic treatment. Notably it is also possible that 
the extent of nNOS inhibition may have differed between marmosets and rats in any case, but primates 
could not be spared for sacrifice and this is a shortcoming of the present study.       
Contrary to the predicted reduction in dyskinesia priming by nNOS inhibition, there was a trend towards 
an increase in dyskinesia over the full priming period. Based on the rat priming data (Chapter 4) where a 
similar effect was seen during L-dopa priming with 7-NI on AIMs, and indeed statistical significance was 
achieved, it seems plausible that again this increase may be due to the MAOB inhibitory properties of 7-
NI (Castagnoli et al., 1997; Di Monte et al., 1997; Desvignes et al., 1999) in addition to possible eNOS 
effects as discussed previously. Once dyskinesia had been induced the required switch of nNOS inhibitor 
to ARR17477 (with less evidence for MAOB inhibition-see Chapter 3, section 3.4.2) may have occured 
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This is the first time that nNOS inhibition has been investigated in the priming of MPTP-treated 
primates. There are a number of other agents that have been used as adjuncts to L-dopa successfully 
lessening the development of dyskinesia including the COMT inhibitor entacapone (Smith et al., 2005), 
the mGluR5 antagonist fenobam (Rylander et al., 2010), CI-1041, a selective antagonist of the NR1A/2B 
subtype of NMDA receptor (Hadj Tahar et al., 2004; Samadi et al., 2008) and D3 antagonist S33084 
(Visanji et al., 2009). These studies demonstrate the potential for manipulation of the priming process in 
this model and the capability to reduce the development of dyskinesia. In particular these reported 
studies support the modulation of glutamate for attenuating priming for dyskinesia, thus suggesting that 
nNOS is not of key involvement despite its implicated role downstream of glutamatergic changes. 
Indeed antagonism at the glutamate receptors themselves (mGluR5 or NMDA NR1A/2B) appears to be 
critical, perhaps because it can lead to broader effects than solely altering levels of NOS which the 
present studies have revealed is insufficient.   
This priming study shows that nNOS is not a crucial factor in the development of L-dopa-induced 
dyskinesia in MPTP-treated primates. 
 
5.4.6 Conclusion 
The data presented here from MPTP-treated primates confirm the findings obtained in 6-OHDA-lesioned 
rats of previous chapters. It leads to a conclusion that nNOS inhibition is ineffective in reducing 
expression and priming for dyskinesia in these animal models. Given the likeness of MPTP-treated 
primate motor dysfunction and dyskinesia to associated behavioural manifestations in PD, coupled with 
studies which have in fact shown that expression and priming for dyskinesia can both be attenuated in 
this translational model, these findings have strong implications. Thus in conclusion, it is unlikely that 
nNOS inhibitors would provide any relevant benefit for dopaminergic medication-induced dyskinesia in 













































  Chapter 6 
6.1 Summary and discussion of findings 
It was hypothesised that NO produced by nNOS is critically involved in the occurrence and evolution of 
dyskinesia in PD, via synaptic plasticity mechanisms, and this can be controlled by inhibition of nNOS. 
Thus these studies investigated whether nNOS inhibition could reduce the expression of dyskinesia in 
animals already treated long-term with dopaminergic agents and also the priming for dyskinesia from 
first exposure of animals to dopaminergic treatment. In order to explore these phenomena two animal 
models of PD were employed, both of which display abnormal involuntary movements following 
dopaminergic treatment; the 6-OHDA-lesioned rat and the MPTP-treated marmoset.  
 
6.1.1 Dyskinesia expression and NO 
In 6-OHDA-lesioned rats already L-dopa-primed to show AIMs, the rodent form of dyskinesia, the 
inhibition of nNOS had no beneficial effect on L-dopa- or ropinirole-induced AIMs expression. In fact 
some potentiation of total AIMs scores and duration of AIMs was evident following 7-NI treatment, 
although this effect may have been the result of inhibition of MAOB and/or eNOS. Similarly in L-dopa-
primed MPTP-treated marmosets, the expression of dyskinesia was unaltered by the inhibition of nNOS 
in combination with L-dopa or ropinirole treatment, whilst locomotor activity and motor disability 
reversal increased in the same manner as for dopaminergic treatment alone.    
 
6.1.2 Dyskinesia priming and NO 
The inhibition of nNOS during de novo L-dopa treatment in 6-OHDA-lesioned rats did not prevent the 
development of AIMs. Indeed, as seen in the expression studies, AIMs were worsened following 7-NI 
treatment, most likely the result of inhibition of MAOB and/or eNOS. Whilst there was some tendency 
for ARR17477 to reduce the development of AIMs, no statistical significance was achieved. These 
findings were corroborated by the L-dopa priming study in MPTP-treated marmosets showing that the 
inhibition of nNOS does not influence the development of dyskinesia, whilst locomotor activity and 
motor disability reversal over the priming period were also unaffected. 
 
 
This is the first time that the role of nNOS inhibitors has been investigated in the expression and priming 
of dyskinesia in both rodent and primate models of PD. Importantly, the accompanying ex vivo studies 
thoroughly verify the inhibition of nNOS by ARR17477 and 7-NI at the doses employed in the 
behavioural investigations, allowing confidence in concluding that nNOS does not play a significant role 
in these phenomena. These findings lead to a rejection of the proposed hypothesis that NO underlies 
the motor complications and indeed suggest that the inhibition of nNOS is unlikely to be of any value in 
the treatment of dyskinesia in the clinic. Interestingly these findings are in contrast to those described in 
the literature, published whilst the present work was undertaken (Padovan-Neto et al., 2009; Takuma et 
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Padovan-Neto et al. (2009), reported a reduction in expression of dyskinesia by nNOS inhibiton in 6-
OHDA-lesioned rats and more recent research by Takuma et al. (2012), only in publication at the 
conclusion of writing this thesis, reported attenuation of the development of dyskinesia by nNOS 
inhibition also in this rat model. Both studies have significant drawbacks, firstly their use of only two 
time points for AIMs assessment at 60 and 120 min after dopaminergic treatment which may well 
obscure any changes occurring at other times. This monitoring period is not in keeping with the 
established methods of AIMs evaluation in 20 min cycles as developed by Cenci et al. (1998) and widely 
employed across AIMs studies (e.g. Monville et al., 2005; Pinna et al., 2006; Putterman et al., 2007; 
Marin et al., 2009). In fact the experiments carried out in the present studies measured AIMs every 15 
min rather than 20 min, so are yet more stringent in portraying the ongoing changes in behaviour over 
the full time-course of analysis.  
Secondly the suitability of the doses of drugs employed in the published studies was questionable. 
Extraordinarily high doses of L-dopa (up to 30-100 mg/kg) were utilised by both groups suggesting that 
locomotive behaviour would obscure the capacity to score AIMs, as already discussed in Chapter 3 (see 
section 3.4.2). Higher doses of L-dopa are known to promote dyskinesia, but are rarely employed in PD 
patients these days making these published studies less clinically relevant. Additionally, in neither 
investigations were ex vivo experiments reported to validate their chosen doses of 7-NI. In particular 
Takuma et al. (2012) used only 7-NI 10 mg/kg which is low compared to the typical dose of 25-30 mg/kg 
used for priming in Chapter 4 and commonly reported in the literature (Mackenzie et al., 1995; Jiang et 
al., 2002; de la Torre & Aliev, 2005; Wangensteen et al., 2006). Additionally according to the ex vivo data 
shown in Chapter 3 whilst their dose is likely to cause some inhibition of nNOS it may not be optimal, 
although it is possible at this lower dose that non nNOS-specific effects are indeed minimised. In neither 
study is there any hint of 7-NI increasing AIMs as seen in both the expression and priming experiments 
as reported in this thesis, despite Padovan-Neto and colleagues using 7-NI 30 mg/kg. Moreover the only 
nNOS-specific inhibitor employed in both of these studies was 7-NI, whereas the experiments reported 
here additionally test ARR17477 which is more potent and indeed specific for nNOS over other NOS 
isoforms (see section 6.1.3).  
Constructively, Takuma and colleagues (2012) carried out some biochemical investigations to 
accompany their behavioural findings showing that 7-NI lessened the L-dopa-induced increases in ΔFosB 
and phosphorylated DARPP-32 in the 6-OHDA-lesioned striatum. As no significant benefit was conferred 
by nNOS inhibitors in the presented studies there was no rationale for investigating the biochemistry 
any further. 
Importantly the present studies used well established protocols in both rodent (Cenci et al., 1998; 
Winkler et al., 2002; Putterman et al., 2007)  and marmoset models (Pearce et al., 1995; Silverdale et al., 
2005; Jackson et al., 2007), which have been fully characterised to show a reduction in dyskinesia with 
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in AIMs/dyskinesia as seen with such drugs would have been observed in both models but this was not 
the case. 
   
6.1.3 Specificity of NOS inhibitors 
The availability of specific CNS penetrant inhibitors for in vivo assessment of the role of inhibition of 
nNOS on dyskinesia was somewhat limited. In these studies ARR17477 was chosen as the best available 
tool for this purpose, in addition to 7-NI which has been employed in many studies for nNOS inhibition 
(e.g. Przedborski et al., 1996; Li et al., 2002; Wangensteen et al., 2006). Compared to similar drugs 
ARR17477 in particular is reportedly relatively specific for nNOS over other NOS isoforms (Vallance & 
Leiper, 2002; Paige & Jaffrey, 2007). Additionally results from the ex vivo studies of Chapters 3-5 
strongly support the capacity for NOS inhibition by ARR17477 and 7NI using the chosen doses and 
routes of administration.  
The increased duration of AIMs following 7-NI is consistent with the reported inhibitory effect on MAOB 
and/or eNOS inhibitory activity as already discussed in Chapters 3 and 4.  Indeed, the notable trend for 
ARR17477 to attenuate AIMs suggesting a possible antidyskinetic function that was masked by other 
effects of the drug, possibly through binding to DAT, VMAT, NET or adrenergic α2 receptors as identified 
in a ligand binding assay (See Appendix; Table 0-1). Although the excitatory/inhibitory nature of the 
interaction cannot be deduced there is evidence for a role for these transporters and receptors in 
worsening dyskinesia (Fox et al., 2001; Nutt et al., 2004; Lee et al., 2006; Arai et al., 2008).    
Ideally the nNOS inhibitors would have been more specific and the differences in their behavioural 
effects on dyskinesia in some instances highlight this (worsening of dyskinesia evident with 7-NI but not 
with ARR17477 particularly suggests 7-NI is by no means a perfect probe for investigating nNOS specific 
effects). It was therefore important to consider the effects of two different inhibitors thus adding 
further weight to the present findings in comparison to those of Padovan-Neto et al. (2009) and Takuma 
et al. (2012), whereby 7-NI was the only nNOS inhibitor tested.    
Several groups are working on producing more specific inhibitors of nNOS and provided these prove 
effective in vivo a more valuable tool set is likely to be available for investigations in the future (Joubert 
& Malan, 2011; Annedi et al., 2012; Ramnauth et al., 2012). Additionally the direct intracerebral delivery 
of nNOS inhibitors could provide an approach to overcome reported issues of blood-brain barrier 
penetration associated with more recently synthesized nNOS-specific compounds (Xue et al., 2010a).   
Notably the most consistent finding overall in these studies was that neither of the nNOS inhibitors 
significantly reduced dyskinesia in the 6-OHDA-lesioned rat or MPTP-treated primate at doses shown to 
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6.1.4 The animal models 
6.1.4.1 6-OHDA-lesioned rat 
6-OHDA-lesioned rats are the most commonly used animal model for investigating motor complications 
of PD treatment, as they are both accessible and readily demonstrate quantifiable behaviours (Cenci & 
Ohlin, 2009). The pharmacological profiling of the AIMs model employed in these studies support 
validation of AIMs within the literature. The characterisation experiments presented in Chapter 2 
showing amantadine, MK-801 and 8-OHDPAT all reduce AIMs are in agreement with reported studies 
(Dekundy et al., 2007; Dupre et al., 2008). Additionally the dopaminergic AIMs expression and priming 
studies demonstrated in Chapters 3 and 4 with only L-dopa or ropinirole treatment in 6-OHDA-lesioned 
rats further support findings in the literature (e.g. Carta et al., 2008a; Monville et al., 2009; Papathanou 
et al., 2011). These confirm the reliability and reproducibility of the model for displaying AIMs and its 
validity within the context of experiments presented in this thesis. 
AIMs in 6-OHDA-lesioned rats consist of locomotive, axial, limb and orolingual parameters (Cenci et al., 
1998; Lundblad et al., 2002). The significance of locomotive AIMs as a measure of dyskinesia is uncertain 
and although originally included in the classification of the model (Cenci et al., 1998), it has since been 
described as a ‘non-specific’ motor response (Winkler et al., 2002). This may be true to a certain extent 
in that its exact cause is ambiguous although the response does seem specifically related to 
dopaminergic drug treatment. Rotational behaviour in 6-OHDA-lesioned rats was traditionally used to 
assess anti-parkinsonian activity, although sensitisation that develops following chronic dopaminergic 
treatment has been used as a model of priming for dyskinesia (Ungerstedt & Arbuthnott, 1970; Henry et 
al., 1998). However, there exist several important differences between the manifestation of rotational 
behaviour and dyskinesia as measured by ALO AIMs: a) The levodopa dose necessary to induce stable 
rotational behaviour is higher than that for ALO AIMs expression, b) dopamine agonists with proven 
low-dyskinesiogenic potential induce a full rotational response and c) where 6-OHDA lesions are 
restricted to the dorsal striatum L-dopa induces ALO AIMs without rotational activity (Marin et al., 2006; 
Cenci & Ohlin, 2009).  
In the studies presented here locomotive AIMs tended to follow a similar pattern to ALO AIMs with both 
parameters showing significant changes or trends following drug treatments. However, locomotive AIMs 
have been considered independently in line with the literature where they are often omitted in more 
recent papers, or at least considered separately from the other three AIMs subtypes, and it is generally 
accepted that these are not representative of dyskinesia (Taylor et al., 2005; Dupre et al., 2007; Lindgren 
et al., 2010). Furthermore, the essence of locomotive AIMs is undoubtedly different from the other 
AIMs subcategories which appear more analogous to the choreic and/or dystonic movements 
characteristic of dyskinesia in PD patients. 
Similar to the clinical scenario AIMs are expressed following dopaminergic treatment and can be 
attenuated by various adjuncts, some of which are also beneficial in man. However there are 
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translate effectively to humans such as the 5-HT1a agonist sarizotan and the α2 adrenoceptor 
antagonist idazoxan (Marin et al., 2009; Buck et al., 2010). One explanation for failure of translation may 
be down to limitations of the model itself. Extreme levels of dopaminergic depletion occur rapidly 
following administration of 6-OHDA almost incomparable to the slow progressive nature of 
degeneration characteristic of PD thus creating a model most reminiscent of end-stage PD. Additionally 
effects of the toxin tend to be restricted to dopaminergic neurones whereas pathology is more wide-
spread affecting multiple neural pathways in PD.  The extent of the damage is controlled by the quantity 
of toxin injected and the number and location of the injection sites, but typically the damage is severe 
and highly selective to the dopamine system. Indeed extensive neurodegeneration is necessary for 6-
OHDA-lesioned rats to develop AIMs (Cenci, 2007).  Furthermore the model centres on peak-dose 
dyskinesia, without displaying any ‘on-off’ phenomena or ‘end of dose deterioration’ as is seen in the 
clinic or indeed demonstrated in MPTP-treated primates (Langston et al., 2000; Kuoppamaki et al., 
2002). 
Whilst this model is not entirely predictive of clinical outcome, it does however demonstrate a reduction 
in L-dopa-induced dyskinesia with amantadine, the one agent that affords some proven benefit in PD 
patients (Luginger et al., 2000; Lundblad et al., 2002). Therefore whilst keeping its limitations in mind it 
can still provide a beneficial tool for investigating dyskinesia, especially where experimental outcome is 
considered alongside findings from another model of PD such as the MPTP-treated primate.. 
 
6.1.4.2 MPTP-treated marmoset 
The MPTP-treated primate offers some clear advantages for assessing dyskinesia compared to the 6-
OHDA rat AIMs model, not least the strikingly human-like choreic and dystonic movements they are 
capable of displaying upon dopaminergic medication affording strong face validity. Despite these 
benefits, the model also suffers many of the same mechanistic problems that have been associated with 
the 6-OHDA-lesioned rat.  
Whilst dyskinesia induced by dopaminergic agents tend to develop a little more slowly from first drug 
exposure in MPTP-treated primates compared to 6-OHDA-lesioned rats, it still manifests within a very 
short period as compared to humans (weeks compared to years). Again, the rapid onset of dyskinesia is 
likely to be a reflection of the extensive degree of nigral denervation following toxin treatment, which 
lowers the threshold for dyskinesia induction. The situation in this primate model is obviously akin to 
the rapid appearance of treatment complications, including dyskinesia, in MPTP-exposed parkinsonian 
drug addicts (Langston et al., 1983). It also more closely resembles the outcome seen in young-onset PD 
patients or in untreated late stage PD patients where dyskinesia promptly develop after initiating 
dopaminergic medication (Fabbrini et al., 2007; Jenner, 2008b). The model may therefore have limited 
applicability to early stages of PD, where surviving nigrostriatal presynaptic terminals maintain a 
capacity to ‘buffer’ dopamine and hence striatal concentrations of dopamine do not show dramatic 
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stage of disease dyskinesia development and expression is now relatively well controlled by titrating 
dopaminergic therapy, keeping doses low and plasma levels constant. 
If a lower dose of L-dopa were to have been used this may have slowed down the rate of onset of 
dyskinesia (Kuoppamaki et al., 2007). Similarly, it would be expected that dyskinesia induction and/or 
expression may be less severe with limited nigral denervation. In an ideal model the process of 
neurodegeneration would be more progressive, thus better resembling the course of events seen in 
man, and providing a wider window for development of dyskinesia. Indeed, the MPTP treatment 
regimen has been modified in some instances to induce partial lesions of the nigro-striatal pathway 
(Blanchet et al., 1998b; Meissner et al., 2003; Iravani et al., 2005). However, L-dopa-induced dyskinesia 
is not demonstrated in the partially lesioned marmoset model, although some dyskinesia is seen in the 
partially lesioned squirrel monkey without overt symptoms of PD. This discrepancy may be due to 
differences in the number of L-dopa treatments given (Di Monte et al., 2000; Iravani et al., 2005).  
Another significant drawback of the MPTP-model, is the lack of resemblance of pathology in 
noradrenergic and serotinergic neurons as seen in PD. As the MPTP-treated primate tends to act as a 
bridge between pre-clinical rodent studies and clinical investigations, it is even more significant at this 
stage that the model can distinguish between treatments likely to be effective in reducing dyskinesia 
and those that aren’t. Whilst the MPTP-treated primate has been valuable in translation of 
dopaminergic agents to the clinic including adjuncts such as entacapone and dopamine agonists (Smith 
et al., 1997; Fariello, 1998), the model has not shared similar success in progressing non-dopaminergic 
approaches to therapy. Failures including glutamatergic, noradrenergic, adenosinergic and serotonergic, 
acting drugs have occurred showing no translational benefit or an antidyskinetic action accompanied by 
worsened motor control in human trials (Fox et al., 2006; Jenner, 2009).  
 
 
In general behavioural data tend to show wide variability as has been consistently demonstrated 
throughout this thesis (see Chapters 3-5), for both rat and primate studies. In one respect this finding 
mimics more closely the clinical scenario where there are frequently large differences in drug response 
between individuals, however, it also can make it necessary to use very large sample sizes to achieve 
significant power. In terms of ethical concerns, practicality and costs it tends not to be possible to 
employ the number of animals designated by power analysis especially in the case of primates. The 
quantities of animals used in these studies are similar to those commonly reported in the literature by 
different groups where 8-10 6-OHDA-lesioned rats is typical of AIMs studies (Taylor et al., 2005; 
Dekundy et al., 2007; Putterman et al., 2007; Monville et al., 2009), and 5-6 MPTP-treated primates is 
usual for the purpose of investigating dyskinesia (Pearce et al., 1998; Blanchet et al., 1999; Henry et al., 
2001; Silverdale et al., 2004; Gregoire et al., 2009).  
Ideally a perfect animal model would mimic all aspects of the disease with respect to the symptoms and 
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Whilst this imitation may be possible to some extent with genetic models these only tend to show 
pathological changes in specific pathways and so far seem not to display dyskinesia. Meanwhile, both 
the 6-OHDA-lesioned rat and MPTP-treated primate have shown the capacity for dyskinesia to be 
reduced by adjunctive agents in dyskinesia expression and priming studies with dopaminergic drugs as 
described in individual chapter discussions (See Chapters 3-5). Therefore, despite their shortcomings, 
they are useful tools for investigating dyskinesia pre-clinically and the lack of effect seen with nNOS 
inhibition is highly unlikely to be due to inherent faults of the models employed. These qualities further 
validate the conclusion reached from experiments in these models, that nNOS inhibition does not 
reduce the expression or priming of dyskinesia.  
 
 
6.2 Is there a role for glutamate derived NO in dyskinesia? 
Despite robust pre-clinical and clinical evidence for a key role of NO in PD and dyskinesia expression 
and/or priming, the current results imply that NO is not critical and indeed attenuation of NO levels 
confers no obvious benefit for addressing motor complications. Whilst the studies of Padovan-Neto et 
al. (2009) and Takuma et al. (2012), employing 7-NI for reduction of AIMs in 6-OHDA-lesioned rat 
suggest otherwise, as discussed fully in section 6.2.1, the more rigorous and clinically-relevant 
investigations presented in this thesis lead to an overriding conclusion that NO is not fundamental in 
dyskinesia expression or priming.   
NO is known to interact with multiple neurotransmitter pathways and so reducing NOS activity by nNOS 
inhibition is unlikely to exclusively reduce NO production associated with glutamatergic activity and 
synaptic plasticity. It would also be expected to influence other neurotransmitters including serotonin, 
adenosine, noradrenaline and dopamine (Prast & Philippu, 2001), all of which could further impact upon 
dyskinesia. Furthermore, moderating NO effects may not be achievable to the same degree as for 
conventional neurotransmitters e.g. 5-HT, where receptors tend to be specifically associated with 
neuronal membranes and interactions highly localised. NO acts as an atypical 
neurotransmitter/neuromodulator not constrained by cellular membranes and can freely diffuse 
through aqueous and lipid environments in three dimensions, yet adding further complexity to 
predicting its CNS effects. 
The regulation of molecular events may also be required further upstream from NO release as additional 
changes resulting from overactive (NMDA) glutamate levels as well as increased NO may significantly 
contribute towards dyskinesia. For example, selective antagonism of the NR1A/2B subtype of NMDA 
receptor has shown promise in alleviating the expression and development of dyskinesia in animal 
models although translation to the clinic is yet to prove successful (Blanchet et al., 1999; Samadi et al., 
2008). The modulation of Group I mGluR’s has shown considerable potential in both the reduction of 
pre-existing dyskinesia and also in attenuating the development of dyskinesia in animal models (Mela et 
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Figure 6-1 Schematic representation of mGluRs at the synapse (Niswender & Conn, 2010). Generally 
group I mGluRs (green) are localized postsynaptically, and group II (blue) and III (red) receptors are 
localized in presynaptic locations, although exceptions do occur. Group II and III receptors inhibit release 
of glutamate (left, yellow circles) or GABA (right, red circles), whereas group I receptors promote release 
when present 
glutamate to modulate synaptic transmission via second messenger pathways and may contribute to 
both NMDA-receptor dependent and independent forms of synaptic plasticity (Collingridge et al., 2004; 
Niswender & Conn, 2010). In the striatum, the activation of group I mGluRs, particularly mGluR5, can 
cause potentiation of NMDA receptor-mediated responses recorded electrophysiologically from 
medium spiny neurons (Pisani et al., 2001; Domenici et al., 2003). Antagonists of mGluR5 might 
therefore provide an opportunity to reduce the hyperactivity of glutamatergic transmission and 
attenuate dyskinesia, indeed negative allosteric modulators of mGLuR5 are currently in clinical trials by 
Novartis and Addex (Meissner et al., 2011). Other NMDA associated effects such as increased cellular 
Ca2+ or overactivity at AMPA receptors may also be prominent (Nash & Brotchie, 2000; Bibbiani et al., 
2005b). Indeed, there is evidence that dyskinesia is increased by an AMPA receptor agonist and reduced 
by an AMPA receptor antagonist in MPTP-treated primates (Konitsiotis et al., 2000). 
It therefore seems likely that glutamatergic mechanisms contribute to the expression and/ or 
development of dyskinesia and as such NO may be involved indirectly. Regulation of ionotropic and 
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6.3 What does cause the priming and ongoing expression of dyskinesia? 
The changes underlying dyskinesia are still not fully understood and as more evidence accumulates the 
picture becomes ever more complicated. One major issue in trying to understand what is happening is a 
discrepancy between methods employed across different laboratories, which can further distort 
findings. Whilst changes in ‘synaptic plasticity’ provide a valuable framework, and more specifically 
changes in glutamate pathways appear relevant in priming and expression as mentioned in section 6.2, 
evidence also supports other important post-synaptic alterations throughout the basal ganglia.  
Altered intracellular signalling cascades appear a key factor in dyskinesia induction whereby 
phosphorylated forms of various proteins associated with D1 receptor sensitisation mainly concerning 
the direct pathway are persistently increased in the striatum following chronic L-dopa treatment 
(Barroso-Chinea & Bezard, 2010; Cenci & Konradi, 2010). In particular increased phosphorylation of the 
DA- and cAMP-regulated phosphoprotein of 32 KDa (DARPP-32) is evident at the threonine-34 residue in 
the ‘dyskinetic’ rodent striatum (Picconi et al., 2003; Santini et al., 2007). Furthermore increased striatal 
extracellular signal regulated kinases 1 and 2 (ERK1/2) phosphorylation, which can be modulated by 
DARPP-32, have also been demonstrated in AIMs displaying rodents treated with L-dopa (Pavon et al., 
2006; Santini et al., 2007; Westin et al., 2007). More recently Santini et al. (2010) have shown in a 
primate model that coordinated activation of cAMP/PKA/DARPP-32 and ERK is implicated in the initial 
priming processes underlying the emergence of dyskinesia after acute L-dopa treatment, whereas long-
term administration of L-dopa leads to declining ERK activation, and persistent or even increased 
cAMP/DARPP-32 signalling. This decline in ERK signalling has not been seen in rodents but the 
discrepancy may be due to species difference or a longer period of L-dopa administration employed in 
the primate study.  
Downstream targets of these altered signalling cascades are also implicated in dyskinesia. Increased 
expression of immediate early genes including fosB, prodynorphin, zif268 and Arc in nigrostriatal 
neurones have been demonstrated in dyskinetic rodents (Andersson et al., 1999; Carta et al., 2005; 
Sgambato-Faure et al., 2005). Indeed viral vector-induced overexpression of ΔFosB enhances the ability 
of L-dopa to induce dyskinetic behaviour (Cao et al., 2010), and fosB activation is closely associated with 
expression of the other aforementioned genes (Feyder et al., 2011). In addition to transcription factors, 
modulation of mRNA translation by the mammalian target of rapamycin complex 1 (mTORC1) is also 
implicated in dyskinesia (Costa-Mattioli et al., 2009). The selective inhibition of mTORC1 leads to a 
reduction in the emergence of abnormal involuntary movements in dopamine- depleted mice (Santini et 
al., 2009). 
Meanwhile far less is known about the role of D2-associated receptor pathways and their role in 
dyskinesia. D3 receptors have been shown to exert a synergistic effect on D1R-mediated transmission 
through direct intramembrane inter- action (Fiorentini et al., 2008; Marcellino et al., 2008). Accordingly, 
the co-treatment of L-dopa with a D3 receptor antagonist has been shown to normalise levels of 
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showing modulation of D3 receptors can attenuate development and expression of dyskinesia in animal 
models of PD (Kumar et al., 2009; Visanji et al., 2009).  
Collectively these changes may be markers of modified synaptic plasticity and could represent further 
angles for therapeutic intervention of dyskinesia in the clinic. Targeting downstream expression of 
striatal mRNA could overcome the conflicting effects associated with modulation of broader acting 
signalling molecules involved in dyskinesia, perhaps such as NO.   
 
6.4 Future outlook for treatment and prevention of dyskinesia 
The role of glutamate in dyskinesia has been described in some detail elsewhere (see section 6.2) and 
there are currently mGluR antagonists in ongoing clinical trials for this purpose, whilst the search 
continues for effective and clinically safe NMDA and AMPA receptor antagonists. Serotonin (5-HT) is an 
important modulator of dopamine release and transmission, especially following dopaminergic nerve 
terminal depletion, where ‘false release’ of dopamine from 5-HT neurones can lead to non-physiological 
stimulation of dopamine receptors (Carta et al., 2007; Munoz et al., 2008). Drugs acting on serotonergic 
pathways offer some promise in the treatment of dyskinesia, and agonists of 5-HT1a and 5-HT1b 
receptors, as well as antagonists of 5-HT2A and 5-HT2C receptors, are in development (Meissner et al., 
2011). The 5-HT1a agonist sarizotan was effective in reducing L-dopa induced dyskinesia in rat and 
primate PD models and also showed benefit in Phase II clinical trials (Bara-Jimenez et al., 2005; Goetz et 
al., 2007; Gregoire et al., 2009; Marin et al., 2009). However the drug failed to reach primary endpoints 
in two large Phase III trials, although this may be due to a prominent placebo effect or dose limitations 
resulting from low potency of sarizotan and partial antagonism at dopamine D2 receptors acting to 
worsen motor symptoms. Piclozotan, a 5-HT1a agonist, also offers agonistic properties at D3 receptors 
(Asubio Pharmaceuticals), and in 2011 completed a placebo-controlled, phase II, short duration proof-
of-concept study, improving ON time without dyskinesia.  
Adenosine A2a receptors are highly abundant in the basal ganglia, concentrated in GABA-containing 
medium spiny neurons of the indirect pathway, and their antagonism may contribute to restoring the 
altered balance in the output pathways of the basal ganglia implicated in PD (Ferre et al., 1997; Jenner 
et al., 2009). Adenosine A2a antagonists also show promise and convincing results have been seen pre-
clinically whereby co-administration with L-dopa or dopamine agonists improves motor function 
without exacerbating dyskinesia (Kanda et al., 2000; Koga et al., 2000). In contrast to pre-clinical findings 
clinical trials with the A2a antagonist istradefylline showed a reduction in OFF-time but with an increase 
in ON-time with dyskinesia, although most patients showed non-troublesome dyskinesia (Hauser et al., 
2008; LeWitt et al., 2008). The selective A2a antagonists SCH-4208140 (Schering-Plough Corp) and 
SYN115 (Synosia/Roche Holding AG) are currently in stage II clinical trials. V2006/BIIB014 (Biogen Idec) 
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There appears to be a lack of translation of non-dopaminergic approaches to managing dyskinesia from 
pre-clinical studies to clinical trials. According to Meissner and collegues (2011) three major limitations 
have hindered the development of new treatments to date; firstly the pharmacology of dyskinesias is 
not fully understood. Secondly there is a lack of validated clinical outcome measures that are responsive 
to treatment, despite the availability of multiple dyskinesia rating scales. Thirdly, the variety of 
dyskinesias, their temporal patterns, anatomical distributions and associated disabilities have made the 
development of a unitary, sensitive and robust rating scale extremely challenging. As seems to be the 
case for amantadine, the only drug with proven efficacy in attenuating dyskinesia, it may be that the 
best symptomatic treatment for involuntary movements in PD involves modulation of multiple 
neurotransmitter pathways. 
Ultimately dyskinesia occur due to continuing neurodegeneration accompanied by dopaminergic 
therapy. Therefore, rather than concentrating on their symptomatic management, an alternative and 
more holistic solution may come from neuroprotective or neurorestorative strategies which aim to 
minimise or slow down the progression of the disease itself and in so doing could reduce the chances of 
dyskinesia onset. Viral vector-mediated gene transfer offers the ability to enhance endogenous 
dopamine levels in the basal ganglia via delivery of therapeutic genes such as TH, AADC, GAD and GDNF 
(glial-derived neurotrophic factor)/neurturin (Wakeman et al., 2011). The combined delivery of several 
genes in one vector is also a promising approach. Neural grafting of dopamine-secreting cells sourced 
from foetal tissue may also provide benefit, although graft-induced dyskinesia and emergence of Lewy 
bodies in grafts have compromised efficacy. There are also shortcomings with foetal tissue availability 
and standardisation of the grafts, but these may be overcome by employing stem-cells (Politis & 
Lindvall, 2012). However, it remains to be seen whether dopaminergic neurons derived from stem cells 
can successfully re-innervate the striatum and provide functional recovery in PD patients.  
 
 
6.5 Final conclusion 
The findings described in this thesis suggest that NO is not critically involved in either the expression or 
development of dyskinesia in PD. It is therefore unlikely that reduction of nNOS activity would afford 
any benefit in the clinic. This is the first time that studies have been collectively carried out into the 
effects of nNOS inhibitors on dyskinesia employing both the 6-OHDA-lesioned rat and MPTP-treated 
primate model of PD and also utilising not only the widely applied nNOS inhibitor 7-NI but also the more 
nNOS-specific inhibitor ARR17477. The exact mechanisms underlying dyskinesia induction and 
expression are still not fully understood despite considerable ongoing research effort, but as more 
knowledge is gained further targeted treatment by adjunctive drugs or gene therapy may provide 





















































Table 0-1 Results of radioligand binding assays for ARR17477 as undertaken by MDS Pharma 
Services, Taiwan. Data are presented as the percentage inhibition of specific binding ( % 
inhibition), showing the lowest concentration with a significant response. The half maximal 









Figure 0-1 Modified latin-square design for treatment Chapter 3, section 3.2.4.3; Acute dopaminergic 








Figure 0-2 Modified latin-square design for treatment Chapter 5, section 5.4.3; L-dopa - dyskinesia 




  Appendix 
Table 0-2 Tables of statistics (2-way ANOVA) according to figure labels. 
Fig 3-4a F  Df  (sig)      fig 3-10a F  Df  (sig)  
time  46.52 14 ***   
 
time  71.37 14 ***  
treatment  0.19 3 ns   
 
treatment  2.08 3 ns 
interact  0.77 42 ns  
 
interact  2.47 42 ***  
  
  
        
fig 3-5a F  Df  (sig)  
  
fig 3-10b F  Df  (sig)  
time  29.23 14 ***   
 
time  39.08 14 ***  
treatment  0.05 3 ns  
 
treatment  0.24 3 ns 
interact  1.03 42 ns  
 
interact  2.03 42 ***  
  
  
        
fig 3-6a F  Df  (sig)  
  
fig 3-10c F  Df  (sig)  
time  18.52 12 ***   
 
time  15.52 14 ***  
treatment  0.19 3 ns  
 
treatment  0.52 3 ns 
interact  0.61 36 ns  
 
interact  2.79 42 ***  
  
  
        
fig 3-7a F  Df  (sig)  
  
fig 3-10d F  Df  (sig)  
time  40.19 14 ***   
 
time  86.75 14 ***  
treatment  3.16 3 *  
 
treatment  0.40 3 ns 
interact  2.60 42 ***  
 
interact  4.58 42 ***  
        
  
        
fig 3-8a F  Df  (sig)  
  
fig 3-12a F  Df  (sig)  
time  56.57 14 ***   
 
time  59.25 12 ***  
treatment  0.003 3 ns  
 
treatment  1.56 3 ns 
interact  0.63 42 ns  
 





        
fig 3-8b F  Df  (sig)  
  
fig 3-12b F  Df  (sig)  
time  51.74 14 ***   
 
time  35.01 12 ***  
treatment  0.36 3 ns  
 
treatment  1.13 3 ns 
interact  0.50 42 ns  
 





        
fig 3-8c F  Df  (sig)  
  
fig 3-12c F  Df  (sig)  
time  24.45 14 ***   
 
time  12.43 12 ***  
treatment  0.74 3 ns  
 
treatment  4.14 3 ** 
interact  0.47 42 ns  
 





        
fig 3-8d F  Df  (sig)  
  
fig 3-12d F  Df  (sig)  
time  67.08 14 ***   
 
time  53.30 12 ***  
treatment  0.56 3 ns  
 
treatment  0.95 3 ns 
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fig 3-14a F  Df  (sig)  
  
fig 4-9b F  Df  (sig)  
time  88.41 12 ***   
 
time  25.36 9 ***  
treatment  3.52 3 *  
 
treatment  0.45 2 ns  
interact  2.07 36 ***   
 
interact  0.85 18 ns  
          fig 3-14b F  Df  (sig)  
  
fig 4-9c F  Df  (sig)  
time  40.99 12 ***   
 
time  31.46 9 ***  
treatment  5.71 3 **  
 
treatment  1.62 2 ns  
interact  2.56 36 ***   
 
interact  2.32 18 ** 
          fig 3-14c F  Df  (sig)  
  
fig 4-11a F  Df  (sig)  
time  4.33 12 ***   
 
time  21.33 9 ***  
treatment  1.73 3 ns  
 
treatment  1.16 2 ns  
interact  0.91 36 ns  
 
interact  2.11 18 **  
          fig 3-14d F  Df  (sig)  
  
fig 4-11b F  Df  (sig)  
time  58.85 12 ***   
 
time  36.78 9 ***  
treatment  6.25 3 **  
 
treatment  2.53 2 ns  
interact  2.00 36 ***   
 
interact  1.61 18 ns  
          fig 4-7a F  Df  (sig)  
  
fig 4-11c F  Df  (sig)  
time  36.78 9 ***  
  
time  23.61 9 ***  
treatment  2.53 2 ns  
  
treatment  0.93 2 ns  
interact  1.61 18 ns  
  
interact  0.49 18 ns  
          fig 4-7b F  Df  (sig)  
  
fig 4-11d F  Df  (sig)  
time  9.91 9 ***  
  
time  51.69 9 ***  
treatment  1.03 2 ns  
  
treatment  1.09 2 ns  
interact  1.40 18 ns  
  
interact  1.28 18 ns  
          fig 4-7c F  Df  (sig)  
  
fig 4-12a F  Df  (sig)  
time  10.27 9 ***  
  
time  34.10 9 *** 
treatment  0.96 2 ns  
  
treatment  0.99 2 ns 
interact  1.03 18 ns  
  
interact  1.68 18 * 
          fig 4-9a F  Df  (sig)  
  
fig 4-12b F  Df  (sig)  
time  17.10 9 ***  
  
time  55.14 9 *** 
treatment  1.64 2 ns  
  
treatment  1.34 2 ns 
interact  0.94 18 ns  
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fig 4-12c F  Df  (sig)  
  
fig 4-15c F  Df  (sig)  
time  35.91 9 ***  
 
time  14.00 9 ***  
treatment  0.97 2 ns  
 
treatment  2.85 2 ns 
interact  2.12 18 **  
 
interact  0.74 18 ns 
          fig 4-12d F  Df  (sig)  
  
fig 4-15d F  Df  (sig)  
time  67.13 9 ***  
 
time  37.27 9 ***  
treatment  0.26 2 ns  
 
treatment  4.86 2 * 
interact  1.01 18 ns  
 
interact  1.61 18 ns 
          fig 4-13a F  Df  (sig)  
  
fig 4-16a F  Df  (sig)  
time  29.50 9 ***  
 
time  63.54 9 ***  
treatment  1.71 2 ns  
 
treatment  3.70 2 * 
interact  2.08 18 **  
 
interact  1.73 18 * 
          fig 4-13b F  Df  (sig)  
  
fig 4-16b F  Df  (sig)  
time  62.88 9 ***  
 
time  16.52 9 ***  
treatment  4.44 2 *  
 
treatment  1.11 2 ns 
interact  1.85 18 *  
 
interact  0.61 18 ns 
          fig 4-13c F  Df  (sig)  
  
fig 4-16c F  Df  (sig)  
time  18.72 9 ***  
 
time  15.54 9 ***  
treatment  0.03 2 ns  
 
treatment  1.09 2 ns 
interact  1.37 18 ns  
 
interact  1.05 18 ns 
          fig 4-13d F  Df  (sig)  
  
fig 4-16d F  Df  (sig)  
time  105.80 9 ***  
 
time  57.46 9 ***  
treatment  9.09 2 **  
 
treatment  1.75 2 ns 
interact  3.05 18 ***  
 
interact  0.98 18 ns 
          fig 4-15a F  Df  (sig)  
  
fig 4-17a F  Df  (sig)  
time  36.13 9 ***   
 
time  41.70 9 ***  
treatment  5.74 2 **  
 
treatment  5.34 2 * 
interact  2.43 18 **   
 
interact  2.12 18 ** 
          fig 4-15b F  Df  (sig)  
  
fig 4-17b F  Df  (sig)  
time  11.90 9 ***   
 
time  13.24 9 ***  
treatment  2.13 2 ns  
 
treatment  2.28 2 ns 
interact  1.24 18 ns  
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fig 4-17c F  Df  (sig)  
  
fig 5-9a F  Df  (sig)  
time  18.48 9 ***   
 
time  2.76 8 * 
treatment  1.98 2 ns  
 
treatment  0.01 1 ns 
interact  0.69 18 ns  
 
interact  0.68 8 ns 
          fig 4-17d F  Df  (sig)  
  
fig 5-9b F  Df  (sig)  
time  46.30 9 ***   
 
time  3.74 8 ** 
treatment  3.47 2 *  
 
treatment  0.05 1 ns 
interact  1.31 18 ns  
 
interact  0.57 8 ns 
          fig 5-3a F  Df  (sig)  
  
fig 5-10a F  Df  (sig)  
time  14.23 12 ***   
 
time  10.64 8 *** 
treatment  0.46 3 ns  
 
treatment  0.01 1 ns 
interact  0.59 36 ns  
 
interact  0.55 8 ns 
          fig 5-4a F  Df  (sig)  
  
fig 5-10b F  Df  (sig)  
time  32.08 12 ***   
 
time  24.68 8 *** 
treatment  1.22 3 ns  
 
treatment  0.01 1 ns 
interact  1.05 36 ns  
 
interact  1.04 8 ns 
          fig 5-5a F  Df  (sig)  
  
fig 5-10c F  Df  (sig)  
time  20.74 12 ***   
 
time  10.27 8 *** 
treatment  0.39 3 ns  
 
treatment  0.05 1 ns 
interact  0.95 36 ns  
 
interact  0.11 8 ns 
          fig 5-6a F  Df  (sig)  
  
fig 5-11a F  Df  (sig)  
time  17.81 12 ***   
 
time  9.79 8 *** 
treatment  0.20 3 ns  
 
treatment  0.85 1 ns 
interact  0.48 36 ns  
 
interact  0.43 8 ns 
          fig 5-7a F  Df  (sig)  
  
fig 5-11b F  Df  (sig)  
time  60.29 12 ***   
 
time  8.01 8 *** 
treatment  1.38 3 ns  
 
treatment  1.04 1 ns 
interact  1.60 36 *  
 
interact  0.74 8 ns 
          fig 5-8a F  Df  (sig)  
  
fig 5-11c F  Df  (sig)  
time  25.05 12 ***   
 
time  7.67 8 *** 
treatment  0.27 3 ns  
 
treatment  0.01 1 ns 
interact  0.74 36 ns  
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